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ISOLATED LIMB PERFUSION FOR MALIGNANT MELANOMA: 
CLINICAL AND LABORATORY STUDIES.
SUMMARY
Malignant melanoma is usually considered a rare cancer but 
data from countries with good records show the incidence 
doubling in recent decades. Only lung cancer in women is 
increasing at a higher rate. The current incidence rate of 
malignant melanoma in Scotland is 8-10 new cases per 
100,000 annually. Public education may help to prevent the 
disease and increase the rate of diagnosis at an early
curable stage, thereby improving the overall prognosis.
%
There is, however, a need for an effective treatment of 
high risk primary lesions and advanced malignant melanoma.
In this thesis I assess the value of isolated limb 
perfusion as treatment for malignant melanoma. This 
technique presents unique clinical opportunities to 
control the physio-pharmacological environment of a tumour 
and thus to maximise the therapeutic effects of the 
cytotoxic drug. Although isolated limb perfusion has been 
used clinically for thirty years there has been 
surprisingly little study of the physio-pharmacology. 
Different perfusion techniques have evolved empirically 
around the world.
I was involved in making isolated limb perfusion available 
in Scotland. I have studied the physio-pharmacology of 
isolated limb perfusion in both the clinical setting and 
using in vitro models.
In Chapter I the cutaneous melanocyte system and benign
10
pigmented naevi are reviewed to introduce the pathology of 
malignant melanoma. Treatment is considered in the light 
of the clinical pathology. Important surgical
controversies (including excision margins and elective 
lymph node dissection) are discussed in particular detail. 
The rationale, history and published results of isolated 
limb perfusion are given and this treatment is thus set in 
the context of a comprehensive review of malignant
melanoma.
Chapter II describes the introduction and preliminary 
validation of isolated limb perfusion in Scotland. 
Patients were referred to us through the Scottish Melanoma 
Group. In a consecutive series of our first 61 isolated 
limb perfusions we have shown that we can safely perform
the procedure in Glasgow. Our initial results for
therapeutic perfusion are comparable with other published 
series. In pilot studies of the physiology of isolated 
limb perfusion, it was soon apparent that many aspects 
were incompletely understood, and that there was scope for 
basic research.
The clinical pharmacology of melphalan isolated limb 
perfusion is described in Chapter III. In a phase I study 
we showed that melphalan can be given safely in a bolus 
dose of 1.75mg/kg body weight (up to 165mg) . Using a 
sensitive and specific HPLC (high performance liquid 
chromatography) assay we measured melphalan concentrations 
in the perfusate, in the systemic circulation, and in the 
tissues of the perfused limb. The pharmacokinetic data 
show that isolated limb perfusion consistently achieves
11
the aim of exposing the tumour-bearing limb to high 
concentrations of melphalan, while minimising systemic 
exposure. Estimates of tissue uptake of melphalan suggest 
that the drug is taken up by the tissues of the leg mainly 
during the first 3 0 minutes of isolated limb perfusion. 
However perfusion should last longer than 3 0 minutes to 
maintain the concentration gradients which drive the drug 
through diffusion barriers to the target cells.
There is no pharmacokinetic advantage in divided dose 
compared with bolus dose administration, and no increased 
regional toxicity as a consequence of the high peak levels 
generated by single bolus dose administration.
Isolated limb perfusion achieves levels of melphalan in 
large necrotic tumours which are significantly higher than 
the levels in fat, and similar to the levels in well 
vascularised healthy skin.
The physio-pharmacology of isolated limb perfusion is 
quite unlike that of systemic administration of cytotoxic 
drug and in Chapter IV I describe the use of in vitro 
models to study ways of controlling melphalan cytotoxicity 
at the cellular level.
Multicellular tumour spheroids were grown from three 
established human melanoma cell lines. Spheroids were used 
in studies of experimental chemotherapy with melphalan, in 
physio-pharmacological conditions based on those measured 
in our patients. The multicellular tumour spheroid model 
is particularly valuable in the study of factors which are 
difficult to isolate as variables in other experimental 
systems.
The important conclusions of my in vitro studies are that:
12
1) Hyperthermia (>37°C) enhances the cytotoxic effect of 
melphalan, though heat alone is not cytotoxic to spheroids 
at temperatures less than 43°C for one hour.
2) Hypothermia (<37°C) tends to reduce the cytotoxic 
effect of melphalan.
3) There is a simple relationship between duration of 
exposure and cytotoxic effect.
4) Verapamil does not enhance melphalan cytotoxicity.
5) The B0010 cell line forms spheroids which grow poorly 
in conditions which allow B0008 and MEL57 spheroids to 
grow well.
6) Melphalan cytotoxicity is enhanced at lower pH 
values, and this effect is not simply due to decreased 
hydrolysis of melphalan.
7) Similar dose-survival curves are derived from
spheroid experiments by back-extrapolation from growth 
curves, from colony forming assay of disaggregated 
spheroids and from colony forming assay of exponential 
monolayers.
The implications of the in vitro studies for clinical 
isolated limb perfusion are that:
a) the limb should be warmed to at least 37 °C during 
isolated limb perfusion because melphalan cytotoxicity is 
enhanced by hyperthermia and reduced by hypothermia.
b) the results of one hour exposure to the achieved 
tissue concentrations may be improved by longer exposures; 
and shorter periods of clinical perfusion are probably 
inappropriate.
c) the addition of verapamil during isolated limb 
perfusion with melphalan would not be expected to improve
13
results, unless the vasodilator effect is important,
d) the cytotoxic effect of melphalan may be enhanced by 
correcting the alkalosis which develops if the perfusate 
is oxygenated with 100% 02.
Isolated perfusion with melphalan is now the treatment of 
choice for recurrent or advanced malignant melanoma 
confined to one limb, and patients with high risk limb 
primaries should be entered in trials of adjuvant 
perfusion. We are now involved in studies designed to 
optimise the treatment by manipulating physio-pharmacology 
during isolated limb perfusion with melphalan, and by 
exploring the use of monoclonal antibodies armed with 
radio-isotopes in this system.
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CHAPTER I
A REVIEW OF CUTANEOUS MALIGNANT MELANOMA
1.1. SKIN, MELANOCYTES AND PIGMENTED NAEVI
1.1.1. Introduction
Malignant melanoma is the name given to cancer arising 
from specialised cells called melanocytes which produce 
the pigment melanin. Melanocytes are normally found in 
various tissues of the body. In the study of cutaneous 
malignant melanoma it is essential to have an 
understanding of the melanocyte system in healthy skin. In 
this chapter a brief description of the important benign 
melanocytic lesions is also included as a necessary 
introduction to, cutaneous malignant melanoma.
The aims of this chapter are to consider the features of 
cutaneous malignant melanoma which are of clinical 
importance and to set isolated limb perfusion in the 
context of other available therapies.
1.1.2. The skin
The skin is the major site of interaction between the 
environment and the body. Skin provides protection against 
many potentially damaging environmental influences. Some 
of these, such as mechanical forces, thermal and chemical 
injuries, or invasion by micro-organisms are obvious; 
others, such as osmotic gradients and radiation are more 
subtle. The skin is the largest sensory organ, and 
provides friction for manipulation and locomotion. It is 
an organ of heat exchange and insulation. Vitamin D is 
activated in the skin by ultraviolet light.
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The two main layers of the skin are epithelium, the 
epidermis and underlying connective tissue, the dermis. 
The strength and elasticity of the skin is provided by the 
dense, fibrous tissue of the dermis which is richly 
supplied with blood vessels, lymphatics and nerves. The 
epidermis protects the dermis from injury and particularly 
from drying out. It is a stratified squamous epithelium 
which is sub-divided into various layers (Fig.l). The 
majority of epidermal cells are keratinocytes derived from 
embryonic ectoderm. These cells are produced by cell 
division in the basal layer and at the end of their life 
cycle they are continuously shed as dead cells from the 
surface of the cornified outermost layer. There is no 
direct blood supply to the epidermis which is nourished by 
diffusion of nutrients through tissue fluids from the 
richly vascular underlying dermis. The epithelial 
melanocytes (melanoblasts, clear cells, dendritic cells) 
are found among the basal keratinocytes in the epidermis.
1.1.3. The melanocyte system
Normal melanocytes are not conspicuous on routine 
histological sections of skin but they may be detected by 
the presence of an artefactual clear space around a 
shrunken cell body, in the basal layer of the epidermis. 
Mammalian melanocytes are derived from cells of neural 
crest origin1 which migrate to invade the skin of the 
foetus between three and six months in utero2 .. The 
concentration of melanocytes varies from site to site on
'i
the body surface .
Most melanocytes are found among the basal cells of the
16
epidermis, but some are found in hair bulbs and in the 
dermis. Melanocytes are also found in the pia arachnoid of 
the central nervous system and in the uveal tract and 
retinal epithelium of the eye. In all of these sites 
(except the retinal pigment epithelium) malignant melanoma 
may develop4 .
Skin pigmentation is controlled by several genes5 which 
determine the "constitutive" skin colour. Various 
modifiers of pigmentation interact to induce reversible 
"facultative" changes in skin colour4 .
Melanocytes produce the brownish-black pigment melanin 
(from the Greek, melas meaning black). The melanin pigment 
is transferred from melanocytes to keratinocytes and this 
transfer is essential for the pigmentation to be 
clinically apparent4 . Melanin is not the sole determinant 
of human skin colour which depends on the interplay of 
many factors6 including the reflectivity and absorbance 
characteristics of the skin surface, the thickness of the 
skin and the oxygen saturation of the haemoglobin in the 
cutaneous blood vessels.
The study of melanin biochemistry has been complicated by 
the difficulty of dissolving the virtually insoluble 
pigment4 . The amino acid tyrosine is converted via 
dihydroxy-phenylalanine (dopa) to melanin by a series of 
reactions (Fig.2) in which the enzyme tyrosinase is 
important. In 1928 Raper^ was the first to describe the 
role of tyrosinase in melanogenesis. This enzyme is an 
aerobic oxidase which, for activity, requires copper to be 
present. Tyrosinase is found exclusively within the 
melanocyte, where melanin is formed on specific sub-
17
cellular organelles called melanosomes.
The cell body of the epidermal melanocyte is found in the
basal layer. Long, slender processes called dendrites
ramify from the cell body of the melanocyte among the
surrounding keratinocytes. The melanocyte does not form
keratin. The function of the melanocyte is to synthesise
melanin and transfer melanosomes to keratinocytes.
Melanosomes are formed in the cell body as spherical
vesicles containing tyrosinase without melanin. As the
melanosome matures it becomes more elongated, and develops
a regular fibrillar or lamellar inner structure. With
increasing deposition of melanin the internal structure of
the melanosome becomes obscured8 . The melanosome matures,
accumulating melanin, as it moves down the dendrite away
from the cell body. Racial differences in skin colour do
not depend on variations in melanocyte number. The
melanocytes of darkly skinned races contain many mature
melanosomes (1-1.3^m in transverse diameter) laden with
melanin whereas the melanocytes in pale Caucasian skin
contain fewer, smaller melanosomes which are less 
i nmature*1- .
The pigment is transferred from the dendrites of the 
melanocyte to the surrounding keratinocytes which appear 
to take up intact melanosomes11. Each melanocyte supplies 
approximately 30 keratinocytes with pigment, and this 
group of cells is described as the epidermal melanin 
unit-*-**. As the keratinocytes mature they carry the pigment 
up through the epidermis.
Tyrosinase activity is regulated by various inhibitors and 
activators. The activity of tyrosinase is enhanced by
18
increased levels of cyclic AMP within cells (e.g. 
Melanocyte Stimulating Hormone or theophylline), but it is 
inhibited by phenols, catechols and quinones4 . The tanning 
effect of ultraviolet radiation (solar and artificial) is 
well known, and it has become a recreational obsession for 
many people. Exposure to ultraviolet light tends to 
enhance the activity of tyrosinase13 and increase melanin 
production. The actual number of melanocytes can also be 
increased by exposure to ultraviolet light14. Excessive 
exposure to ultraviolet radiation can cause sunburn, 
malignant melanoma and non-melanoma skin cancer. In normal 
skin the light absorbing property of melanin protects 
underlying tissues by reducing the transmission of 
damaging ultraviolet radiation4 . The relatively low 
incidence of malignant melanoma in darker races15'16
compared with Caucasians, who develop sunburn more
• 1 7 .easily-1-, suggests that melanin has an important role in
protecting the skin from the harmful effects of solar 
radiation.
1.1.4. Benign cutaneous melanocytic lesions
There is such confusion about the nature and terminology 
of benign and malignant pigmented lesions that a 
consideration of benign cutaneous melanocytic naevi is 
appropriate in this thesis. Undeniably there are some 
difficult aspects where experts cannot agree. Nonetheless 
clinicians must have a working knowledge of pigmented 
lesions, in order that appropriate clinical management 
decisions are made for the benign mole as well as the 
malignant melanoma.
19
The discrimination of benign from malignant lesions is 
especially important because the incidence of cutaneous
malignant melanoma is increasing across the Western
T R •World . More patients are likely to present with
pigmented lesions as a result of public education 
campaigns and a greater proportion of the lesions 
presenting will be seen when their malignant potential may 
not be clinically obvious and when histological mis­
diagnosis could be most damaging. In recent years there 
has been increasing interest in certain benign lesions 
which may be precursor lesions or indicators of melanoma 
risk.
An understanding of the terminology which is used to 
describe benign melanocytic naevi and their biology will 
clarify the subsequent discussion of cutaneous malignant 
melanoma.
1.1.5. Freckles and lentigines
In a freckle (ephelis) there is a focal increase in the 
quantity of pigment in and around the basal epidermal
layer, and no other microscopic change. The appearance is 
distinct from that of a lentigo (from the Latin, lens
meaning lentil) where there is an increase in basal
pigmented melanocytes plus lengthening and widening of the 
rete ridges. Lentigines are usually 2mm or less in 
diameter , tend to occur on sun-exposed sites and they 
are often associated with changes of solar keratosis in 
the epidermis. Clinically a lentigo may be difficult, if 
not impossible, to distinguish from a small pigmented 
naevus.
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1.1.6. Moles and pigmented melanocytic naevi
Melanocytes tend to be regularly spaced, singly, among the 
cells of the basal epidermis. The ratio of melanocytes to 
basal cells averages about 1:10 but more melanocytes are 
found on the face and fewer on the trunk20. Melanocytes 
may be found in the dermis where they are known as naevus 
(from the Latin, natus meaning born) cells.
The various lesions which we call moles (from the Old High 
German, meil meaning spot) consist of clusters of 
melanocytes and naevus cells in the skin. The 
characteristics of naevus cells are variable (e.g. site 
and extent of pigmentation) but they all share a common 
embryonic origin with melanocytes. The melanocytic lesions 
are termed "pigmented melanocytic naevi" to distinguish 
them from the angiomas and other congenital naevi.
This account is simplified to introduce widely accepted 
concepts, but the detailed natural histories of the 
various types of pigmented melanocytic naevi have not been 
fully determined. Various controversies have yet to be 
resolved, and the emphasis here is on those aspects which 
may be important in relation to malignant melanoma.
1.1.7. Congenital pigmented melanocytic naevi
The congenital pigmented naevi are divided on the basis of 
size into the categories giant, medium and small. All are 
present at or appear within a few weeks of birth. In 
careful studies, with assessment of neonates and biopsy of 
moles, the true incidence of congenital pigmented 
melanocytic naevi in Caucasian babies is about 1% 21. The 
natural history of the small (diameter <1.5cm) and medium
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(1.5-19.9cm) congenital naevi is that they tend to persist 
unchanged throughout life. Congenital pigmented naevi are 
usually larger than the common acquired pigmented naevi. 
The histological features of congenital pigmented naevi 
are variable but most of these moles have features typical 
of compound naevi (see 1.1.8.).
• 2 2 2 3 2 A •Growing evidence ' J  ^ suggests that small and medium 
congenital naevi may be more likely to be associated with 
subsequent malignant melanoma than acquired naevi. Hence 
the management of smaller congenital pigmented naevi is
controversial, with some recommending prophylactic
• • 25excision .
Giant congenital naevi are rare and do not regress 
spontaneously. These lesions (diameter >20cm) may be very 
large e.g. "bathing trunk" naevus. They show variable 
pigmentation and may be hairy like the smaller congenital 
lesions. There is an increased risk of malignant melanoma 
in patients with giant congenital moles. The lifetime risk 
of malignant melanoma is about 3-6%26'27 in this group. 
The giant congenital pigmented naevi present difficult 
clinical problems. The appearance of the lesion is often 
disfiguring and excisional surgery leaves an extensive 
area for skin grafting. Although excision and grafting may 
be justifiable on the basis of risk of malignancy, surgery 
is rarely a practical proposition. Multistage procedures 
involve repeated distress for the child and the cosmetic 
results may be poor. Management often consists simply of 
regular examinations and comparative photography, with 
biopsy of any suspicious change. Early shave excision for 
cosmetic improvement is advocated by some plastic surgeons
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but this treatment may not prevent malignant change, 
especially since melanoma arising in giant congenital 
naevus may arise from cells deep in the dermis27.
1.1.8. Acquired pigmented melanocytic naevi
There are several different types of acquired pigmented 
naevi. Common acquired naevi account for the greatest 
proportion, and they occur at any site on the skin. Common
acquired pigmented naevi mainly appear in the second
decade of life as small brown spots which grow to a
diameter of about 5mm, and by the age of twenty a young 
adult usually has about thirty of these lesions. Such 
moles may remain unchanged or protrude a little, but they 
tend to fade and may disappear in later life28'29.
The histological appearances at each stage are
characteristic and give rise to a further classification 
of the naevi. In infancy and childhood the flat, 
impalpable acquired moles consist of local concentrations 
or clusters of pigmented naevus cells which are in contact 
with the dermo-epidermal junction (junctional naevus).
As the acquired naevus ages, an increasing proportion of 
the naevus cells are found in the superficial part of the 
reticular dermis. An intradermal pigmented naevus consists 
of numerous aggregates of small, polygonal naevus cells in 
the dermis. There is some associated fibrosis in the 
overlying papillary dermis and the naevus cells tend to 
become depigmented. Some of the deeper naevus cells 
concentrate around hair follicles and others are 
associated with peripheral nerve endings. The latter group 
of naevus cells may take on the characteristics of Schwann
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cells in a process called "neurotization". Schwann cells 
arise from the embryonic neural crest like melanocytes, 
and they normally form the myelin sheath of peripheral 
nerve axons. At a final stage in the natural history of an 
acquired mole the intradermal naevus may regress 
completely leaving little or no histological evidence of 
the pre-existing mole.
A compound naevus has histological features of both a 
junctional and an intradermal naevus, and it represents an 
intermediate stage in the development of an acquired 
naevus. Moles on the palms, soles and genitalia do not 
follow the general pattern of ageing but they tend to 
remain compound into adult life.
The halo naevus is fairly common, occurring on the back in 
young people. In a patient aged between five to fifteen a 
symmetrical depigmented halo may appear around one or more 
pre-existing moles. After a few months the mole disappears 
leaving a depigmented area which may persist for years. 
Histologically the most characteristic feature is a dense 
lymphocytic infiltrate associated with the dermal 
component of the naevus. The halo naevus is entirely 
benign and thus there is no need for excision.
The Spitz naevus or "juvenile melanoma" is a rare lesion 
which can be much more difficult to discriminate from 
malignant melanoma. The Spitz naevus can appear at any age 
but classically the lesion appears on the cheek of a child 
as a pink, hairless nodule. For several months the lesion 
grows and it may persist as an indolent lesion about 5mm 
in diameter or it may disappear spontaneously. The blue 
naevus is a rare, but interesting mole which appears in
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the teens and persists unchanged throughout life. It 
tends to occur on the face, extremities and buttocks. A 
blue naevus in the sacral region forms the "Mongolian blue 
spot", which is characteristic of oriental races. 
Histologically the cells of a blue naevus are elongated, 
heavily pigmented and associated with collagen bundles in 
the reticular dermis. These features account for the 
characteristic bluish coloration29 but there is very 
little risk of malignant transformation.
1.1.9. Dysplastic naevi
The dysplastic naevus has excited particular interest and 
controversy because it has histological features and 
clinical associations which suggest that it is a potential 
precursor of malignant melanoma.
In 1977 Frichot & Lynch30 described the association of 
familial melanoma with unusual benign pigmented lesions, 
which they termed the "familial atypical multiple mole 
syndrome". Clark and colleagues used the terms "B-K mole 
syndrome"31 and later "dysplastic naevus syndrome"32 for 
this familial condition. Elder and colleagues33 were first 
to describe identical histological features in non- 
familial cases, and they provided criteria for the 
diagnosis of the sporadic dysplastic naevus which were 
later adopted and modified by the Consensus Development 
Conference of the National Institute of Health in the 
USA34.
As stated in the report of the Consensus Conference 
"dysplastic naevi are acquired pigmented lesions whose 
clinical and histological definitions are evolving"34. A
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typical dysplastic naevus is a maculo-papular lesion, 5- 
12mm in diameter (larger than common naevus) with an 
irregular, poorly defined edge. The colour of a dysplastic 
naevus may vary from tan to dark brown, and the lesion may 
occur anywhere on the body. Individuals with multiple 
dysplastic naevi may have more than 100 lesions, and there 
is typically considerable lesion to lesion variability. 
Dysplastic naevi begin to appear in adolescence and 
continue to appear into adult life. Single dysplastic 
naevi have been reported in 4% of the population in a 
study from California35. Multiple dysplastic naevi are 
much less common, although this is the variant which was 
first recognised.
The typical histological features of a dysplastic naevus 
are superimposed on those of a junctional or compound 
naevus. There is elongation of the rete ridges and 
melanocytic hyperplasia. Individual melanocytes show 
cellular atypia with enlarged hyperchromatic nuclei. The 
melanocytes are often aggregated in nests which tend to 
fuse with adjacent rete ridges producing bridging. 
Fibrosis of the papillary dermis occurs and there is a 
patchy or diffuse lymphocytic infiltrate of the 
superficial dermis. It is important to note that these 
features may only occur focally within a lesion. According 
to the Consensus Conference, these appearances can be 
distinguished from malignant melanoma in situ34.
Familial dysplastic naevi may be inherited as an autosomal 
dominant trait. The term "dysplastic naevus syndrome" is 
applied when two or more members of a family have multiple 
dysplastic naevi. Sporadic dysplastic naevi occur in
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patients with no family history of dysplastic naevi or 
malignant melanoma.
The risk of subsequent malignant melanoma is not uniform 
for patients with dysplastic naevi. The classification of 
dysplastic naevi according to Kraemer and colleagues is 
given in Table 1. It is well established that the risk is 
very high in patients with the dysplastic naevus syndrome 
who also have a positive family history of malignant 
melanoma (D-l, D-2)36'37. Conversely, any increased risk
is probably very small in sporadic cases with few 
dysplastic naevi and no family history of malignant 
melanoma (A,B & C).
Although the dysplastic naevus appears to be an 
appropriate step in a hyperplasia-dysplasia-neoplasia 
sequence32 and despite wide acceptance of the concept, 
there are still controversial aspects. Ackerman and Mihara 
have claimed that patients with familial melanoma do not 
always have the dysplastic naevus syndrome38. They cite 
families with many cases of malignant melanoma, in which 
none had dysplastic naevi. They found that malignant 
melanoma rarely developed in association with sporadic 
dysplastic naevus, and that it was only a little more 
common in the familial type. In spite of the commonly held 
view that the dysplastic naevus is a melanoma precursor, 
Ackerman and Mihara report that even in patients with the 
dysplastic naevus syndrome most of the melanomas arise de
• o o
novo, and not m  association with any dysplastic lesion . 
In their view the dysplastic naevus is thus a marker for 
malignant melanoma risk rather than a precursor lesion.
27
1.1.10. Atypical naevi
Although the histological features of dysplastic naevi are 
now established, clinically atypical naevi do not always
O Q # #
show these features . Recent studies have indicated that 
there may be an increased risk of malignant melanoma in 
people with many benign or "banal" pigmented naevi of the 
junctional or compound type22'40'41. In a recent Scottish 
case-control study it was shown that patients with large 
numbers of benign pigmented naevi, and those with 
clinically atypical (not necessarily histologically 
dysplastic) naevi are at increased risk of malignant 
melanoma19.
People with many pigmented naevi may be at increased risk 
of developing malignant melanoma because they have more 
pigment cells than do those with few moles. In those with 
many moles the individual pigment cells may be more 
susceptible to malignant transformation. Alternatively the 
naevus cells and melanocytes in moles may be initiated 
cells, awaiting a critical promoting stimulus which makes 
them transform and express malignant behaviour. The 
relative importance of heredity and environmental factors 
in the natural history of benign pigmented lesions has yet 
not been elucidated, and the relationship between benign 
pigmented melanocytic naevi and malignant melanoma is an 
area of active investigation.
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1.2. CUTANEOUS MALIGNANT MELANOMA: THE DISEASE
1.2.1. History
Robert Carswell (1838)42 is credited with naming 
"malignant melanoma" which had been discussed earlier as 
"la melanose" by Laennec in 1806 (cited by Pemberton43). 
It is likely that the first recorded mention of cutaneous 
malignant melanoma was much earlier, in the writings of 
Hippocrates which date from the fifth century B.C.44 
Malignant melanoma was a relatively rare tumour, becoming 
more common during this century for reasons which will be 
discussed. Only in the last three decades has our 
understanding of the biological behaviour of malignant 
melanoma become clear enough to allow it to begin to 
influence our clinical management of the disease.
The importance of malignant melanoma is not solely due to 
its rising incidence. The reputation of cutaneous 
malignant melanoma is of a sinister, capricious and 
frequently fatal malignancy. Although cutaneous malignant 
melanoma has the potential for metastasis and eventual 
fatality, early lesions have an excellent prognosis if 
managed properly.
1.2.2. Clinico-pathological classification
Four major types of cutaneous malignant melanoma are 
recognised:
1) superficial spreading melanoma
2) nodular melanoma
3) lentigo maligna melanoma
4) acral lentiginous melanoma.
The first three were described by Clark and colleagues in
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196745, and the last by Reed29'46 in 1976.
According to the hypothesis of Foulds47, malignant tumours 
acquire differing capacities for invasion and metastasis 
by sequential changes which may proceed gradually or 
abruptly, in a process known as "tumour progression". The 
biological behaviour of melanoma can be described in terms 
of the pattern of tumour progression which characterises 
each type.
1.2.3. Superficial spreading melanoma
In studies of Caucasian populations this is the commonest
type of cutaneous malignant melanoma and in the Scottish
population it accounts for 48.5% of melanomas48. Typically
the lesion is one centimetre or greater in diameter,
irregularly pigmented brown or black, with a notched 
4 Qlateral border . There may be a faint pink flare at the 
margin, representing neo-vascularisation and ectasia. 
Thicker lesions may have a palpable edge. Later lesions 
tend to have a more prominent nodular component which may 
be more or less pigmented and associated with 
ulceration, bleeding and crusting.
Superficial spreading melanoma may arise by malignant 
transformation of epidermal melanocytes or by malignant 
transformation of a pre-existing naevus50. This type of 
melanoma may exist for several years without metastasis 
occurring. It seems that the typical lesion may enlarge 
steadily at the periphery or grow radially (hence the
r
term radial growth phase) over a period of about five 
years51. During the radial growth phase the tumour is 
invasive but metastases are not apparent. The work by
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Holmes and colleagues52,53 provides evidence that the 
malignant cells tend to remain locally rather than to 
spread early and lie dormant. In these studies there was a 
low incidence of lymph node metastasis in patients whose 
primary lesions were in the radial growth phase (compared 
with patients whose lesions were in the vertical growth 
phase) and they suggested that the cells in such lesions 
were not yet capable of full-blown metastasis.
In the radial growth phase histological examination shows 
tumour in the epidermis and in the papillary dermis, with 
a prominent local immune response by lymphocytes and 
macrophages. For the diagnosis of malignant melanoma there 
must be a break in the epithelial basement membrane and 
invasion of the dermis by melanoma cells54.
At a later stage focal change in the superficial 
spreading melanoma may occur in a process named "intra- 
lesional transformation"51. When this occurs new 
populations of cells, distinct from those of the radial 
growth phase, invade the dermis deeply and the "vertical 
growth phase"55 becomes established. The vertical growth 
phase co-exists with the radial growth phase but the 
capacity for metastasis may now be manifest. The host 
cellular response is less apparent than in pure radial 
growth phase. The step-wise development of superficial 
spreading melanoma exemplifies "indirect tumour 
progression" as described by Foulds47.
1.2.4. Nodular malignant melanoma
Nodular malignant melanoma presents as a rapidly growing, 
more or less pigmented nodule. In the Scottish Melanoma
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Group experience, 22.6% of malignant melanomas are of the
A D
nodular type . They grow rapidly, becoming raised with 
loss of normal epidermal surface markings, and ulceration. 
Nodular malignant melanoma is an example of "direct tumour 
progression" because pure vertical growth phase, with full 
malignant potential, is apparent from the onset and there 
are no demonstrable intermediate appearances51. By the 
time of presentation this lesion has usually penetrated 
the dermis more deeply than a superficial spreading 
melanoma of comparable age.
1.2.5. Lentigo maligna melanoma
Lentigo maligna is the pathological term used to describe
Hutchinson's melanotic freckle (1892)56,57 and this is the
pre-invasive form of lentigo maligna melanoma.
Lentigo maligna is seen as a characteristic slowly 
enlarging brown macule on sun-exposed skin, usually the 
face of an elderly person54. Over many years there is 
centrifugal enlargement of the lesion. It is characterised 
by variable pigmentation and depigmentation, and there are 
often islands of virtually normal skin surrounded by tan 
and black areas. Histologically there are signs of actinic 
damage with an atrophic epidermis in addition to abnormal 
melanocytes. The depigmented areas may show histological 
signs of the host response or regression. Subsequent 
invasion is not inevitable in lentigo maligna, and a 
recent study suggested that the lifetime risk of lentigo 
maligna melanoma is 2% at age 6558.
Lentigo maligna melanoma is less common than the 
superficial spreading and nodular types, constituting
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14.5% of cases in the Scottish population48. There is a 
very long radial growth phase (5-25 years) and a slow
vertical growth phase51. Lentigo maligna melanoma is 
regarded by some authorities as a separate disease entity 
because of the different relationship to cumulative sun 
exposure and because it seems to have a better prognosis 
than other types of cutaneous malignant melanoma'' . 
However recent evidence from the West of Scotland suggests 
that thickness for thickness the prognosis of lentigo 
maligna melanoma is similar to the other histological
types of malignant melanoma60.
1.2.6. Acral lentiginous melanoma
This type of malignant melanoma was first described by
Reed29'46, and it is a characteristic lesion which occurs
on the extremities. Superficial spreading melanoma and 
nodular melanoma occur rarely on the palms, soles and 
subungual areas where acral (from the Greek, akros meaning 
limb) lentiginous melanoma usually develops. This lesion
accounts for 6% of cutaneous malignant melanoma in
4 8 .Scotland . Two thirds of acral lentiginous melanomas
occur on volar sites and the remainder arise in subungual
sites.
The volar tumours present clinically as an irregular brown 
or black "stain" on the palm or sole with normal skin 
markings preserved initially. During the radial growth 
phase this type of melanoma may come to occupy a large 
surface area, especially on the sole where it may not be 
noticed by the patient. Two thirds of the subungual 
lesions develop on the hallux or the thumb. A
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characteristic feature of this "melanotic whitlow" (as 
subungual melanoma was first described by Hutchinson in 
188661) is pigmentation in the nail-bed matrix with a halo 
of pigmentation in the eponychium.
In acral lentiginous melanoma the radial growth phase is 
of intermediate duration between superficial spreading and 
lentigo maligna melanoma. There is usually an exuberant 
"lichenoid" host reaction and regression is common. Intra- 
lesional transformation may occur, and the onset of a 
vertical growth phase is often an abrupt, dramatic change. 
Clinically a blue or pink nodule develops in the long­
standing lesion and metastases are common.
1.2.7. Epidemiology
The precise sequence of events which results in the 
development of cutaneous malignant melanoma has not been 
elucidated. The disease is probably caused by a 
combination of several factors. Epidemiological studies 
from around the world have begun to establish the relative 
importance of these factors.
There is clear evidence that the incidence of cutaneous 
malignant melanoma is rising in white-skinned people 
world-wide. The incidence is doubling each decade in
Scandinavia62, and quadrupling each decade in New Mexico63
64.and Arizona . Malignant melanoma is most common in the 
sub-tropical coastal area of Queensland, Australia65 where 
the annual age-standardised incidence rate (near 
population-based) is 37.2 per 100,00066 and the incidence 
is doubling there every fifteen years. The increase in 
Australia may be due to the high proportion of "Celtic"
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immigrants from Scotland and Ireland, who may be 
particularly susceptible to malignant melanoma67. In New 
Mexico63 and Arizona64 the increasing incidence is 
confined to the "Anglo11 population which is descended from 
north European immigrants.
Good epidemiological data shows that the incidence rate
of malignant melanoma is rising rapidly18 and there does
not seem to have been a parallel increase in non-melanoma 
• 6ft • . •skin cancer^ (though the epidemiological data for non­
melanoma skin cancer is less satisfactory) . It is 
important to note that the increasing incidence of 
cutaneous malignant melanoma is independent of improved 
diagnosis or certification69'70.
When considering incidence data it is important to know 
whether the figures are based on the population at large 
and reflect the true incidence of the disease. If they 
are not population-based then clinical series will tend 
to reflect the interests of involved clinicians and local 
referral patterns. Comparisons between countries may be 
impossible if melanoma is included with other skin cancers 
in the national registry.
Data from British epidemiological studies show that the 
incidence of malignant melanoma is rising in England and 
Wales71 and in Scotland48'72'73. The Scottish Melanoma 
Group has been gathering national data since 1979. In 
Scotland we are fortunate that this organisation provides 
accurate information on over 95% of the patients 
presenting with primary cutaneous malignant melanoma48. 
The incidence of malignant melanoma in Scotland has nearly 
doubled between 1979 and 1986.
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The average age of those dying from malignant melanoma is
7 0 • •falling because the incidence of malignant melanoma is
higher in people born in more recent years than in people 
born earlier this century69'74. Malignant melanoma is very 
rare in childhood but the average age at onset of
malignant melanoma is lower than that of non-melanoma skin 
cancer.
The increasing incidence could be due to greater 
susceptibility of succeeding generations to the disease, 
an increasing exposure to or increasing power of causative 
factors.
+ The most recent figures published by the Scottish Melanoma
A O
Group give annual age-standardised incidence rates of 
2.77 per 100,000 for males and 4.75 per 100, 000 for 
females. A similar female preponderance was reported in a 
previous large Scottish series75 and in English 
studies76'77. In areas of high incidence, such as
Australia, the incidence of melanoma in the sexes is
• 7 fiapproximately equal. It has been postulated that a minor 
hormonal influence may be overridden by the critical 
effects of sun exposure in Australia.
Associations have been demonstrated between malignant 
melanoma and high socio-economic status, and with indoor 
rather than outdoor workers78. These findings support the 
theory which implicates intermittent recreational sun 
exposure in the aetiology of cutaneous malignant melanoma.
Although malignant melanoma is less common overall in
outdoor workers, in this group there is an excess of 
malignant melanoma of the face, head and neck78 (where 
lentigo maligna melanoma tends to occur).
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In occupational studies an excess incidence of cutaneous
malignant melanoma has been reported among workers in a
* 7Q .chemical p l a n t a n d  specifically among workers involved
in the production of polychlorinated biphenyls (PCBs)80.
The incidence of cutaneous malignant melanoma is greatest
in white-skinned populations living in sunny climates and
the incidence generally increases with proximity to the
7 0 . .equator . In Europe however, there is a higher incidence
in the Scandinavian countries than in the Mediterranean
ft i • •countries x and this may be due to differing
susceptibility of the predominant skin types to malignant
change in these populations. In Queensland the high
incidence of malignant melanoma in the sub-tropical
coastal area around Brisbane has been attributed to
greater indulgence in coastal sun-bathing by the city-
dwellers66.
As previously stated melanin is an effective sun-screen82 
and malignant melanoma is widely considered to be less 
common in the darker skinned races than in Caucasians 
although there is a lack of good population-based 
incidence data. Several clinical studies show that a high 
proportion of melanomas which do occur in those of African 
descent tend to develop on the sole of the foot83'84'85. 
This tendency is not explained by the trauma of walking 
barefoot in the tropics because the excess risk is also 
apparent in North American Negroes84, and instead it may 
be related to the greater proportion of acral lentiginous 
melanoma in those of African descent.
In white-skinned patients the distribution of malignant 
melanomas by anatomical site seems to reflect sex
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differences of dress in relation to sun exposure. The site 
distribution of malignant melanoma has been compared with 
the distribution of melanocytes by site and there were 
apparent excesses of melanoma on the head and trunk of the 
male, and on the leg of the female86.
Among white-skinned people, those at particular risk for 
malignant melanoma include those with blond or red hair 
and who burn easily in the sun8^, those who tan poorly and 
who freckle readily after sun exposure88. These features 
are quite common in some white populations and they are 
therefore weak indicators of an "at risk" group.
1.2.8. Aetiology
Solar radiation is heavily implicated in the aetiology of 
malignant melanoma. In addition to the general trend for 
rising incidence with decreasing latitude, a correlation 
between sun-spot number and melanoma incidence has been
o q ,
demonstrated . There is a very low incidence of malignant
melanoma at sites on the body which are rarely or never
7 nexposed to sun-light . In the rare disease xeroderma 
pigmentosum, where there is defective repair of actinic 
damage to DNA with the development of multiple cutaneous 
malignancies, there is an increased incidence of malignant 
melanoma90. Swerdlow91 reported a clear jump in the 
incidence of melanoma in the Oxford area two years after 
an especially warm summer. In a Scottish study a 
correlation was demonstrated between severe sunburn and 
the development of malignant melanoma in the subsequent
qn # ,
five years . The tendency is for intermittent intense 
exposure to be associated with the development of
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malignant melanoma on the intermittently exposed sites18. 
This pattern holds for nodular and superficial spreading 
melanoma but does not apply to lentigo maligna melanoma. 
Lentigo maligna melanoma is associated with high 
cumulative exposure to sunlight and, like non-melanoma 
skin cancer5 , occurs m  the elderly. Sunlight is the 
major source of ultraviolet (UV) radiation encountered by 
the skin. In recent years there has been increasing use of 
artificial sources of UV radiation e.g. sunbeds, lasers, 
arc welding equipment and ordinary white fluorescent tube 
lights.
Ultraviolet A (UVA) radiation has a wavelength of 315- 
400nm and it penetrates the skin more deeply than 
ultraviolet B (UVB). UVB has a wavelength of 280-315nm and 
is the more active radiation, causing more tissue damage, 
despite the poorer tissue penetration. UVB with wavelength 
less than 295nm does not reach the earth's surface because 
of filtering by the layer of ozone in the stratosphere. 
The ozone layer also significantly reduces the quantity of 
UVB with wavelength 295-310nm which reaches the earth. 
There is growing evidence that the layer of ozone 
(chemical symbol 03) which absorbs UVB is being depleted 
by chlorine which is liberated from chlorofluorocarbons
Q A
(CFCs) . Chlorofluorocarbons are man-made compounds which 
are widely used as propellants in aerosol sprays and they 
are used in great quantities in industrial refrigeration 
plants. Chlorofluorocarbons have a half-life of many years 
in the stratosphere, and a single liberated chlorine atom 
may destroy thousands of ozone molecules95.
Recent evidence suggests that there is already a
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particular lack of ozone over Antarctica, a "hole" in the 
ozone layer which may act as a sink, draining the general 
level of ozone in the stratosphere94. Concern about the 
ecological consequences (including possible rise in skin 
cancer) led to the Montreal Convention which aimed to 
reduce the production of chlorofluorocarbons by half by 
the end of the 1990s96.
The initial rise in incidence of malignant melanoma
antedated the widespread use of sunbeds and solaria. In
females there has been a particular increase in the
proportion of melanomas occurring on the leg below the 
7 0knee . In males there has been an increase in the 
proportion of malignant melanomas occurring on the trunk . 
In both sexes there has been an increase in arm lesions70. 
It is tempting to blame these changes on obvious changes 
in the patterns of behaviour and dress in Caucasians 
around the world. Translucent stockings were first worn 
commonly by young women in the 1930s. Since World War II 
it has been more socially acceptable for men to work bare­
backed in the sun. During this century it has become 
generally accepted that sunlight is beneficial and that a 
suntan is desirable because it indicates good health. 
Although the weight of scientific evidence does not 
support these misconceptions, the suntan cult shows little 
sign of abating.
Sunbeds emit UVA almost exclusively but recently UVA has 
been shown both to accelerate and potentiate the 
carcinogenic potential of UVB97. Exposure to UV from 
commercial solaria may also be associated with changes in 
the human immune system98. There is not yet enough
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evidence to confirm that regular use of a sunbed is a risk 
factor for malignant melanoma18'99 but circumstantial 
evidence is strong.
The role of sunlight in the pathogenesis of malignant 
melanoma is complex but an understanding of the 
interaction between individual phenotype (e.g. eye, hair 
colour), behaviour and sunlight is emerging.
In rare instances heredity may be directly involved in the 
aetiology of malignant melanoma100. Greene and Fraumeni101 
have reviewed the heritable variants of melanoma in 
depth.
Placental transmission to the foetus from a pregnant woman 
suffering from malignant melanoma has occurred several
, *i rjp ,
times The influence of heredity on the development of
malignant melanoma is much more subtle and complex in most 
instances, and may concern the occurrence or distribution 
of benign pigmented naevi or some other unidentified 
factor. The relationship between familial malignant 
melanoma and dysplastic naevi is described in 1.1.9.
An excess risk of malignant melanoma was reported in renal 
transplant recipients (who are routinely immuno- 
suppressed) and it has been postulated103 that the 
immunosuppressed patient fails to mount an appropriate 
cellular response to malignant change in a precursor 
naevus. There is also an association between chronic 
lymphatic leukaemia and malignant melanoma104. Those with 
a previous primary melanoma are at increased risk of a 
second primary, and there may be an association between 
breast cancer and primary cutaneous malignant melanoma105.
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1.2.9. Prognosis: Staging
It is widely realised that the prognosis of a patient with 
cancer depends largely on the extent to which the disease 
has spread by the time of presentation. Generally, 
disseminated disease carries a poorer prognosis than 
locally or regionally confined disease. In order to 
describe groups of patients and compare treatments, 
systems have evolved to "stage" the disease.
One of the problems in the study of malignant melanoma is 
that different terminologies and various staging systems 
are used by different authors. In comparing published work 
on melanoma it is important to establish which particular 
staging systems have been used. Furthermore it cannot be 
ignored that the interpretation of the same staging system 
may vary from centre to centre and interfere with 
analysis106.
For most clinicians a staging system simply offers a 
shorthand description which gives an estimate of tumour 
burden, and an indication of likely prognosis. In 
compiling a database for an epidemiological study or a 
clinical trial much more is required of a staging system. 
Here the system should convey comprehensive information 
concerning the stage at diagnosis and thereafter, enabling 
detailed analysis.
The two most widely quoted staging systems are the 
original three stage system107 (Table 2) and the M.D. 
Anderson system108 (Table 3), both based solely on 
clinical information. The simplicity of the former is both 
its main attraction and its major weakness. The M.D. 
Anderson system conveys more information about the pattern
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of spread and is particularly useful in describing 
candidates for treatment by isolated limb perfusion. 
Neither system takes the characteristics of the primary 
lesion into account. In both of these systems, and in the 
more detailed T.N.M. (tumour, node, metastases) system 
recommended by the U.I.C.C. (Union Internationale Contra 
le Cancer), patients are not distributed evenly between 
the groups. Particularly in recent years there has been a 
great preponderance of patients in stage I at
1 HQpresentation . An alternative system, which addresses 
these criticisms, has been proposed110 and adopted by the 
American Joint Committee on Cancer, but it is much more 
complicated and is unlikely to be used widely, outside of 
American clinical trials.
In this thesis I will specify which staging system is used 
when appropriate.
Modern medical practice has available a multitude of 
investigations and tests which may be used by clinicians 
when assessing extent of disease. It is not ethical to 
subject a patient to any investigation which is unlikely 
to affect their clinical management, unless the 
investigation is part of a research protocol to which the 
patient has consented. In practice most patients with 
primary cutaneous malignant melanoma can be managed 
satisfactorily after a proper clinical assessment 
supplemented by a few simple and inexpensive 
investigations.
Even in the absence of specific symptoms or physical 
signs, routine postero-anterior chest X-ray and serum 
assays for alkaline phosphatase and lactate dehydrogenase
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Ill("liver function tests") -LJ--L are appropriate.
When major surgery, such as isolated limb perfusion, is 
proposed for any patient then additional pre-operative 
tests are indicated. Before embarking on aggressive 
regional therapy of any sort it will usually be 
appropriate to exclude the presence of otherwise occult 
metastases by further investigation. The "gold standard" 
at present is imaging by computerised tomography112, but 
when this is not available abdominal ultrasound or radio­
isotope scans of liver, spleen and brain may be useful. 
Nuclear magnetic resonance imaging (N.M.R./M.R.I.) and the 
use of radio-labelled monoclonal antibodies113 are new 
methods which are presently being developed and evaluated. 
In a recent study of 90 patients with newly diagnosed 
primary melanoma (Clark level III & IV, see Table 4) and 
no symptoms or signs of metastases an extensive screening 
protocol was evaluated114. The scheme included chest X- 
ray, full blood count, biochemical screening, C.T. brain 
scan and radio-isotope scans of liver, spleen and bones. 
This regime failed to detect any evidence of metastatic 
disease in any of the patients and the authors conclude 
that for patients in this category the scheme of 
investigation added nothing to clinical assessment.
If a patient has symptoms or signs suggestive of 
metastasis then investigations should be performed to 
exclude benign treatable conditions, to provide accurate 
staging for estimation of prognosis, and to plan 
appropriate therapy. Just as histological confirmation of 
the primary diagnosis is mandatory, so suspected 
metastasis should ideally be confirmed histologically.
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Pigmented regional lymph nodes in a patient with malignant
_ lie
melanoma are not always metastasesxx . Modern biopsy 
techniques, such as fine needle aspiration biopsy are 
being used increasingly in surgical oncology, but depend 
ultimately on the skills of the cytologist. At present 
open biopsy is usually required. The incidence of occult 
residual melanoma is high after "node-picking" of 
clinically positive lymph nodes116, and hence definitive 
regional lymph node dissection is preferred in these 
circumstances. The value of elective node dissection of 
clinically uninvolved nodes is discussed in I.3.5-7. In a 
world-wide review of five year survival in relation to 
stage (original three-stage system) of disease117 the 
survival rates ranged from 65-85% for stage I and 27-42% 
for stage II. A previous literature review by Mastrangelo 
and colleagues118 found reports of 55-80% five year 
survival rates for stage I, 14-39% for stage II and 0-18% 
for stage III disease.
Certain characteristics of the primary lesion are of 
particular prognostic significance (see 1.2.10.), but it 
is not surprising that once overt metastasis occurs the 
characteristics of the primary lesion lose much of their
, , , , 1 1 Q
prognostic significance-1--^.
Although loco-regional "recurrence" has been associated 
with a prognosis as bad as for distant metastases120•121, 
in one recent large retrospective series (including 1722 
extremity melanomas) patients with loco-regional 
metastases survived significantly longer than those who 
presented with systemic metastases122.
In stage II disease it appears that the number of involved
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regional lymph nodes117'121'124 is a major prognostic 
determinant.
In a large (477 patients) retrospective series from the 
South-east of Scotland, the clinical stage (three-stage 
system) at diagnosis was considered75. 88% were in stage 
I, 10% stage II and 2% stage III. It is hoped that the 
recently initiated public education campaigns will 
influence the pattern of presentation so that an even 
greater proportion of melanomas will present in clinical 
stage I .
1.2.10 Prognosis: Primary lesion
Although malignant melanoma has a reputation for 
capricious behaviour, features of prognostic value have 
been recognised for many years. Allen and Spitz, in
TOC
1953 , recognised that deeply invasive cutaneous
melanomas had a poorer prognosis than superficial lesions. 
A prognostic classification based on level of invasion 
into the dermis was first defined by Mehnert and Heard in 
1965126. The classification proposed by Clark and 
colleagues127 has been accepted internationally128, and is 
now commonly used (Table 4).
In the late 1960s Breslow was investigating the 
relationship between volume of primary tumour and 
prognosis, and he found that volume was itself unimportant 
but that tumour thickness was a good prognostic 
indicator . He defined thickness as the greatest 
vertical distance in millimetres between the granular 
layer of the epidermis and the deepest invasive cell in 
the dermis 129. The measurement is made on routine
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paraffin sections using a simple ocular micrometer. In
most situations the Clark level and Breslow thickness give
similar information ,but in comparative studies the Breslow
technique has been shown to be a more accurate guide to 
130 131prognosis
The prognostic value of Breslow thickness has been
confirmed by many authors132'130'133'134'135'136'137'138', 
and it has also been established in the Scottish 
population48. Day and colleagues have found that the 
inverse relationship between Breslow thickness and 
survival may be a step-wise relationship and they have 
proposed that the natural "break-points" for cutaneous 
melanoma are 0.85mm and 3.6mm . Other workers have 
reported "break-points" which fit the data from their own 
study populations e.g. 0.75 mm & 3mm140, 1mm & 4mm 138. In
the Scottish series the limits, 1.5mm & 3mm, were decided
• • i ft . .arbitrarily . In all series thinner lesions are
associated with fewer local recurrences and longer 
survival than thicker lesions.
The reasons why Breslow thickness is a better prognostic
guide than Clark level are clearly discussed by Schmoeckel
140. The Clark method relies more on the subjective 
judgement of the pathologist and its reproducibility is 
limited. The histological interface which separates level 
III and IV lesions (papillary and reticular dermis) is not 
distinct. Level I lesions are rarely reported, and are 
often omitted18'48 because of the difficulty in 
distinguishing between level I lesions and dysplasia. The 
good prognosis level II group and poor prognosis level V 
group both contain few patients. For the majority in level
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Ill and IV categories the survival rates are similar. 
Breslow thickness takes account of the exophytic portion 
of a nodular tumour, which may be only superficially 
invasive according to the Clark level. Pedunculated 
tumours have a reputation for being particularly 
aggressive, but Schmoeckel and colleagues135 have shown 
that exophytic and endophytic lesions have similar 
recurrence rates when Breslow thickness is similar. 
Although in general the measurement of tumour thickness 
has proved to be relatively easy and reproducible, some 
problems may arise141. It can be difficult to 
differentiate the deepest tumour cells from other cell 
types; there may be intra-epidermal spread of tumour down 
hair follicles and sweat ducts or there may be 
accumulations of naevus cells at the base. The granular 
cell layer may be absent due to ulceration. Obliquely cut 
sections do not cause significant inaccuracy unless the 
angle is greater than 22 degrees. Thus, in general the 
problems with Breslow thickness are minor and guide-lines 
for special circumstances have been provided.
Studies have shown that overall there is no additional 
benefit from combining Clark level with Breslow 
thickness130'134'140.
In recent series there is an increasing proportion of 
lesions less than 1mm thick142'143'144 and there is some 
evidence that Breslow thickness may be a less important 
prognostic determinant in patients with such thin primary 
lesions. For primary melanomas of 0.75mm or less, Clark 
levels II and III may be associated with differing 
recurrence rates135. Furthermore in most series the
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prognostic determination is made with reference to a 
database which is disproportionately loaded with thicker 
lesions145. In a regression analysis of 331 patients with 
lesions less than 1.5mm thick, it was found that tumour 
thickness had no influence on survival but females had a 
better chance of survival, and extremity tumours were 
associated with longer survival than axial lesions145. It 
will be important to know whether these results are 
reproduced in other large series of thin melanomas. As 
primary lesions are increasingly diagnosed and treated 
when less than 1mm thick, it will be important to define 
the likely prognosis for identifiable sub-groups, since 
high-risk patients are potential candidates for adjuvant 
therapies.
Histological evidence of ulceration in a primary malignant 
melanoma has been associated with a poor 
prognosis125'146•147, especially when the ulcer is wider
1 A Rthan . The advantage of this histological feature as
a prognostic determinant is that it is rather less 
subjective than some of the others.
In some studies the mitotic activity of a primary melanoma 
has shown some value as a prognostic 
indicator127'134'148'149. However, the detection of 
mitotic figures is subjective and other nuclear changes, 
or other cell types e.g. polymorphonuclear leukocytes may 
be confused with mitotic melanoma cells. The mitotic index 
is defined as the maximum number of mitoses seen in 1mm2 
of the tumour. When the mitotic index is greater than 
25/mm2 a 98% incidence of subsequent metastases has been 
reported140.
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Microscopic vascular invasion has been reported as an 
indicator of poor prognosis140'146' 147' 150 but it is rarely 
seen convincingly, its detection is time consuming and in 
at least one report138 it was of no clear prognostic 
value.
The host inflammatory response to malignant melanoma 
consists of a lymphocytic cellular infiltrate, associated 
with fibrosis and new vessels. The term "regression11 is 
sometimes used to describe these histological features, 
which are common in superficial spreading melanoma. When 
these appearances extend more deeply than the measured 
Breslow thickness of a thin malignant melanoma, it may 
indicate that the original lesion was thicker before 
regression occurred. Hence the presence of regression in 
thin lesions may be associated with subsequent metastasis 
and a poor prognosis151'152 though more recent reports 
have not confirmed these results153'154.
In clinical practice a history suggestive of partial 
spontaneous regression is common. Complete clinical 
regression is very rare, though widely recognised in 
malignant melanoma and other cancers. Everson and Cole155 
collected 176 cases of spontaneous regression, including 
20 instances in patients with metastatic malignant 
melanoma. Nine further examples in melanoma patients have 
been collected and the full series was reviewed by 
Bodurtha156. Regression of cutaneous and lymph node 
metastases was much more common than regression of 
visceral lesions. There was only one instance of 
histologically proven complete spontaneous regression of a 
visceral metastasis.
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The syndrome of metastatic melanoma from an unknown 
primary is more commonly encountered, and it is generally 
considered to be due to spontaneous regression of the 
primary lesion prior to the patient presenting with 
metastatic melanoma157. Although an earlier report158 
indicated that the prognosis is almost hopeless for 
patients like this, in the series reported by Milton and 
colleagues*1-3 the prognosis of patients with metastases 
from an occult primary had a similar survival to patients 
with metastases from a known primary.
In various reports a poor prognosis has been associated 
with histological features e.g. severe cellular 
atypia140'149, the small lymphocyte-like melanoma cell 
type140 and poorly pigmented lesions149. The 
clinicopathological subtype is not an important 
independent prognostic factor130'140'148.
1.2.11. Prognosis: Patient characteristics.
Female patients seem to have a better prognosis than males 
in many series117'136'159'160'161'162 and this has also 
been observed in Scottish melanoma patients163. As 
mentioned above, sex may be the most important prognostic 
determinant for patients with thin primary malignant 
melanomas145. Females with clinical stage I melanoma have 
a better survival than males136'160, but women with nodal 
metastases have a similar survival rate to men. In the 
Scottish series the better survival in females (especially 
in middle age) was related to thinner lesions in women and 
a preponderance of lower limb lesions163.
A better prognosis has been reported for limb lesions as
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compared with axial lesions164'165 but the W.H.O. group 
findings did not support this162. Day and colleagues 
found that lesions on the back, posterior arm, posterior 
neck and posterior scalp (B.A.N.S. regions) seemed to have 
a particularly poor prognosis166 but the significance of 
these findings is contested167.
The age of patients at diagnosis has not been shown to be 
of prognostic value
1.2.12. Prognosis: Interaction of factors
Various factors which are known to be of prognostic 
significance have been combined in attempts to enhance the 
quality of prognostic determination146'169'170. Ideally 
the factors used should each be of independent prognostic 
value. Many of the factors which have been shown to be of 
prognostic value in primary malignant melanoma are inter­
related. For example, malignant melanoma tends to occur on 
the trunk in males and on the female lower limb, is the 
favourable prognosis in women due to sex, average 
thickness or site? Several histological features derive 
their apparent prognostic importance from a strong 
correlation with Breslow thickness. To determine which of 
many interacting factors are likely to be most important a 
multi-factorial analysis is required.
Applying multi-factorial analyses to data from eight major 
centres from around the world, the most significant 
prognostic determinants for a patient with stage I primary 
cutaneous malignant melanoma were117:
(1) tumour thickness,
(2) tumour ulceration,
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(3) tumour site and
(4) patient's sex.
Overall the single most important prognostic determinant 
is Breslow thickness.
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1.3. SURGERY FOR CUTANEOUS MALIGNANT MELANOMA
1.3.1. Introduction
The surgical management of cutaneous malignant melanoma is 
controversial. In the last four decades there has been a 
proliferation of information concerning the disease and 
its natural history. This knowledge should provide a 
rational basis for therapy. In assessing the place of 
isolated limb perfusion in the management of malignant 
melanoma it is essential to consider the other treatment 
options, surgical and non-surgical.
It is vital that critical appraisal of therapeutic studies 
is made because the quality of published data and analysis 
is variable, and the conclusions drawn can be misleading. 
The great value of a population-based database has already 
been discussed, and there is no doubt that well conducted 
randomised prospective controlled trials generate the most 
appropriate data to compare treatment options. Cohort 
effects have been reported to account for changes in the 
prognosis of melanoma in succeeding generations172, and 
thus the use of historical controls is unsatisfactory.
A minority of studies are population-based, and there have 
been relatively few prospective randomised trials of 
available therapies. Although the advantages of 
prospective randomised trials in minimising bias are well 
recognised, even these can give rise to controversy.
In this section the appropriate surgical management for 
the various manifestations of cutaneous malignant melanoma 
will be discussed, based on critical assessment of the 
literature and our own experience.
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1.3.2. Primary lesion: biopsy, excision margins
Any skin lesion which the clinician suspects, or which the 
patient reasonably fears may be a malignant melanoma 
should be completely excised for histological examination. 
Rarely one or more incisional biopsies may be appropriate 
where there is little spare skin e.g. face, hands, feet or 
if the lesion is large. There is no evidence that
, i 7 0  . 1 7 1
mcisionx,J or excision biopsy induces subsequent local 
recurrence or metastases so there is no place for 
immediate wide excision on the basis of clinically 
suspected melanoma, without prior histology.
An adequate excision biopsy includes a comfortable margin 
(l-2mm) of adjacent normal tissue to minimise distortion 
of the specimen. Such a specimen gives the pathologist the 
best chance of complete histological staging174'175, 
including the Breslow thickness, and hence a more accurate 
estimate of prognosis is possible.
There is no evidence that the time interval between 
initial diagnostic biopsy and definitive wide excision 
(when indicated) has any influence on the incidence of 
local recurrence or metastases173'176'177.
The margin of normal skin which should be excised around a 
primary malignant melanoma has been the subject of both 
debate and dogma in the past. For much of this century 
"wide local excision" of the primary melanoma was 
supported and advocated on the basis of the Hunterian 
Lectures of Sampson Handley published in 1907178. 
Unfortunately this influential work was based on the study 
of patterns of spread in metastatic melanoma nodules, from 
a single post mortem study, and not on the behaviour of
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primary lesions. Furthermore Handley advised margins of 
"about an inch" from the edge of the tumour, rather than 
the more radical excisions subsequently attributed to 
him179'180.
The optimal excision margin for primary cutaneous 
malignant melanoma is still controversial, but the modern 
approach is based on an understanding of the natural 
history of the disease. As described in 1.2.10., thick 
primary lesions are associated with a greater risk of 
loco-regional recurrence and metastasis. In general it is 
accepted that thin (good prognosis) lesions can be treated 
adequately by conservative excisional
surgery181'182'183'184 and that thicker lesions require 
wider margins182'184'185'186.
Unfortunately authors have defined their terms 
differently. For some the term "local recurrence" includes 
disease in the vicinity of a scar from a previously 
excised melanoma as well as in transit metastases and
• 1 R7invasion of the regional nodesxo'. Others apply the term 
more precisely to biopsy proven recurrent malignant 
melanoma within or contiguous to the scar of a previous
, , 1 Q /
local excision104. Ackerman has indicated that "true" 
local recurrence, due to the persistence of tumour because 
of incomplete excision of a primary, is now rare188. A
1 O f) 1 O 1 .
third g r o u p s u s e  terminology which implies that 
loco-regional recurrences (including "satellite" and in 
transit lesions- see below) are manifestations of systemic 
metastatic potential e.g. "regional non-nodal metastases" 
and "local metastases".
Whether "recurrent" melanoma in the vicinity of the scar
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of primary excision is "true11 recurrence or metastasis, 
the recognition of primary lesions likely to be 
complicated in this way prompts most authorities to 
recommend wide local excision for such primaries. The risk 
of "local recurrence" has been shown in several studies to 
correlate closely with Breslow thickness of the primary 
and not with excision margins162'181'1841 187/189 *190. in 
thin primary lesions ( <0.75mm Breslow thickness) there is 
a minimal risk of "local
recurrence"126'149'162'181/182,184,186  ^ For primary
cutaneous malignant melanomas of >0.76mm Breslow thickness 
there is a greater risk of local recurrence and 
satellitosis (metastases <5cm from the site of the 
primary). In patients with lesions >4mm Breslow thickness, 
the risk is 10-20%182'184'186.
Historically the extent of "wide local excision" for 
melanoma has been the subject of dispute. Wide local 
exqision may remove occult foci of malignant cells191 and 
it may remove some of the "fertile soil" or "field change" 
which surrounds the site of a primary malignant melanoma. 
Wong showed that there were abnormal melanocytes in 
apparently normal skin up to five centimetres from the
1 n o  ,
tumour-1-^ and Cochran demonstrated increased numbers of 
melanocytes in the skin around many melanomas193.
There is however no evidence that wide local excision 
favourably influences survival and several recent studies 
have questioned the value of wide excision194'181'184'188 
by demonstrating that survival is independent of excision 
margin. This is despite the evidence of a high rate of 
local recurrence in thick primary lesions treated by
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narrow excisions compared with similar lesions treated by 
wide local excision195, and in spite of the poor prognosis 
associated with the appearance of local recurrence120'121. 
Logically, the modern approach is to tailor excision 
margins to the Breslow thickness of the primary. Hence an 
excisional biopsy with a margin of 5-10mm can be 
considered adequate treatment for malignant melanoma of 
<0.75mm Breslow thickness.
In modern practice there is general agreement that for 
primary lesions of >2mm Breslow thickness, 3cm of 
surrounding normal skin is a reasonable excision margin, 
although even this seems too radical for some185. The 
W.H.O. (World Health Organisation) recently reported a 
prospective randomised controlled clinical trial (Trial 
10) comparing excision margins in lesions <2mm Breslow 
thickness, and there was no benefit from wide margins196. 
Wide, deep excisions were routinely performed for 
cutaneous malignant melanoma in the past179, following the 
radical example of Hogarth Pringle197. However Olsen 
demonstrated an apparently increased incidence of 
metastases in patients treated by resections which 
included the deep fascia159 and it was postulated that 
this might be due to the removal of an important barrier 
to metastases. More recently Kenady showed no difference 
in "local recurrence" or overall survival whether deep 
fascia was excised or not198. Anatomically the deep fascia 
proper is only found in the limbs and neck. Excision of 
this structure where it forms part of a muscular 
attachment, or where it is blended with the periosteum 
increases the morbidity of the surgery. It is therefore
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considered adequate to excise down to deep fascia, without 
excising it, in most cases.
After conservative excisions direct primary closure of the 
wound can often be achieved. The development of modern 
plastic surgical techniques has resulted in the 
availability of a variety of possible methods of 
reconstruction after radical excisions. Although there is 
a theoretical risk, there is no evidence that primary 
closure conceals tumour to the detriment of patient
, 1 QQ
survivalA^^. Nonetheless most surgeons apply a thin split- 
skin graft to the site of a wide local excision in the 
belief that this gives the best chance of early detection 
of local recurrence200. There is no definitive study to 
commend either routine primary closure (with or without a 
flap) or routine skin grafting and the decision can safely 
be made according to technical considerations180.
In the management of primary malignant melanoma arising on 
a digit, especially subungual melanoma, amputation of the 
digit is often the most appropriate procedure. 
Papachristou and Fortner reported a 22% incidence of local 
recurrence after conservative amputations for subungual 
melanoma, and no recurrence after amputation at the 
metacarpo-phalangeal joint201. It may be possible to 
select patients for conservative amputations (e.g. 
proximal to the inter-phalangeal joint of the thumb) which 
preserve function depending on tumour size, thickness and 
stage202.
1.3.3. Loco-regional recurrence/ advanced disease
As discussed in 1.3.2. above, there is a lack of
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uniformity in the terminology used to describe loco- 
regional relapse after treatment of a primary cutaneous 
malignant melanoma.
In this thesis, unless otherwise stated, (cf. MD Anderson 
staging system, Table 3) "local recurrence" describes 
relapse in relation to the wound of primary excision, or 
skin graft? "satellitosis" refers to multiple cutaneous 
and subcutaneous metastases within 5cm of the primary 
excision? and "in transit lesions" are found in the skin 
or subcutaneous tissues between the primary site and the 
regional nodes. These definitions are somewhat arbitrary, 
and it is by no means certain that they are of prognostic 
value since these various manifestations of loco-regional 
relapse may occur together and thus the distinctions 
become blurred.
There have been no controlled trials of appropriate 
treatments for local recurrence202. The most widely 
considered options are surgical excision, isolated limb 
perfusion and radiotherapy. Although it is tempting to 
manage a solitary local recurrence by simple excision, the 
weight of recent evidence supports the view that "local 
metastases"120 or "regional non-nodal metastases"121 may 
be the harbingers of repeated recurrences, systemic 
metastases and death. As noted in 1.2.9., the prognosis 
for loco-regional recurrence is better than for systemic
TOO # '
metastases . The median survival after local recurrence 
in clinical series is between 10203 and 30121 months, and 
the ten year survival rate is between 15121 and 20%202.
We have already considered how treatment of the primary 
lesion may influence the risk of subsequent local
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recurrence (1.3.2.)* The conventional explanation for 
satellitosis and in transit metastases is that they 
develop from lymphatic spread of melanoma203. It has been 
suggested that in transit disease and satellitosis are 
related to lymphoedema after lymphadenectomy, or to 
seeding of cells after cutting across lymphatics in 
discontinuous (as opposed to in continuity) procedures204. 
There is no convincing evidence to support these putative 
mechanisms, and the patients most at risk are those with 
thick, ulcerated primary lesions and patients with lymph 
node metastases186'187'204 ' 205' 206.
The incidence of these various manifestations of loco- 
regional relapse varies from centre to centre, and it may 
seem particularly high in series reported from centres 
which attract referrals for specific treatments such as 
isolated limb perfusion.
Amputation of the limb has been advocated for recurrence
• • ? n 7confined to an extremity . There are few reports in the
literature describing the results of major amputations for
malignant melanoma. McPeak208 reported 34% 5-year survival
in 46 patients treated by hip disarticulation for
recurrent melanoma, but the amputation series of Bowers209 
on nand Cox^xu yielded 5-year survival rates of 18% and 15%. 
Major amputation is now rarely performed for advanced or 
recurrent malignant melanoma but this option may have to 
be considered when other treatments have failed and when 
the patient has distressing symptoms. The considerable 
morbidity and questionable quality of life after such 
extensive surgery encourages the application of limb- 
sparing procedures, such as isolated limb perfusion. Some
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are convinced that the advent of isolated limb perfusion 
with cytotoxics has significantly reduced the numbers of 
melanoma patients coming to amputation211'212'213'214'215. 
Objective assessment of the value of major amputations is 
complicated by confounding variables which include the 
changing attitudes of patients and surgeons to radical 
surgery for malignant disease, and the changing prognosis 
of malignant melanoma. In general it seems inappropriate 
to inflict a major amputation, which requires prolonged 
rehabilitation, on a patient whose survival is probably 
limited because of advanced disease.
1.3.4. Involved regional lymph nodes
Management of lymph nodes is an important consideration in
malignant melanoma because the regional nodal basin is the
commonest site of first metastasis121'187. In malignant
melanoma the importance of the regional nodes has long
been established. Pemberton, in 1858, advocated wide deep
excisions for primary lesions plus excision of the
regional nodes if involved43. A few years after the
influential publications of Sampson Handley178, Hogarth
1Q7 • . •Pringle introduced his radical, m  continuity excision 
of primary lesion, intervening skin ,lymphatics and 
regional lymph nodes. This kind of excisional surgery for 
cancer found favour with the generations of surgeons who 
practised Halsted's radical mastectomy for breast cancer. 
In this thesis, consideration will be restricted to the 
management of the regional nodes draining the limbs, since 
limb primaries are common, lymphatic drainage is 
predictable in the limbs and major studies have
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concentrated on this aspect.
The commonest initial presentation of metastatic melanoma 
is involvement of the nodes draining the site of the 
primary lesion. Nodes containing metastatic melanoma are 
clinically firmer, rubbery, and less tender than in 
inflammatory lymphadenopathy. Fine needle aspiration 
cytology or open biopsy may be helpful when the clinical 
findings are equivocal203, but if the nodes are clinically 
malignant then block dissection without biopsy is 
justifiable. There is no dissent about this indication for 
dissection of the regional nodes203'216'217 but there is 
debate about the extent of surgery required.
For clinically involved inguinal nodes the surgical 
options are to perform an inguinal or ilio-inguinal 
dissection. An inguinal dissection involves clearing all 
the nodes in the femoral triangle including those 
superficial to the inguinal ligament, in relation to the 
femoral vessels down to the apex of the triangle, and the 
node of Cloquet (i.e. including the deep inguinal lymph 
nodes). In an ilio-inguinal dissection the inguinal 
ligament is divided and all the above lymph nodes are 
excised in continuity with the iliac and obturator nodes. 
In patients with involved inguinal lymph nodes 25-50% will 
have involved iliac nodes as well, indicating to some that 
the ilio-inguinal operation is more appropriate and may
P1 o
offer better disease control*A°. Others have observed that 
the more radical operation may be associated with greater 
morbidity203'217, that positive iliac glands indicate a 
poor prognosis203, and that an inguinal dissection is 
sufficient when the disease appears to be confined to the
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inguinal nodes^ .
1.3.5. FOR elective lymph node dissection
The point at issue is whether there is an identifiable 
sub-group of patients with primary malignant melanoma who 
may benefit from dissection of clinically uninvolved nodes 
("prophylactic11 or "elective lymph node dissection") or 
whether dissection of the lymph nodes should only be 
performed if and when the nodes are clinically involved 
(therapeutic or delayed dissection). Even the strongest 
supporters of elective node dissection agree that only a 
selected group of patients may benefit from the 
procedure217'220.
The debate about routine elective lymph node dissection
has been usefully summarised by Balch and Milton, who
favour elective lymph node dissection, and by Cascinelli
and Sim, who prefer delayed lymph node dissection220. In a
recent review Balch has restated his position, but he
0 1 7presents no new evidence^-1- . The debate is an important 
consideration for all surgeons involved in the management 
of cutaneous malignant melanoma, because it raises many 
important questions, ranging from interpretations of the 
natural history of the disease to motives for surgical 
intervention.
The rationale for elective node dissection is based on the 
hypothesis that cutaneous malignant melanoma spreads in a 
step-wise manner, from the primary to the regional nodes 
and thence to distant sites217. If this concept is true, 
then patients with occult micro-metastases in the regional 
nodes should benefit from elective node dissection,
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because it is performed when the tumour burden is small 
and before systemic spread occurs. By the time clinically 
detectable nodal metastases are established most patients 
(70-85%) will already have distant micro-metastases124 and 
the ten year survival is around 25%. According to the 
hypothesis the aim of elective lymph node dissection is 
therefore to provide definitive treatment at an early 
stage in the natural history of the disease.
. O O f)Balch and Milton contend that Breslow thickness of the 
primary melanoma is the major indicator of the group which 
might benefit most from elective lymph node dissection. 
They argue that primary melanomas of Breslow thickness 
0.76-4mm have a high risk of occult regional metastases 
and a low risk of systemic metastases, and that this is 
the group which should benefit from elective lymph node 
dissection120' 102' 122'22lf222.
There is no evidence to suggest whether inguinal or ilio­
inguinal dissection is more appropriate in the management 
of lower limb disease by "elective node dissection. The 
major proponents perform an inguinal dissection217'222 and 
the iliac glands are spared unless the inguinal nodes are 
found to contain metastases, when an iliac dissection is 
considered appropriate.
It has been argued that lymphatic stasis (common after 
elective node dissection) may provide a favourable 
environment for the survival and proliferation of melanoma 
cells204. Furthermore immediate elective node dissection 
may result in the seeding of intralymphatic cells in 
transit which might otherwise reach and be contained by 
the draining nodes. Such a mechanism might explain in
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transit disease occurring in post-lymphadenectomy lymph 
stasis, and provides a rationale for "interval" node 
dissection. Petersen and colleagues170 found that 
"interval" node dissection, delayed more than fourteen 
days after primary excision, was associated with a lower 
incidence of loco-regional recurrence. Wanebo and 
colleagues132 and McCarthy and colleagues204 found no 
benefit from similar approaches, and the only prospective 
study which addresses this question is too small to 
provide a definitive answer223. In the absence of good 
evidence to favour "interval" elective node dissection, 
protagonists thus tend to perform definitive excision of 
the primary and elective node dissection under the same 
general anaesthetic220.
The main studies cited for and against elective lymph node 
dissection have been summarised in Tables 5-12 for ease of 
comparison.
1.3.6. AGAINST elective node dissection
Although the theory invoked in favour of elective node 
dissection is attractive, there are important objections 
to it.
Firstly, malignant melanoma does not always spread via the 
regional lymph nodes. Balch's contention that Breslow 
thickness allows prediction of site of 
metastases147'182'217 has not been confirmed. In a W.H.O. 
study of 1164 Stage I patients treated without elective 
lymph node dissection, 51% of the 516 who suffered a 
relapse within ten years of treatment suffered first 
recurrence in the regional nodes, 22% presented with
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distant metastases and 31% had simultaneous regional 
lymphatic and distant metastases . The major prognostic 
determinants of primary melanomas (Breslow thickness etc.) 
can identify patients at risk of metastases and death, but 
these criteria do not accurately predict the site of 
recurrence-1 J ' * . In Milton's own study of the site and
time of first recurrence after wide excision alone for
• 1 R 7stage I disease he excluded a number who developed 
first recurrences at multiple sites, and a significant 
minority presented first with distant metastases.
Secondly, clinical stage I/pathological stage II (i.e. 
microscopic nodal metastases) is not directly comparable 
with clinical stage II (original three-stage system, Table 
2). Protagonists^ '• of elective node dissection often 
argue that the prognosis for patients who have occult 
regional nodal metastases, diagnosed after elective node 
dissection (referred to as clinical stage 1/ pathological 
stage II), is better than the prognosis of those who have 
a therapeutic node dissection for clinically apparent 
nodal metastases (clinical stage II). It is not surprising 
that there is a survival advantage for patients with a 
microscopic tumour burden compared with patients who have 
clinically obvious malignant lymphadenopathy, since it has 
also been shown that the number of involved nodes is 
itself of prognostic value117. Although the overall 
survival figures for groups having elective lymph node 
dissection seem favourable (Tables 5-10) it does not 
follow logically that elective node dissection benefits 
all patients having the operation. This is because many 
patients treated by elective node dissection may be
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subjected to an unnecessary operation,1 since they have no 
demonstrable metastases in their excised glands, and their 
prognosis would be excellent in any case. Conversely, 
patients having therapeutic dissection all have clinically 
apparent nodal metastases and their comparatively poor 
prognosis is due to the advanced stage of their disease. 
The two major prospective randomised studies which have 
addressed the question of routine elective node dissection 
have both shown no benefit from the 
procedure223'225'226'227 (Tables 11 & 12). Even the
strongest advocates of elective node dissection agree with 
the principal finding, that not all patients with melanoma 
will benefit from elective node dissection217'220.
In the W.H.O. study (Table 11) 19.7% of those having
elective node dissection were discovered to have occult 
nodal metastases, and 24.2% of those having excision of 
the primary alone developed nodal metastases225'226 in a 
five year follow-up period. There was no significant 
difference between these two sub-groups in terms of five 
year survival.
The data from both the W.H.O. study226 and the Mayo Clinic 
study227 support therapeutic node dissection when 
required, as opposed to routine elective node dissection. 
Both of these major prospective studies of elective node 
dissection were mainly concerned with the general 
applicability of the operation and neither the W.H.O. 
study225'226 nor the Mayo Clinic223'227 study was designed 
to determine whether specific small sub-groups might 
benefit.
The W.H.O. Melanoma group study225 was initiated before
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the identification of some factors which are now 
recognised to be of considerable prognostic significance. 
Neither Breslow thickness nor ulceration was originally 
included in the stratification criteria. Balch has 
indicated that although tumour thickness splits evenly 
between the treatment arms217 in the W.H.O. study, in the 
intermediate thickness group (1.5-4.99mm) there was a 
higher incidence of ulceration in those having elective 
node dissection (52%) than in those having wide excision 
alone (19%) . However, less than 10% of the entire study 
population fell into this sub-group of patients having 
elective node dissection, and the "mal-distribution" 
occurred at random.
Balch states that in this small, highly selected group 
there may be a survival advantage from elective node 
d i s s e c t i o n ^ * a f t e r  accounting for ulceration. Even 
if this advantage in the 20% with intermediate thickness 
lesions is real it represents only a 4% improvement in the 
whole group, of whom a majority would have been subjected 
to unnecessary surgery.
Furthermore the risks of mortality and morbidity 
associated with surgical intervention cannot be ignored. 
There were two deaths in the Sydney experience of elective 
node dissection22 *^, probably occurring in the early 
experience of the operation, but it would be difficult to 
justify any adjuvant treatment with a significant risk of 
mortality today. Elective lymph node dissection is also 
associated with morbidity. In a series of 58 patients from 
Birmingham, Alabama the incidence of lymphoedema after 
inguinal node dissection was 26%, 23% developed a seroma,
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5% had a wound infection, 55 had persistent pain and 8% 
had a persistent "functional deficit"203.
In his criticisms of the multi-national W.H.O. trial
(Table 11) Balch points to differences between surgical 
treatment results and clinical staging according to
917 9 9 0 . .  . .country ' .  Variability m  treatment results could be 
explained by the small numbers contributed by certain 
centres and randomisation within the participating centres 
would mitigate the effects of variable clinical staging. 
Another possible criticism of the W.H.O. trial is that 
since only limb lesions were selected for study, 85% of 
the patients in this study were women. Thereby a group at 
particularly low risk of metastases may have been selected 
and the overall good prognosis might dilute any benefit 
from elective node dissection. Breslow228 compared the
mortality rates of patients in the W.H.O. study with those 
from patients in the study of Wanebo and colleagues132
(Table 10), where there was twice the proportion of men. 
This comparison showed that thickness for thickness there 
was no significant difference in survival, and the W.H.O. 
group had a particularly high proportion of lesions 
thicker than 3mm.
In the Mayo Clinic trial223'227 (Table 12) there were few 
patients in the categories which Balch and colleagues 
consider likely to benefit from elective node dissection. 
In both prospective trials (Tables 11 & 12) there was
careful follow-up of the group managed by wide local 
excision alone, to facilitate the early detection of any 
regional nodal metastases. In the W.H.O. trial the overall 
ten year survival was 15-20% for patients needing a
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• 0 0 f\ •therapeutic node dissection . Those patients with a
single positive node at therapeutic dissection had a 44% 
ten year survival, and this is an incentive to the early 
detection and treatment of nodal metastases when elective 
node dissection is not practised. Clinical accuracy in the 
diagnosis of metastatic lymph nodes is poor. Gumport and 
Harris229 noted clinical under-diagnosis of 29% 
(clinically negative/histologically positive) and over­
diagnosis in 23%.
Balch argues that the incidence of nodal micro-metastases 
is as high as 60% in patients with intermediate thickness
0 17
primary melanoma (1.5-4. 9 9 m m ) . From the W.H.O. data he 
argues that, because 56% of patients treated by excision 
alone for lesions in this category subsequently required 
therapeutic lymph node dissection, this figure gives an 
estimate of the true incidence of nodal metastases at the 
time of treatment of the primary. The fallacy in this 
argument is that there is no reason to suppose that all 
subsequent nodal disease is the result of micro-metastases 
dating from or before the time of treatment of the 
primary. At least a proportion of nodal metastases will 
develop as a result of delayed spread from loco-regional 
or distant sites. Balch1s theory derives some support from 
the 42% incidence of occult nodal metastases in elective 
node dissection specimens, serially sectioned and reported 
in retrospective studies by Lane and colleagues in 
1958230, and Das Gupta in 1977231. However in the patients 
treated by elective node dissection in the major 
prospective studies we have seen that the incidence of 
nodal micro-metastases is 19.7% overall in the W.H.O.
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trial226 (21% in the intermediate thickness group) and 6% 
overall in the Mayo Clinic trial227.
The studies performed by Balch and Milton, and cited by 
them in favour of elective node dissection168'221'2 2 2 1 7  
are described in the later publications as "prospective 
but non-randomised" trials. Unfortunately this is not an 
accurate description of their impressively large clinical 
series. In both the Alabama and the Sydney series a 
significant proportion of the data was retrospectively 
culled from case records, and in the "prospective" parts 
of these studies the criteria which were actually used to 
select patients for elective node dissection are not 
clearly defined. The University of Alabama- Melanoma 
Registry began in 1975168 but includes patients treated 
since 1955. The Sydney study comprises patients treated 
from 1950-1980 and its retrospective nature is made clear
• • • ?  ? i .m  an early publica t i o n ^ b u t  it is described differently 
in later papers168'203'217'220.
O OQ , .
Breslow'1 has indicated that the literature concerning 
elective lymph node dissection prior to 1977, including 
some of his own work, is very difficult to evaluate 
because the studies were retrospective and liable to bias 
in patient selection. Breslow found, on reanalysing the 
data from his 1975 paper232, that his surgical colleagues 
had been selecting patients for elective node dissection 
because they had limb lesions, rather than axial lesions 
which had a less predictable lymphatic drainage. In 
addition none of the Clark Level V lesions had elective 
node dissection. Inadvertently the surgeons had thus 
selected the patients with the best prognosis for elective
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node dissection.
This kind of problem appears again in the retrospective 
study of Reintgen and colleagues (Table 8)222, where 
patients were referred by thirty different surgeons for 
adjuvant therapy after initial surgery. A minority of 
patients actually had elective node dissection and there 
was a bias towards elective node dissection for limb 
lesions. As in the work of Balch and Milton the problem of 
selection bias is partly dealt with by retrospectively 
analysing the patient groups after stratification 
according to dominant prognostic factors revealed by 
multi-factorial analysis221. Statistically this is less 
satisfactory than prospective randomisation with 
stratification. None of these studies can deal with the 
improvement in prognosis which has occurred in recent 
succeeding decades.
Such criticisms do not render the studies supporting 
elective node dissection null and void, but they serve to 
emphasise that conscious and unconscious bias can corrupt 
retrospective studies. An alternative way for the vocal 
protagonists of elective lymph node dissection would be to 
present the truly prospective parts of their series as 
separate "trials", since presumably selection criteria 
were used to allocate patient to the different treatments; 
but to date this information is not available.
1.3.7. Elective lymph node dissection: Conclusions
The evidence of the two major prospective randomised 
studies (Tables 11 & 12) suggests that there is no overall 
survival advantage conferred by elective lymph node
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dissection, but this conclusion is not accepted by the 
proponents of the procedure who cite large, mainly 
retrospective, series (Tables 5-10) to support their 
position. A proper answer to this important question 
should emerge from the trials of elective lymph node 
dissection in sub-groups of Stage I melanoma patients, 
which have been activated by the National Cancer Institute 
of the U.S.A. (primary melanomas l-4mm Breslow thickness) 
and by the W.H.O. Melanoma Group (trunk lesions >2mm 
Breslow thickness). Until the results of these studies are 
forthcoming a clinician must manage patients on the basis 
of his interpretation of the available evidence.
Any advantage due to elective node dissection is likely to 
be small, even in selected sub-groups. For this reason, 
and because the risks of significant morbidity in the 
majority of patients who do not need the operation are 
considerable, I favour a policy of therapeutic rather than 
elective node dissection.
Evidence is emerging which may explain why, in both 
malignant melanoma and breast cancer233, treatment of the 
regional lymph nodes fails to influence survival. It is 
now known that lymphatico-venous anastomoses often by-pass 
lymph nodes, and there are naturally occurring channels 
which allow intact cells to pass through lymph 
nodes234'235. Thus, cancer cells may disseminate 
simultaneously by the blood-stream and lymphatic pathways, 
and hence lymph node metastases can be considered 
"indicators, but not governors" of survival234.
Furthermore studies have shown that the demonstration of 
circulating malignant cells236, nodal malignant cells233,
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and even distant micro-metastases237 are not invariably 
associated with clinical metastases or death. Therefore 
there is no inevitable advantage from excising nodes 
containing micro-metastases.
There is no evidence from the trials discussed that the 
removal of healthy nodes confers any advantage or 
disadvantage to the patient with malignancy.
If there was an effective adjuvant therapy for cutaneous 
malignant melanoma, then (as in breast cancer) elective 
node dissection might be justified as a sampling 
procedure for staging.
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1.4. NON-SURGICAL TREATMENT OF MALIGNANT MELANOMA
1.4.1. Introduction
The only treatment which reliably cures patients with 
cutaneous malignant melanoma is surgical excision of thin, 
low-risk lesions. Once a patient with cutaneous malignant 
melanoma develops systemic metastases cure is unlikely. At 
this late stage the priorities of treatment should be to 
relieve symptoms, improve quality of life and prolong of 
survival.
For all stages of cutaneous malignant melanoma many 
different modes of therapy have been tried to improve 
prognosis. When a variety of treatments are advocated for 
a disease it usually means that none of the treatments are 
entirely satisfactory. The role of excisional surgery for 
early disease is beyond dispute, save for details of 
extent, and in many early cases no other treatment is 
necessary. Sadly for patients with advanced disease, there 
are many possible treatment options using a range of 
modalities, but few treatments are of proven efficacy, and 
several are associated with significant toxicity.
We have seen that the risk associated with a primary 
melanoma can be quantified according to Breslow thickness 
(1.2.9.). Both loco-regional recurrence and distant 
metastases are associated with a poor prognosis. The 
challenge for clinicians is to develop effective (and 
ideally non-toxic) treatment strategies which will improve 
the prognosis of patients who are likely to develop, or 
who already have developed advanced disease.
As in breast cancer therapy, some treatments which show 
benefit in advanced disease have been used as "adjuvants"
76
to surgical excision of a high-risk primary malignant 
melanoma, in the belief that such treatments are more 
likely to have a greater benefit when the tumour load is 
less (see also 1.4.6). In animal models it is recognised 
that the failure of macroscopic disease to respond to 
chemotherapy does not automatically predict a similar 
failure of micro-metastases to respond to the same 
drug240. Macroscopic tumour nodules may be more resistant 
to treatment because of their smaller growth fraction and 
poorer blood supply.
The balance of evidence concerning adjuvant therapy for 
breast cancer has recently been pooled and scrutinised in 
a meta-analysis, with the result that survival benefit has 
been established for adjuvant chemotherapy in pre- 
menopausal women^ . A major problem is that to establish 
such benefit requires the study of large numbers of 
patients in trials of many years duration, because of the 
long natural history of diseases like breast cancer and 
cutaneous malignant melanoma.
1.4.2. Advanced disease: Systemic chemotherapy
There are no universally accepted treatments for systemic 
melanoma metastases and clinical decisions have to be made 
on an individual basis. Obviously the patient and 
relatives should have an appropriate understanding of the 
situation, and they will require support no matter how the 
patient's disease is managed.
In the absence of a curative treatment it may be 
inappropriate to offer active therapy with available 
modalities to patients who are asymptomatic, elderly or
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terminally ill. If the aims of treatment for a particular 
patient are realistic, and risks or toxicity are 
acceptably low, then active treatment may be appropriate. 
Few effective chemotherapeutic agents have been discovered 
for malignant melanoma, and even the strategy of combining 
active agents has proved largely disappointing in this 
disease242.
As in the consideration of surgical treatment options, the 
literature concerning chemotherapy for malignant melanoma 
is replete with studies which fall short of established 
ideals for clinical trials. Again the "gold standard" for 
assessing the value of any proposed treatment is the 
prospective randomised controlled clinical trial with 
survival, rather than "response rate" as the end point. 
All too often the early promise of new agents in 
uncontrolled studies has not been confirmed when the same 
treatment is subjected to the rigours of a prospective 
controlled trial in comparison with established regimens. 
Unfortunately, the prospective trials which have been 
performed are often subject to the criticism of small 
sample size, which may preclude the detection of small but 
significant differences between regimes243. Rarely is 
valid survival data available for assessment.
The agent which is widely regarded as most effective in 
the treatment of malignant melanoma is dacarbazine (5- 
[3,3-dimethyltriazeno]-imidazole-4-carboxamide; DTIC)244. 
The details of dose and schedule vary from study to 
study245'246, but the overall (complete plus partial) 
response rates are fairly consistent in the range of 14- 
25%243'247'248'249. There are very few complete responses
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247,248 an(j reSponses are often transient250.
There are various toxic side effects associated with 
dacarbazine therapy250. Significant gastro-intestinal 
toxicity is common, and marrow toxicity is dose limiting 
in the short-term. Unlike the nitrosoureas (see below), 
which may cause cumulative marrow damage leading to 
irreversible marrow failure, dacarbazine marrow toxicity 
usually recovers rapidly.
It has been reported that women respond more frequently 
than men, and that cutaneous and nodal metastases are more 
likely to respond than visceral metastases248'251'252'253. 
It has been reported that patients who respond to 
chemotherapy live longer than non-responders252'253. It 
can be argued that response to chemotherapy is associated 
with, but not causally linked to the improved prognosis. 
Vindesine (desacetyl vinblastine amide sulphate) was 
first reported as a promising single agent for patients 
with advanced malignant melanoma by Retsas and 
colleagues254'255. In these early studies the objective 
response rate was 24%, and similar results were obtained 
in a Scottish Melanoma Group study256. In this latter 
study a 26% response rate was achieved, with 17% complete 
remissions. Responses were longer lasting than in previous 
studies. Furthermore these results were achieved with 
less toxicity than is associated with DTIC. In particular 
gastro-intestinal upset was relatively infrequent and 
mild.
In conventional doses the alkylating agents (melphalan, 
cyclophosphamide, chlorambucil etc.) produce modest 
response rates244. From the early days of chemotherapy
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with alkylating agents it was recognised that the major 
dose limiting toxicity was myelosuppression257'258. 
Various strategies have been developed in order to
circumvent this problem (including isolated limb 
perfusion) . The practice of high dose systemic 
chemotherapy and autologous bone marrow rescue was 
pioneered by Ariel and Pack259. McElwain and 
colleagues260'261 have shown that the response rate can be 
boosted to 70% using very high doses of melphalan and 
intensive support, including autologous bone marrow
transplant. Unfortunately these responses were of short 
duration, but the results indicate that regional delivery 
or effective targeting to tumour may be ways of exploiting 
the potential of melphalan.
Melphalan is discussed in much greater detail later in 
this thesis (Chapters III & IV) because it is currently
the agent of first choice in the treatment of malignant
melanoma by isolated limb perfusion.
Anti-metabolites. including high-dose methotrexate 
regimens262'263, have not yielded encouraging response 
rates in malignant melanoma.
The nitrosoureas. including lomustine (CCNU), carmustine 
(BCNU) and semustine (methyl-CCNU), were once considered 
as suitable single agents242, but they have been replaced 
by newer, less toxic drugs like vindesine and DTIC. 
Cis-platinum is an active single agent264 which has been 
incorporated into recent combination chemotherapy 
regimens.
Despite the large number of studies, there is no 
prospective controlled clinical trial of adequate size242
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which conclusively demonstrates the superiority of any 
combination chemotherapy regime compared with the same 
drugs used singly for advanced malignant 
melanoma262' 262' 2i42' 266' 266 ^
The lack of proven long-term benefit, and potential for 
toxicity, should preclude the use of systemic chemotherapy 
outwith clinical trial protocols.
1.4.3. Advanced disease: Hormonal therapy
There is an apparent hormonal influence over the human 
melanocyte system, both in health e.g. chloasma of 
pregnancy, and in disease e.g. female survival advantage 
in melanoma. In spite of early studies suggesting that 
non-toxic anti-oestrogen therapy with tamoxifen may be of 
benefit, many subsequent studies demonstrated a very poor 
response r a t e ^ 2,244« Pituitary ablation has been 
unsuccessful267.
Corticosteroids, especially dexamethasone, are of proven 
value in relieving symptoms and signs due to raised 
intracranial pressure from brain metastases268. They can 
thus provide good palliation, but have no specific anti­
melanoma activity.
1.4.4. Advanced disease: Radiotherapy
Malignant melanoma has long had a reputation as a radio­
resistant cancer. In an early, oft-quoted study269 there 
was a response rate of only 2.5% in patients with advanced 
disease, but precise details of the radiotherapy regimes 
used were not given. In recent years a greater 
understanding of the radio-biology of melanoma has led to
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modified dose schedules which have resulted in more 
encouraging results.
Habermalz and Fischer270 showed that large fraction sizes 
produced greater response rates in the radiotherapy of
malignant melanoma. Similar results were reported by
2 71 . .Hornsey^ x who explained this m  relation to the large
capacity of melanoma cells to repair sub-lethal damage.
Considering the radiation dose/survival curve for melanoma
cells, there is a broad "shoulder11 during which sub-lethal
radiation damage is repaired by the cells272, and only at
relatively large doses is there a linear relationship
between increasing dose and cell kill. High doses per
fraction overwhelm the cell's capacity to repair sub-
7 7lethal damage .
"Resistance" to radiotherapy may also be partly explained 
by the presence of high levels of superoxide dismutase 
associated with melanin granules274. This enzyme 
scavenges, and inactivates, the free radicals which are 
produced by ionising radiation and which cause cell 
damage275. Superoxide dismutase therefore removes the 
active agents, and larger doses may be required to
overcome this. Furthermore there is evidence that in
larger tumours there are cell compartments which are
relatively hypoxic and resistant to radiation274. 
Retrospective clinical series have confirmed that high 
dose per fraction regimes may produce significantly 
greater response rates than can be achieved with 
conventional fractionated radiotherapy, without excess 
toxicity to normal tissues276'277. However other clinical 
studies suggest that large fraction size does not
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help278'279. In a recent study the authors concluded that 
large fractions may be of value in the treatment of 
superficial metastatic melanoma280, but the proximity of 
node masses and visceral metastases to sensitive 
structures could result in considerable morbidity when 
large fractions were used to treat these lesions. 
Palliative external beam radio-therapy is often used for 
symptomatic bony metastases and may be used for inoperable 
soft tissue masses.
Radiotherapy has also been applied as part of some studies 
of multi-modality therapy for malignant melanoma. The role 
of hyperbaric oxygen, radio-sensitisers (e.g. 
misonidazole), hyperthermia, immunotherapy and
chemotherapy in combination with radiotherapy has been
7 7 4. • .reviewed by Brascho . There is no convincing trial
evidence to suggest that any particular radiotherapy
combination should be applied routinely. Further studies
are indicated, and some are in progress.
Diagnostic lymphangiography was developed by Kinmouth and 
Taylor in the 1950s281, and the technique of intra­
lymphatic injection was soon applied for the 
administration of diagnostic and therapeutic isotopes. The 
rationale for endolymphatic radiotherapy is based on the 
selective accumulation of isotope plus vehicle (e.g. 
lipiodol) in regional lymph nodes. Various isotopes have 
been used including 198Au, 131j and more recently 32P.
Theoretically this treatment should be most advantageous 
in those patients at high risk of harbouring nodal micro- 
metastases (cf. other adjuvants, 1.4.6).
In a prospective randomised trial comparing standard
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surgical treatment with surgery plus endolymphatic 
radiotherapy, in the management of Stage I melanoma, there 
was no significant ten year survival benefit from 
endolymphatic therapy282. This was in spite of an apparent 
reduction in the incidence of nodal metastases in the 
latter group. A major problem with this technique is that 
macroscopic tumour causes distortion of the lymph nodes 
with uneven distribution of isotope and inadequate 
irradiation where it is most needed. In the M.R.C. 
(Medical Research Council) trial there was a 35% rate of 
technical failure of injection. This elegant technique is 
not widely practised.
1.4.5. Advanced disease: Immunotherapy
This is not the place for a detailed critique of the 
immunology of malignant melanoma. Good reviews of the 
topic are provided by Peter283 and Mastrangelo and
T O  A
colleagues .
The rationale for immunotherapy with agents like Bacille 
Calmette Guerin (BCG) or Corynebacterium parvum (C.Parvum) 
is that there are specific tumour associated antigens on 
melanoma cells. These antigens normally produce a weak 
immune response, and melanoma patients seem to have a 
reduced immune response. Vaccination with non-specific 
antigens, like BCG or C.Parvum can produce a demonstrable 
increase in the antibody response to melanoma antigens, 
and the ultimate aim of immunotherapy was to translate 
this into survival benefit285.
Specific immunisation with irradiated melanoma cells, or 
with melanoma antigens, and combinations of
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immunostimulation with chemotherapy and radiotherapy have 
also been used283.
Despite early promise the later trials of non-specific and 
specific immunotherapy have been disappointing, and in 
some clinical studies the results have suggested that 
active immunotherapy may have enhanced tumour 
growth ' .  Systemic chemotherapy plus non-specific 
immunotherapy (chemo-immunotherapy) using C.parvum is not 
effective in the treatment of metastatic malignant
poo , , ,
melanoma^0 . Although mtra-lesional injection of BCG may 
cause regression of injected dermal nodules there is no 
significant effect on subcutaneous nodules, lymph nodes or 
visceral metastases284.
Overall the initial promise of immunotherapy has not been 
fulfilled.
Recent emphasis in the field of immunotherapy has been on 
the use of monoclonal antibodies and biological response 
modifiers. Monoclonal antibodies may be used for targeting 
drugs or radio-isotopes against melanoma but this approach 
is still largely experimental244. Initial trials with 
interferons (with and without adjuvants like cimetidine) 
have produced low response rates289'290. Early results 
with lymphokine-activated killer T-cells (LAK-cells), 
produced by stimulating the patient's T-cells in vitro 
using interleukin-2 (IL-2), seem to offer a new approach 
to immunotherapy in advanced malignant melanoma291. This 
regime is however relatively toxic and it is not as yet 
widely available. The same team of workers have recently 
reported that autologous tumour-infiltrating leukocytes 
(TILs) may be effective in producing regression of
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advanced melanoma, though the response may be short­
lived292.
1.4.6. Adjuvant therapy: Principles
We have seen that surgical treatment is central to the 
management of cutaneous malignant melanoma, and that the 
treatment of advanced disease is unsatisfactory. The 
concept of multi-modality treatment is of proven value in 
animal models and in certain human cancers (e.g. seminoma, 
osteosarcoma). In the animal models the best results have 
been obtained by combining an effective local treatment, 
usually surgery, with systemic treatment e.g. 
chemotherapy, or occasionally immunotherapy.
Schabel reported improved survival in tumour-bearing 
animals treated by surgery plus adjuvant chemotherapy, 
compared to animals treated by surgery alone240'293. 
Similar results have been reported by Balch and Maddox294. 
General principles for adjuvant therapy which have emerged
. . . oocfrom this kind of animal work^OJ are
a) that the efficacy of the regime is greatest when the 
tumour burden is least,
b) occult micro-metastases are more sensitive to 
chemotherapy than larger tumours,
c) treatments which are effective against advanced 
disease are more active against residual metastases after 
excision of apparent disease, and
d) lethal metastatic disease may arise from a solitary 
malignant cell, and therefore curative treatment usually 
requires eradication of all tumour cells.
Applying these principles to the clinical situation in
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patients with malignant melanoma it is likely that the 
patients who should benefit from adjuvant therapy are 
those with occult micro-metastases at the time of primary 
treatment. We have seen that the patients at highest risk 
of bearing occult systemic micro-metastases are those with 
thick primary lesions 1 6 8 '2 2 1 '2 9 5 f and patients with 
involved lymph nodes 124'226.
1.4.7. Adjuvant therapy: Clinical results
Based on the results of treatment of advanced disease, 
dacarbazine has usually been part of the adjuvant 
chemotherapy regimes. In spite of the evidence from animal 
models and encouraging results in other cancers, the 
results of adjuvant chemotherapy for malignant melanoma 
have been poor. In two representative prospective 
randomised studies296'297, no significant benefit was 
demonstrated for surgery plus adjuvant chemotherapy 
compared with surgery alone. In the former study the group 
receiving dacarbazine seemed to have a lower survival, and 
in the latter (W.H.O.) study 18% of patients had to have 
chemotherapy stopped or the dose reduced because of toxic 
side effects. Other drugs and combinations have been 
studied but they are similarly disappointing285.
In a prospective randomised study of Stage II (original 
three-stage system) patients, lymphadenectomy alone was 
compared with surgery plus adjuvant radiotherapy to the 
node-bed298. There was no significant difference between 
the groups in terms of disease control or survival. This 
was to be expected because the risk of recurrence in the 
node-bed after surgery alone is low. There have been no
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other significant prospective trials of adjuvant radio­
therapy.
The results of clinical trials of surgery plus adjuvant 
immunotherapy or chemo-immunotherapy ^have shown no 
convincing benefit from these forms of adjuvant 
treatment297'285.
1.4.8. New drugs, alternative strategies
The rationale for amino-acid derivatives of the nitrogen 
mustards, like melphalan, was to exploit the unique 
biochemical pathway for melanin synthesis which usually 
persists in malignant melanocytes299. Tauromustine (TCNU) 
is an interesting new agent comprising a nitrosourea 
linked to the amino-acid taurine (cf. melphalan, III.1.). 
This drug has a^ remarkably short half-life, and can be 
given orally to out-patients. In a recent study of 
tauromustine therapy in advanced melanoma the overall 
response rate was 16%, no better than other 
nitrosoureas300. In a comparative trial oral tauromustine 
yielded results comparable to intravenous mitozolamide 
(overall response rates 9 and 12%)301. These new drugs 
seem to be no more effective than dacarbazine.
One approach to specific targeted melanoma therapy 
involves the use of agents like 4-hvdroxvanisole which is 
a 11 false precursor" converted by tyrosinase to toxic 
metabolites302. Alternatively, the selective accumulation 
of radio-labelled thiouracil by melanoma cells, and 
incorporation of the agent into the melanin synthetic 
pathway suggest a possible role for thiouracil in targeted 
radiotherapy303. "Neutron capture therapy" is an exciting
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concept which depends on the fact that a non-radioactive
isotope of boron (10B) absorbs thermal neutrons with the
• • • 10 •emission of short range a-particles. J,WB conjugates may be
selectively accumulated by melanoma, and subsequent
external irradiation may produce selective kill of
melanoma cells without injury to surrounding tissues304.
Occasionally there is a need for a simple, atraumatic 
method of dealing with a superficial tumour. In an elderly 
or unfit patient, for example, extensive or risky surgical 
procedures may be inappropriate and topical therapy is an 
option. Intra-lesional thio-tepa305, cryotherapy203 or
i
topical azelaic acid306 are alternative methods which have 
been reported to be simple and effective.
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1.5. ISOLATED LIMB PERFUSION: REVIEW
1.5.1. Rationale
In general, modern cancer chemotherapy involves the use of 
the maximum dose of drug to achieve the greatest 
anticancer effect, without inducing intolerable toxicity. 
Such toxicity limits the dose which can be administered 
and thereby limits the clinical usefulness of the drug. 
The relationship between beneficial and detrimental 
effects of any treatment can be described as the 
therapeutic ratio.
In malignant melanoma few chemotherapeutic agents are
effective, and even for effective treatments the
therapeutic ratio is low. The melanoma cell seems to
possess inherent resistance to drugs which are active
against other malignancies. This resistance (cf.
resistance to radiation, 1.4.4.) may be partly due to the
melanoma cell's ability to accumulate sub-lethal damage
and to repair potentially lethal damage244'307. It has
also been calculated that in melanoma a relatively small
proportion of the malignant cells are actively 
o n s .
dividingJUO (i.e. low growth fraction), favouring the 
repair mechanisms which are most effective in the non­
dividing (Gq ) cells.
A potentially effective drug may also fail because of 
restricted access .of drug to the site of action, for 
various reasons*-^ . Increasing the local concentration of 
drug in the vicinity of tumour should enhance the 
anticancer effect, by increasing tumour uptake (unless 
this is saturable) , and overwhelming the capacity of the 
cell's repair mechanisms. It is clear that simply
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increasing the systemic dose to achieve this will 
eventually result in dose-limiting systemic toxicity. In a 
Phase I clinical study of an anticancer agent the aim is 
to define the maximum safe dose by planned incremental 
dose escalation, until dose-limiting toxicity is observed. 
The dose-limiting toxicity for systemically administered 
melphalan in the treatment of malignant melanoma is 
myelosuppression, which may be partly circumvented by 
autologous bone marrow transplant261'310.
When malignant melanoma is regionally confined, isolated 
limb perfusion is a rational strategy whereby a high dose 
of melphalan can be confined to the treated region, 
sparing the patient from systemic toxicity, and thus 
maximising the therapeutic ratio. Using an extra-corporeal 
pump oxygenator the circulation to a tumour bearing region 
is functionally isolated from the rest of the body and 
high concentrations of cytotoxic agent can be generated 
within and restricted to the limb (Fig.3).
Although high doses and concentrations are fundamental to 
the rationale, no Phase I studies have been previously 
performed in the isolated limb perfusion setting, and dose 
schedules have evolved empirically.
During isolated limb perfusion the physio-pharmacological 
conditions in the treated limb are uniquely well 
controlled, compared with systemic administration. It is 
clear that, in this setting, hepatic and renal handling 
of administered drugs is largely irrelevant, but the 
volume and constitution of perfusate, and the temperature, 
flows, pressures and pH in the circuit may influence the 
bio-availability and efficacy of the cytotoxic drug.
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1.5.2. History
In 1946 Gilman and Philips311 showed that nitrogen 
mustards cause regression of tumours in experimental 
animals. Clinical trials indicated that toxic effects on 
bone marrow limited the dose of nitrogen mustard which 
could be given to patients312'313. At doses which could be 
given safely the therapeutic effect on tumours was 
transient.
In 1950 Klopp258 and Bierman314, working independently, 
showed that by injecting nitrogen mustard into the artery 
supplying a tumour a greater effect on the tumour was seen 
with less marrow suppression than occurred after 
intravenous injection of the same dose. Klopp and 
colleagues258 found that these beneficial effects were 
further enhanced by a proximal tourniquet which blocked 
venous return but permitted arterial inflow.
When phenylalanine mustard (melphalan) was developed it 
was hoped that the phenylalanine moiety would become 
involved in the melanin synthetic pathway in melanoma 
cells (III. 1.1.), and that the drug might therefore have 
some selective effect on these cells299. In 1956 Luck315 
showed that melphalan was the most effective agent 
available to inhibit the growth of the Harding-Passey 
mouse melanoma in vivo. In spite of this early promise 
melphalan is no longer the agent of first choice for 
systemic chemotherapy of malignant melanoma (1.4.2.) 
but it is the drug used most widely for isolated limb 
perfusion.
pep
Klopp and colleagues had considered the use of an 
extra-corporeal circuit with a pump/oxygenator (such as
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that used in open heart surgery) to maintain viability of 
the perfused region during prolonged administration of 
chemotherapy, but the technique was not applied until 1957 
in the report of Ryan and colleagues316. They had 
successfully isolated and perfused the liver, mid-gut and 
limbs in experimental dogs. Ischaemic changes were seen 
after ninety minutes of isolation/perfusion, probably due 
to low flow rates and relatively low perfusion pressures. 
In 1958 Creech, Krementz, Ryan and Winblad of Tulane 
University in New Orleans reported the first clinical case 
treated by isolated limb perfusion with melphalan317. The 
patient was a 76 year old man with satellitosis and in 
transit disease of the leg, two years after a wide 
excision and superficial groin dissection for a primary 
malignant melanoma of the skin at the ankle. At a time 
when systemic chemotherapy produced partial responses in 
less than 10% of patients with malignant melanoma318 this 
man had a complete and permanent remission following 
isolated limb perfusion.
By 1961 the originators of the technique had treated 242 
patients with regional perfusion of various sites in the> 
body affected by different tumours319. Around the world 
other clinicians began to apply regional perfusion in the 
treatment of cancer.
Early U.K. experience was reported by Garai and 
colleagues320 of the Royal Marsden, Westbury of the 
Westminster Hospital321, and Irvine and Luck of St. Mary’s 
Hospital322. In common with others323'319, Westbury found 
that isolation of a limb was more satisfactory than 
visceral isolation, and that malignant melanoma responded
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more convincingly than other tumours. Novel features of 
Westbury's technique at that time included "high flow 
rates" (150-2OOml/min), high oxygen tension and 
hyperthermia of the perfusate. It was reasoned that with a 
"high" flow rate there would be "a more efficient 
distribution to the periphery". Pure oxygen fed the 
oxygenator because the "radiomimetic" drug melphalan might 
be enhanced by this, in the way that therapeutic radiation 
had been enhanced in the studies of Gray324. The 
temperature of the perfusate was raised to 41°C to 
increase the "speed of reaction" of melphalan and increase 
the "utilisation of the drug and consequently decrease the 
spill-over when isolation is incomplete". I will consider 
the importance of flow rates, oxygenation and temperatures 
in more detail in the subsequent chapters.
In 1961, Rochlin and colleagues325 had suggested that at 
temperatures greater than 37 °C the alkylating agent 
triethylene thiophosphoramide (thiotepa) was more rapidly 
bound by tissues, although their results hinged on an 
indirect assay and may have been explained by increased 
breakdown of the drug at higher temperatures.
Cavaliere and colleagues later reported that hyperthermic 
perfusion alone (without any cytotoxic drug) may 
selectively kill cancer cells326. They showed that in 
vitro Novikoff hepatoma cells and Ehrlich ascites cancer 
cells (both established tumour cell lines) consumed much 
less oxygen at 42 °C than at 38°C. There was little 
difference in respiration comparing normal hepatocytes and 
regenerating liver at these temperatures. In the clinical 
part of their study 22 patients had 25 regional perfusions
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at temperatures from 41.5-43.5°C for several hours without 
cytotoxic drugs. There were six deaths and three 
amputations due to complications. Three tumours failed to 
respond and four patients could not be evaluated. However, 
ten tumours "disappeared" and histological evidence of 
"complete massive necrosis" was seen in tissue from eight.
The group which seemed most responsive comprised seven
melanoma patients, of whom four were alive with a 
functional limb at 28 months after heated perfusion. These 
are indeed interesting observations, but the results do 
not suggest that hyperthermic perfusion is an appropriate 
palliative treatment, because of the unacceptable peri­
operative mortality and morbidity.
Following this work, Stehlin adapted his perfusion method 
to administer heat with melphalan in an effort to exploit 
potential "synergy"327. His report also mentions an 
increase in duration of perfusion from 45 to 120 minutes, 
as well as the addition of hyperthermia to the regime. 
There was a conspicuous improvement in tumour response as 
compared with his previous standard regime328 (Table 14), 
and this work is often cited as evidence that hyperthermic 
isolated limb perfusion is more effective than
normothermic perfusion. However serious complications were 
also more common after hyperthermic perfusion and by the 
time of their 1975 publication, Stehlin1s team were 
perfusing with a lower dose of melphalan and at lower
temperatures in an effort to reduce the incidence and 
severity of toxic effects329. The duration and temperature 
were by now varied "according to the extent of the 
melanoma within the limb and the condition of the
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peripheral vessels”. It is probable that most of the 
changes ascribed by stehlin to hyperthermia could have 
been due to the increased duration of perfusion. Similar 
improved results may have been obtained by simply 
increasing the dose of melphalan. Nonetheless hyperthermia 
has become an accepted part of isolated perfusion for 
melanoma in many centres around the world211'212'3 3 3 3 1 , 
including our own. We will consider the role of 
hyperthermia in Chapters III and IV of this thesis.
1.5.3. Results: Introduction
In reviewing the world literature in 1979, Au and
p i p . .  .Goldman indicated how the true value of isolated limb 
perfusion was unclear, despite many favourable reports. 
They observed how the interpretation of existing studies 
was compromised by various limitations, including:
a) the tendency to include patients with early and 
advanced disease in the same group,
b) failure to define clearly the exact nature and extent 
of associated surgery and whether other treatments were 
used,
c) lack of information on established important 
prognostic factors e.g. Breslow thickness, and other 
factors of possible prognostic significance e.g. sex, age, 
arm or leg,
d) comparison of perfusion results with selected
surgical series, which are subject to similar criticisms 
and which report a wide spectrum of results,
e) variations in perfusion technique.
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The need for proper trials to assess the value of isolated 
limb perfusion has long been recognised332 and it is 
perhaps surprising that the technique has been applied so 
widely and for so long without it1 s value having been 
firmly established.
Studies which have made some attempt to address the 
criticisms of Au and Goldman are discussed below, because 
these studies are our best guides, in the absence of 
adequate randomised prospective clinical trials.
1.5.4. Results: Therapeutic perfusion
There have been many studies , since the original case 
report, which attest the value of isolated limb perfusion 
in the management of advanced locoregional 
melanoma211'329'333'334'335'336'337'338'339'340'341'342.
In the following discussion of results it is important to 
realise that, as in so many aspects of melanoma 
management, there is a lack of appropriate controlled 
prospective clinical trial data on which to base the 
arguments.
I will describe the reported results of isolated limb 
perfusion for loco-regional advanced disease in terms of 
response rates, incidence of subsequent recurrence and 
survival.
For any cancer treatment it is appropriate to consider 
first whether the treatment produces a measurable effect 
on obvious tumours. Two categories of tumour response are 
now generally recognised, as recommended by the 
U.I.C.C.343:
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Complete response = "disappearance of all known disease"
Partial response = ">50% decrease in measurable lesions 
and objective improvement in evaluable but non-measurable 
lesions. No new lesions. It is not necessary for every 
lesion to have regressed to qualify for partial response, 
but no lesion should have progressed"
In the management of cutaneous malignant melanoma 
recurrences may be excised before referral for limb 
perfusion, or at the time of perfusion. Thus there are 
relatively few studies of response rates following 
isolated limb perfusion. A summary of studies which do 
include data concerning response rates (using the U.I.C.C. 
criteria) is presented in Table 13. Response rates 
resulting from modern regimes of isolated limb perfusion 
are very encouraging, with overall response rates 
consistently greater than 70% , and superior to any other 
available treatment339'340 *341'344. Disappointingly the 
duration of responses is rarely indicated though it varies 
between months to many years in the studies in Table 13.
A major criticism of response rate analyses is that they 
are founded on a series of subjective assessments, often 
made by the responsible physician or surgeon, and open to 
conscious and unconscious bias. In addition, unless the 
study is truly prospective, one cannot assume that uniform 
criteria of response were rigorously applied. These 
objections are not unique to studies of isolated limb 
perfusion, and apply to studies of other treatments. The 
use of response rates has been critically appraised by 
Watson345.
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If response rate data is not available because of prior 
surgical clearance of recurrent disease, an alternative 
assessment of disease control can be made by determining 
the incidence of further limb recurrence after isolated 
limb perfusion. Disappointingly this information is seldom 
clearly reported in studies of isolated limb perfusion
and, for comparison, there are few studies which describe 
the prognosis for patients with loco-regional recurrence 
managed by excisional surgery 122.
Rosin and Westbury described a series of 116 patients 
who had surgical clearance of recurrent melanoma in 
addition to isolated limb perfusion211, 58 of the patients 
(50%) remained free of further recurrences in the limb
until death or follow-up (up to 15 years). Most of the 
further recurrences occurred in the early years after 
isolated limb perfusion. In another study, with minimum 
two-year follow-up, 22 of 39 (56%) patients treated by
surgical excision of recurrent melanoma plus limb 
perfusion remained free of further loco-regional
recurrences346. It is a consistent finding that if further 
recurrence develops after therapeutic isolated limb 
perfusion it tends to occur in the first year or
so340'347.
In a review of their experience of isolated limb perfusion 
for loco-regional recurrence Schraffordt Koops and 
colleagues achieved 5-year local recurrence-free
survival of 61% overall and 5-year disease-free survival 
of 35% overall (using actuarial methods). Clearly it would 
be valuable to consider this sort of analysis in larger
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groups with better defined long-term follow-up, and 
including sub-group analyses.
There is preliminary evidence that the time interval to 
next recurrence may be prolonged by isolated limb
, O/Q #
perfusion^ , but it is doubtful whether this alone would 
be an appropriate argument for such an elaborate 
treatment.
Ghussen, from Cologne in West Germany, has reported the 
only prospective randomised trial of isolated limb 
perfusion compared with excisional surgery350'351 there 
were 37 patients with stage II disease (M.D. Anderson) and 
33 with stage III disease. In both categories disease-free 
intervals were significantly prolonged by isolated limb 
perfusion, but the trial was prematurely ended once this 
difference was evident and the sub-groups are too small 
for survival analyses.
There is considerable variability in reported survival 
rates following isolated limb perfusion for patients with 
loco-regional advanced and recurrent melanoma (Table 14). 
This is not surprising because this category is 
heterogeneous, including the patient with a single small 
indolent recurrence near the wound as well as the patient 
with rapidly advancing extensive in transit metastases and 
ulcerating lymph nodes. In Table 14 the M.D. Anderson 
staging system is used because it describes patterns of 
loco-regional disease.
From Table 14, it is apparent that patients with different 
patterns of loco-regional recurrent or advanced melanoma 
have often been studied as one group and hence reported
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five-year survival rates after isolated limb perfusion 
vary from 25-74%. The influence of other factors, e.g. 
age, sex and race of patients; number, timing and type of 
recurrences? treatment before perfusion and variations in 
perfusion technique, has not yet been determined. Hence 
the groups of perfusion patients reported in these various 
studies are not directly comparable, and there is a lack 
of appropriate surgical controls.
As we have seen (1.2.9. , 1.3.3.) , patients with loco-
regional advanced or recurrent melanoma are at high risk 
of developing early systemic
metastases120'121'186'202'203, and therefore survival 
after conventional surgery is often limited. Survival
rates have been reported as 50% at three years after
. on? .first recurrence , 33% at eleven years from primary
ion 191
treatment , and 15% at ten yearsx<sx. In the series of 
patients with regional non-nodal metastases reported by 
Cascinelli and colleagues 41% of their 291 cases had 
involved nodes at some time, 22% had distant metastases 
at diagnosis of regional non-nodal disease and 27% 
developed distant metastases within six months from 
diagnosis-*-*1 . The long term survival is greater in the 
study by Griffiths and Briggs120 because they record 
survival from time of primary treatment, and because they 
did not include patients with overt nodal and systemic 
metastases at the start.
The only study with comparable long term follow-up after 
isolated limb perfusion is that of Krementz318, which 
indicates ten-year survival rates of 59% for patients in 
M.D. Anderson stage II, 23% in IIIA and 28% in IIIAB
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(Table 14).
Unfortunately, there is insufficient evidence to decide 
whether isolated limb perfusion improves survival of 
patients with loco-regional advanced and recurrent disease 
or not. Apparent improvements in survival318'347'352 could 
arise because of patient selection, or because of spurious 
comparisons with disease in less favourable anatomical 
sites.
In an attempt to identify important prognostic 
determinants of the efficacy of isolated limb perfusion, a 
retrospective study of patients with loco-regional 
recurrence of melanoma treated by therapeutic perfusion 
was made using a multi-factorial analysis353. In this 
study the number of involved lymph nodes was an important 
prognostic factor, and subcutaneous lesions seemed to 
confer a poorer prognosis. Vaglini341 has indicated that 
patients with a solitary loco-regional recurrence may 
respond better to isolated limb perfusion than those with 
multiple lesions, but this has yet to be confirmed.
The study of variables related to different perfusion 
techniques is in its infancy. It is not proven that 
hyperthermic isolated limb perfusion with melphalan is 
more effective than normothermic perfusion but the weight 
of published opinion is broadly in support of 
this318'329'340'351'354. Kroon and colleagues, however, 
have shown that normothermic (tissues 37-38°C) perfusion 
can still produce an overall response rate of over 80%344. 
This debate is unresolved because of a lack of 
appropriately designed clinical trials.
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1.5.5. Results: Adjuvant perfusion
In view of the encouraging results obtained by isolated 
limb perfusion for advanced disease, it seems logical to 
consider isolated limb perfusion as a possible adjuvant 
to surgical excision.
Clinical series have often included such adjuvant 
perfusions318'329'336'337'350'351'355'356'357'358'359'360. 
Although comparisons with historical controls suggest 
improved loco-regional control and prolonged survival from 
adjuvant perfusion as compared with surgery alone, there 
is no definitive proof.
Since the identification of features of the primary 
melanoma (especially Breslow thickness) which have been 
shown to be important prognostic determinants, it has been 
possible to identify patients at particularly high risk of 
recurrence, metastasis and death. No other form of therapy 
has consistently obtained response rates which are 
comparable with those achieved by isolated limb perfusion 
(see 1.3, 1.4; cf. 1.5.4.) , and no other form of therapy 
has proven to be of value as an adjuvant. Therefore, in 
recent years, there has been great interest in finally 
establishing whether or not isolated limb perfusion may be 
an effective adjuvant to excisional surgery for patients 
with high-risk primary malignant melanoma.
A summary of the important retrospective series which give 
results for isolated limb perfusion as an adjuvant to 
surgery for primary malignant melanoma is given in Table 
15. This is not an exhaustive listing of such studies, but 
a selection of better designed studies, which helps make 
important points about the evaluation of isolated limb
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perfusion in the adjuvant setting.
The studies of Janoff361, Koops362 and Krementz318 are 
reports of clinical series without internal controls, 
relying on the results of surgery alone obtained in other 
centres for comparison. As in similar previous 
studies329'336'363 there appears to be a survival 
advantage for the perfused patients.
Sugarbaker and McBride357 used 71 historical controls from 
their own hospital, demonstrating an apparent long-term 
survival advantage of 26% from adjuvant isolated limb 
perfusion. Concurrent but non-randomised controls were 
used in the small study by Rege and coworkers364 which 
detected a statistically significant survival advantage 
from isolated limb perfusion for clinical but not 
pathological stage I disease. The study by Tonak and 
colleagues365 included a comparison with surgical 
controls, but no account was taken of known prognostic 
factors and the follow up was only three years.
Adjuvant isolated limb perfusion was first used long 
before Breslow thickness was recognised as a major 
prognostic determinant, and hence this important factor 
could not be accounted for prospectively. Hence in major 
series, which include patients from the pre-Breslow era, 
significant numbers of patients with (what are now known 
to be) low-risk, thin malignant melanomas were treated by 
adjuvant isolated limb perfusion. In the report by
TT O
KrementzJXO, retrospective microstaging of 161 of the 381 
patients revealed that 37% had primary lesions less than 
1.5mm Breslow thickness, and in other studies 44%364 and 
50%361 of the patients were in this low-risk category. The
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inclusion of significant numbers of low-risk patients may 
tend to inflate the apparent benefit of adjuvant isolated 
limb perfusion. Today the excellent prognosis of patients 
with such thin malignant melanomas would preclude their 
inclusion in trials of adjuvant therapy. It is interesting 
that when McBride and colleagues366 re-evaluated the M.D. 
Anderson experience of stage I malignant melanoma, 
including the series reported in 1976357, they found a 
significant survival advantage for surgery plus limb 
perfusion (compared with surgery alone = wide local 
excision +/- elective node dissection) only in patients 
with primaries of Clark level III and greater than 1mm 
Breslow thickness.
Perhaps the most interesting retrospective studies of 
adjuvant perfusion have been reported by Martijn, 
Schraffordt Koops and colleagues. In the first study331 a 
retrospective comparison was made between patients with 
high risk primary lesions treated in Groningen, Holland 
(wide local excision plus isolated limb perfusion) and 
similar patients treated in Sydney, Australia (wide local 
excision alone without elective node dissection). There 
was a statistically significant benefit to the perfused 
group as assessed by rate of loco-regional recurrence, 
proportion disease free at ten years and ten-year 
survival. It is somewhat perplexing that a subsequent 
comparison of the same Dutch patients with surgical 
controls from the Westphalia region of Germany and Holland 
has failed to demonstrate benefit from isolated limb 
perfusion367. The reasons for these conflicting results 
have not been elucidated but may include differences of
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skin type, sun exposure and immune function368.
The need for a prospective study of adjuvant isolated limb 
perfusion has long been recognised322. Ghussen's 
prospective study of limb perfusion350'351 included 
patients with stage I melanoma (M.D. Anderson) as well as 
patients with more advanced disease. Although this was a 
randomised study, it is important to look critically at 
this work, because it is commonly cited as evidence for 
adjuvant perfusion on the basis of the longer disease- 
free interval demonstrated. Patients with a primary 
lesion >1.5mm Breslow thickness in the distal two thirds 
of a limb were randomised between surgery alone (including 
"elective" node dissection) and surgery plus isolated limb 
perfusion. There was no stratification for thickness of 
primary or clinical stage. Eight patients were excluded 
after surgery because "final examination of the ... 
specimens revealed a tumour thickness of less than 1.5mm 
or invasion ... less than Clark's level IV". There were 
only 37 patients in stage I (M.D. Anderson). The trial was 
prematurely terminated after an interim analysis350 
revealed a significant difference in disease-free interval 
between the 54 patients treated by surgery alone (all 
stages) and the 53 treated by surgery plus isolated limb 
perfusion. This difference was also observed in the stage 
I sub-group when the average follow-up is extended to five 
years351. There are however only 18 controls and 19 
patients in the perfusion group, and there is no 
information concerning distribution of prognostic factors 
within the sub-groups. This may be critical because the 
incidence of "recurrence" in the stage I control group
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seems rather high (7/18 = 39%) and could be due to a 
preponderance of thick, poor prognosis primary lesions in 
this group compared with the perfused patients.
An international multicentre prospective randomised 
controlled trial of wide local excision +/- elective lymph 
node dissection compared with the same treatment plus 
isolated limb perfusion has been activated by the W.H.O 
and E.O.R.T.C. (European Organisation for Research and 
Treatment of Cancer). 600 patients must be randomised for 
stratification and subgroup analysis, and it is hoped that 
the large numbers accrued, and careful trial design (e.g. 
stratification by Breslow thickness, quality control of 
perfusion technique) will help to provide definitive 
results. Patients are now being entered from centres all 
over Europe, from America and Australia.
In the U.K. a trial of adjuvant isolated limb perfusion 
began under the M.R.C., but support was withdrawn because 
of poor patient accrual. It is hoped that this study will 
continue under the auspices of the British Association of 
Surgical Oncology (B.A.S.O.) and should have the 
advantages of uniform technique and single national 
population (cf. W.H.O./E.O.R.T.C. study).
Clearly patients with appropriate high-risk primary 
malignant melanomas of the limb should be offered entry 
into a prospective clinical trial of adjuvant isolated 
limb perfusion where possible.
1*5.6. Results of perfusion: Summary
On the basis of objective response rates and loco-regional 
disease control, isolated limb perfusion is the treatment
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of choice for patients with advanced loco-regional 
malignant melanoma. Included in this category are 
patients with a single nodule near the primary or its 
excision scar, through to patients with intractable loco- 
regional symptoms (e.g. pain, fungating tumour) who may 
even have manifest systemic metastases. It is important to 
appreciate that the case for isolated limb perfusion in 
the management of loco-regional disease does not depend 
alone on whether it improves survival. We have seen that 
isolated limb perfusion produces consistently high 
response rates which are unattainable with other 
treatments. It seems that isolated limb perfusion can 
achieve control of recurrent or advanced disease in the 
limb, without recourse to other treatments which can be 
associated with serious morbidity or mutilation. The 
patient often derives encouragement from disappearance or 
regression of symptomatic or gross disease.
Adjuvant isolated limb perfusion is not yet proven to be 
of sufficient benefit to recommend routine use. It may be 
of value in the management of high-risk primary malignant 
melanoma, and appropriate patients should be considered 
for entry into one of the current prospective trials.
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1.6. ALTERNATIVES TO ISOLATED LIMB PERFUSION
1.6.1. Intra-arterial chemotherapy
Intra-arterial administration of cytotoxic is not a new
o fr o o I A
idea^30' .  Apart from isolated regional perfusion, other 
interesting related regional infusion techniques were 
developed. In 1959 Sullivan and coworkers described the
continuous intra-arterial infusion of methotrexate, 
combined with the systemic administration of
rif. q , . . .
citrovorum , m  an attempt to reduce systemic toxicity. 
Intra-arterial therapy may be by bolus injection or by 
continuous infusion321. For this kind of regional 
therapy intra-arterial catheters may be placed surgically 
or by per-cutaneous radiological techniques330.
The rationale for arterial infusion chemotherapy is 
similar to that for isolated limb perfusion, but the 
treated region is not isolated from the systemic 
circulation and the total administered dose may have 
access to the rest of the body. With continuous arterial 
infusion chemotherapy, which may last longer than twenty- 
four hours, it would seem likely that tumour cells are 
exposed to chemotherapeutic drugs for a greater proportion 
of the cell cycle than with isolated limb perfusion330. It 
is unlikely that the relatively sustained high 
concentrations of cytotoxic drug achieved with isolated 
limb perfusion are matched by arterial infusion 
techniques. Consequently, in theory, the therapeutic ratio 
with arterial infusion may be less than with isolated 
regional perfusion, and intra-arterial infusion 
chemotherapy should be reserved for anatomical sites where 
isolated regional perfusion is not technically possible
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(e.g. head & neck) or where general anaesthesia is contra­
indicated330.
Although many drugs have been administered by intra-
arterial infusion for malignant melanoma330/ 370 most
experience has been with dacarbazine (DTIC)371*372»330. in
at least one clinical study systemic toxicity was greater
• • • • ^ 7 1than would be expected with isolated limb perfusion . 
Karakousis has developed a novel method of intra-arterial 
administration which he calls "tourniquet infusion 
chemotherapy"373. An intra-arterial cannula is placed per- 
cutaneously and passed so that the tip lies distal to a 
pneumatic tourniquet round the proximal limb. The 
tourniquet is inflated to greater than systolic pressure 
for five minutes, while adriamycin is infused; then the 
tourniquet is deflated to the level of mean arterial 
pressure, and finally the tourniquet is completely 
deflated. Apparently this can be accomplished without 
general anaesthesia, and an initial small clinical series
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yielded encouraging results In a later publication by
the same authorsJ/  ^ the technique was compared with 
hyperthermic regional perfusion in a dog model. In this 
study the levels of cytotoxic drug were rather low in the 
perfused limbs and disappointingly high in the major 
organs, and the levels were at least as good with 
tourniquet infusion. This is simply explained by the 
omission of a proximal tourniquet in the perfusion 
animals, which were therefore not treated by isolated limb 
perfusion.
The development of interventional radiology has led to 
burgeoning interest in percutaneous vascular techniques.
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This new technology has been applied in the field of 
intra-arterial chemotherapy. By inflating an intra- 
arterial balloon catheter to stop arterial inflow, 
cytotoxic drug can be injected intra-arterially through 
the catheter distal to the balloon (cf. first phase of 
tourniquet infusion). In a dog model this technique 
(intra-arterial infusion-occlusion chemotherapy or intra- 
arterial infusion with stop-flow) has been shown to result 
in higher tissue levels of 5-fluorouracil than either 
intravenous or intra-arterial infusion375.
A per-cutaneous technique for isolated limb perfusion, 
using balloon catheters has been reported in a dog model 
and compared to the intra-arterial infusion-occlusion
o 7 fi
method^' . Per-cutaneous isolated perfusion resulted in 
higher levels of cytotoxic drug in the plasma and tissues 
of the perfused limbs, and lower levels in the systemic 
circulation compared with the levels achieved by infusion- 
occlusion.
In an elegant study, using experimental rabbits, Rar and
colleagues have directly compared the pharmacokinetics of
5-fluorouracil after (1) intravenous administration, (2)
intra-arterial injection, (3) intra-arterial
administration with stop-flow, (4) intra-arterial
administration with out-flow occlusion and (5) isolated 
• • T 77 .limb perfusion . Systemic exposure to cytotoxic drug was 
greatly reduced by isolated limb perfusion, compared with 
all other methods. Tissue levels in tumour and normal 
tissues were significantly greater after both isolated 
limb perfusion and intra-arterial administration with 
venous outflow occlusion, compared with those achieved by
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other methods.
On the basis of this evidence it can be seen that in the 
management of regionally confined malignancy there are 
clear theoretical advantages to isolated limb perfusion 
over alternative methods. In clinical practice isolated 
limb perfusion is still a major surgical undertaking and 
development of the experimental per-cutaneous techniques 
offers the prospect tljat in the future isolated regional 
perfusion may be accomplished without general anaesthesia.
1.6.2. Isolated limb perfusion: other drugs
Isolated limb perfusion for malignant melanoma has been 
performed with a variety of drugs apart from melphalan. 
These drugs include nitrogen mustard318'321'378, 
dacarbazine (DTIC)379,380,381,382,383,384  ^ cis-
platinum381' 385* and adriamycin386.
Various combinations of drugs have also been used in 
isolated limb perfusion including melphalan +
• -5 -I o q p 7  ,
thiotepa x ' , melphalan + thiotepa + nitrogen 
mustard318, melphalan + thiotepa + actinomycin-D335, 
melphalan + actinomycin-D342'346, cis-platinum + 
actinomycin-D381, vindesine + dacarbazine + cis- 
platinum388 and cis-platinum + etoposide (VP-16)389.
No single agent or combination has been demonstrated to be 
superior to melphalan alone in isolated limb perfusion. 
Many years of largely empirical development have led to 
the current regimes of melphalan administration in 
isolated limb perfusion. It is unlikely that optimal drug 
schedules have been applied in the few studies listed
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above, which mostly deal with early experience of the 
alternative agents in small clinical series.
There is still much to learn about the use of melphalan in 
clinical isolated limb perfusion and appropriate models. 
Melphalan is currently the drug of first choice. In my 
opinion it is inappropriate to begin using another drug, 
which has not shown better objective response rates than 
melphalan, unless such a drug is shown to be less toxic 
than melphalan in clinical trials, or unless the drug is 
being studied in such a trial.
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CHAPTER II
CLINICAL STUDIES OF ISOLATED LIMB PERFUSION
11.1. INTRODUCTION
11.1.1. The Scottish Melanoma Group (SMG)
. 7 7In 197 8 the Scottish Melanoma Group was formed m
response to an apparently rising incidence of malignant
melanoma. At that time there was no good population-based
epidemiological database for malignant melanoma. The major
American and Australian series came from centres with a
recognised interest in the disease, and the cases seen and
reported by them were not necessarily representative of
the disease in the whole population.
The original aims of the Scottish Melanoma Group72 were:
1) to ensure registration of all patients with cutaneous 
malignant melanoma presenting in Scotland,
2) to promote the use of modern pathological techniques 
and to standardise terminology used in reporting malignant 
melanoma,
3) to follow all patients from registration to death,
4) to define accurately the type of surgery being 
performed on patients with primary cutaneous malignant 
melanoma.
r
These aims were selected because accurate information on 
Scottish melanoma patients was lacking, and this is an 
important prerequisite for the design of valid clinical 
trials.
The initial objectives of the Scottish Melanoma Group have 
been achieved, and the sound database which has been 
established73 provides the basis for current efforts to
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reduce the incidence of cutaneous malignant melanoma, and 
to improve the prognosis of patients with the disease.
II.1.2. The SMG and isolated limb perfusion
Because of favourable reports concerning the use of 
isolated limb perfusion in the management of malignant 
melanoma (see I.5.3-6) Mr. Alan J. McKay, Consultant 
Vascular Surgeon at Gartnavel General Hospital, was asked 
to examine the available evidence and determine whether 
the facility should be available in Scotland, and if so, 
how it could be made feasible.
After studying the techniques of Krementz and Schraffordt 
Koops at first hand, and having considered the evidence 
discussed in the previous chapter of this thesis, it was 
decided by Mr. McKay that isolated limb perfusion was a 
technique which could be performed safely in Glasgow, and 
which should be investigated.
Once convinced that the technique was safe, and following 
initial encouraging results, we made it known through the 
Scottish Melanoma Group that isolated limb perfusion was 
available to patients in Scotland.
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II.2. AIMS OF CLINICAL STUDIES
This chapter reviews our experience with isolated limb 
perfusion for cutaneous malignant melanoma. The 
introduction and preliminary validation of this complex 
technique is described.
Many of our patients were referred with advanced disease 
when conventional therapy had reached its limits, and when 
the alternatives proposed were systemic chemotherapy or
major amputation. Our major initial concerns have been to/
establish the safety of isolated limb perfusion with 
melphalan, and to examine whether the rationale for 
isolated limb perfusion is sound (see also Chapter III).
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II.3. PATIENTS AND METHODS
II.3.1. Patients
Our provisional criteria for suitable candidates for 
isolated limb perfusion were:
1) Patients with recurrent or advanced melanoma confined 
to a single limb (or, rarely, causing severe local 
symptoms in the presence of distant metastases) 
therapeutic perfusion.
2) Patients with primary melanoma >1.5mm Breslow 
thickness (high risk primary lesion) located on a limb. 
Such patients were suitable candidates for randomisation 
in the M.R.C. trial comparing surgery alone with surgery 
plus adjuvant isolated limb perfusion.
The contra-indications to isolated limb perfusion were 
severe cardio-respiratory disease precluding general 
anaesthesia, severe peripheral vascular disease, and 
disseminated melanoma.
Between August 1984 and May 1988 61 clinical isolated limb 
perfusion procedures have been performed in the treatment 
of cutaneous malignant melanoma by our team. This figure 
includes the eight occasions on which we have repeated the 
procedure, but does not include four other occasions when 
isolated limb perfusion was abandoned for clinical or 
technical reasons (see II.4.5.).
The technique has also been used in four patients to treat 
soft-tissue sarcomas, but these cases are excluded from 
the analysis.
12 men and 41 women were treated, and the lower limb (51)
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was treated much more commonly than the arm (2).
II.3.2 Therapeutic isolated limb perfusion
Three patients referred for consideration of therapeutic 
isolated limb perfusion were excluded either because of 
serious cardio-respiratory disease, or very advanced 
malignant melanoma with no significant symptoms due to 
their limb tumours.
50 therapeutic perfusions for advanced or recurrent 
disease have been attempted in 42 patients. All visible 
disease was often excised by the referring surgeon, before 
referral for isolated limb perfusion.
Excluding repeat perfusions, the clinical details of 
candidates submitted to surgery for therapeutic perfusion 
are summarised in Table 16.
11.3.3. Adjuvant isolated limb perfusion
15 patients have been treated by adjuvant isolated limb 
perfusion for high-risk primary malignant melanoma. Their 
clinical details are given in Table 17.
Three of the patients were treated by isolated limb 
perfusion in the context of the Medical Research Council 
trial.
11.3.4. Method of isolated limb perfusion
Routine pre-operative assessment of each candidate for 
isolated limb perfusion was as for any major vascular 
procedure. A full clinical history was taken and clinical 
examination was performed. In all cases full blood count, 
serum biochemistry and chest X-ray were obtained.
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Additional investigations were performed as indicated by 
clinical condition e.g. thoraco-abdominal computerised 
tomography (CT-scan) was performed in most patients who 
were candidates for therapeutic perfusion.
The nature of proposed treatment was explained to the 
patients pre-operatively, and consent for surgery was 
obtained.
Local Ethical Committee approval was obtained for all 
clinical experiments performed.
Separate records were prospectively maintained concerning 
the patients1 clinical status, peri-operative data and 
post-operative follow-up.
Our surgical method of isolated limb perfusion is a 
modification of the techniques described by Krementz390 
and Schraffordt Koops362'391. Since the great majority of 
patients have melanoma of the leg, I will first describe 
isolated perfusion of the lower limb. Fig. 3 shows the 
isolated limb perfusion circuit in diagrammatic form.
With induction of general anaesthesia 1 gram of 
ceftizoxime (Wellcome) is given intravenously, as 
prophylaxis against wound infection. A radial arterial 
line is inserted for per-operative monitoring and for 
repeated systemic blood sampling. In our early experience 
a central venous line was also inserted for haemodynamic 
monitoring peri-operatively, but this is no longer 
routine.
The patient is placed supine on the operating table and 
rolled onto the side opposite the limb to be treated, for 
washing of the perineum and ipsilateral buttock (which 
come into contact with the tourniquet as it is applied) .
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Once the patient is returned to the supine position, 
thermistor skin probes (Yellow Springs) are applied to the 
skin of the calf and thigh of the affected limb, and the 
temperatures are continuously displayed per-operatively on 
a monitor screen (Siemens Sirecust). In eleven patients, 
early in the series, the temperatures were recorded 
simultaneously in the calf muscles using needle 
thermocouples (Ellab) , and on the calf skin using 
thermistor probes. A stockingette (Tubigrip) on the leg, 
and gamgee round the foot protect the skin from direct 
contact with a heated water blanket (Hawksley Ripple-Heat 
system with custom blanket) which is then wrapped around 
the limb (Fig. 4) , and enclosed in sterile drapes. The 
abdomen and inguinal region are washed with iodine
antiseptic and draping is completed.
Under routine balanced general anaesthesia the external
iliac vessels are exposed retro-peritoneally via an 
oblique incision in the iliac fossa. All minor branches of 
the external iliac artery and all tributaries of the 
external iliac vein, from the iliac bifurcation to the 
inguinal ligament, are ligated and divided. The external
iliac lymph nodes are routinely excised during this
dissection.
Heparin (150 i.u./kg) is given intravenously, prior to 
control of the vessels for cannulation. Polyvinyl chloride 
(P.V.C.) cannulae (Bard and Cimid) are placed through a 
longitudinal venotomy and arteriotomy and the cannulae are 
advanced so that the tips lie in the femoral triangle 
inferior to the inguinal ligament, and distal to the lower 
edge of the tourniquet. The cannulae are secured in place
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by firmly applied cotton snares (Fig. 5) . A Steinmann pin
C-
is driven into the iliac crest and is used to anchor a red 
rubber Esmarch bandage which tightly encircles the root of 
the limb proximal to the tips of the cannula (Fig. 6), 
allowing perfusion high up into the femoral triangle 
(Fig.7).
The perfusion apparatus consists of a simple roller pump 
(American Optical) in series with a disposable hybrid 
oxygenator (Bard) which has an integral heat exchanger 
(Fig. 3). The pump/oxygenator (primed with 500ml Ringer's 
lactate solution and 700ml matched packed red cells plus 
3000i.u. heparin, pre-warmed by the integral heat 
exchanger) circuit is then opened to the arterial and 
venous cannulae, and the limb is effectively "on by-pass", 
supplied solely by the isolated circuit. When the isolated 
circuit is stable (after 3-5min) 5ml of 20% fluorescein is 
injected into the perfusate and, using a portable ultra­
violet lamp, the absence of a significant "leak" from the 
leg to the systemic circulation is confirmed by close 
inspection of the skin above and below the tourniquet 
(Figs. 6 & 7) .
When the calf skin temperature is at least 37.5°C 
melphalan is usually administered as a bolus of 1.5-
1.75mg/kg of body weight. Perfusion continues for one 
hour, during which time flow rate and limb temperature are 
monitored and recorded at ten minute intervals. The 
average flow rate during the hour of perfusion was 
calculated for each patient. In each of the eleven 
patients where temperatures were measured by intramuscular 
and skin surface probes the data were analysed by
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calculating the area under the time-temperature curves 
(AUC values) for cutaneous and intramuscular temperatures 
from thirty minutes pre-perfusion until the end of 
perfusion. The paired AUC values for each patient were 
then compared (Wilcoxon signed rank test).
Unlike most other centres we oxygenate the perfusate with 
100% oxygen rather than 95% oxygen/5% carbon dioxide. 
Venous and arterial blood gases have been obtained from a 
series of 22 patients during isolated limb perfusion in 
order to quantify the anticipated alkalosis.
After perfusion for one hour the limb circuit is "washed 
out" with two litres of Ringer's lactate, the tourniquet 
is removed, the cannulae are withdrawn and the vessels are 
repaired. Appropriate doses of protamine sulphate are 
given to reverse the heparin-induced anticoagulation.
The operation is completed about three hours after 
induction of anaesthesia.
Patients are nursed routinely in the high dependency area 
of our ward for 24-48 hours post-operatively. During this 
time, transfusion of two or three units of blood is often 
indicated on the basis of serial haematocrits. In the 
post-operative period the patient is cared for in the 
same way as for any major vascular operation, and any 
systemic or local toxicity is noted. Particular emphasis 
is laid on checking the full blood count 10-21 days after 
isolated limb perfusion, when any delayed myelo- 
suppression, might otherwise go undetected.
The patients are mobilised as soon as possible and they 
can usually be discharged about ten days post-operatively.
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II.4. RESULTS
11.4.1. Therapeutic isolated limb perfusion
Of the patients treated by therapeutic isolated limb 
perfusion 21 (46%) had evaluable tumour which could be
measured after treatment, for an analysis of response 
rates. Response was defined according to U.I.C.C. 
criteria343 and the results are shown in Table 18.
Analysis of disease control is presented in Table 19, 
which shows the pattern and timing of subsequent 
recurrence in patients, from the time of first therapeutic 
perfusion.
Survival after therapeutic isolated limb perfusion was 
analysed from the time of first perfusion by the life-
o q o  , ,
table method and is presented m  Fig. 8. In our
patients the probability of survival to three years after 
therapeutic isolated limb perfusion was approximately 35%.
11.4.2. Repeat isolated limb perfusion
Eight patients had a second isolated limb perfusion. Six 
women with further limb recurrence, 4-18 months after 
first therapeutic perfusion were treated this way. A young 
man initially treated by adjuvant isolated limb perfusion 
suffered loco-regional recurrence and had repeat perfusion 
at 28 months after adjuvant perfusion. In the second 
patient requiring perfusion of an arm, satisfactory venous 
cannulation could not be achieved at the first operation, 
and the attempt was abandoned. Within a month a repeat 
perfusion was successfully performed in this patient.
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11.4.3. Adjuvant isolated limb perfusion
The results of adjuvant isolated limb perfusion are 
summarised in Table 20.
Two of the patients who developed recurrence in the 
inguinal lymph nodes died of disseminated malignant 
melanoma at 9 and 17 months after adjuvant isolated limb 
perfusion. The other patient is alive and apparently 
disease-free at 34 months, six months after second 
(therapeutic) perfusion.
The’patient who is alive with limb recurrence eleven 
months after adjuvant perfusion, had involved iliac lymph 
nodes at the time of perfusion.
11.4.4. Physiology of isolated limb perfusion
The data for flow rates, tissue temperatures and perfusate 
acid/base status are summarised in Tables 21 and 22.
11.4.5. Complications and toxicity
There was no mortality associated with isolated limb
perfusion. None of our patients have required amputation 
for treatment of their disease or as a result of a 
complication of isolated limb perfusion. Our experience of 
problems associated with isolated limb perfusion for 
malignant melanoma is summarised in Table 23.
Attempted therapeutic isolated limb perfusion has been 
abandoned four times. In the third patient in our series a 
large "leak" from the leg to the systemic circulation 
occurred and could not be reduced; no melphalan was 
administered and perfusion was abandoned. Twice there was 
unexpected massive aorto-iliac lymphadenopathy which
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precluded safe vascular cannulation and on these occasions 
isolated limb perfusion was not attempted. The other case 
was the second arm perfusion which was successfully 
performed a few weeks later, using a more extensive 
exposure to achieve satisfactory venous cannulation.
II.4.6. Hospital stay
In all 65 cases (including 8 repeat perfusions and 4 
abandoned perfusions) both the hospital stay and post­
operative stay have been recorded. The median hospital 
stay was 11 days (range 6-43 days) , and the median post­
operative stay was 10 days (5-42).
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II.5. DISCUSSION
11.5.1. Introduction
The clinical series described here includes all the
patients we have taken to theatre for isolated limb 
perfusion, without exception (to May,1988). It is 
therefore a heterogeneous group, and includes the heavily 
pre-treated patients who were our first cases along with 
later cases, usually seen at a much earlier stage.
Nonetheless important general observations can be made.
11.5.2. Mode of referral
It is important to realise that no stable referral pattern
\
has yet been established and that our rate of accrual of 
cases has been accelerating over the last two years. Since 
our unit is committed mainly to vascular and general 
surgery, and because there are established centres nearby 
with an interest in malignant melanoma (University 
Department of Dermatology, Western Infirmary and Regional 
Plastic Surgery Unit, Canniesburn Hospital) nearly all our 
cases come from units other than our own. This is a major 
factor determining the pattern of disease which we see and 
treat.
Our colleagues around Scotland are frequently willing to 
send patients with loco-regional advanced disease for 
therapeutic isolated limb perfusion, but they were 
understandably more cautious about referring patients 
across the country for randomisation in a trial of 
adjuvant perfusion. There is a natural aversion to sending 
an already anxious patient from some distance to Glasgow 
for randomisation, or to obtaining informed consent at the
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referring centre for a trial procedure with which the 
referring clinician is unfamiliar. Hence, although about 
100 new primary limb melanomas are diagnosed in Scotland 
each year (96 lower limb melanomas per annum from 1979- 
83, unpublished Scottish Melanoma Group data), relatively 
few patients have been referred for adjuvant perfusion.
II.5.3. Age and sex of patients
The female preponderance is in keeping with the previously 
reported sex incidence of malignant melanoma in the 
Scottish population73. The average age of candidates for 
therapeutic perfusion (59.5) is well within the range we 
associate with significant cardio-respiratory problems in 
the West of Scotland. Working in a vascular surgical unit 
we were surprised how rarely the melanoma patients had 
evidence of significant peripheral vascular disease. On 
one occasion it was clinically apparent that the patient 
had suffered an acute iliac occlusion eighteen months 
prior to presentation with severe advanced loco-regional 
melanoma. Digital subtraction angiography was performed 
and showed that although the common iliac artery was 
occluded, the external iliac and distal vessels were 
patent. It was thus possible to perform an iliac perfusion 
despite the absence of palpable pulses in the treated 
limb.
Our general impression was that in spite of their age and 
disease, the patients were in good physical condition. 
This is probably due to selection by the referring 
practitioners.
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11.5.4. Stage of disease
28 of the 42 patients for therapeutic isolated limb 
perfusion had local recurrence and/or in transit disease, 
apparently confined to the limb (Table 16) . Others had 
evidence of nodal involvement and one had systemic 
metastases. This group of patients is clearly at high risk 
(1.2.9., 1.3.3).
In the group treated by adjuvant isolated limb perfusion, 
the median Breslow thickness of the primary lesion was 4mm 
(Table 17), though the exact Breslow thickness could not 
be measured for the two subungual primaries. Table 24 
shows the five year survival for Scottish patients 
according to Breslow thickness. There is no doubt that 
with conventional therapy alone, patients with such thick 
primaries are also at significant risk.
11.5.5. Previous treatments
Most loco-regional recurrence of malignant melanoma occurs 
in the first three years after primary surgery394'122.
Hence it is important to note that most of our therapeutic 
perfusions were performed on patients in this phase, and 
that they were not a selected group of long-term survivors 
with indolent recurrences (Table 16). Most of the patients 
had at least one operation since the primary surgery,
sometimes a diagnostic biopsy, but often a series of wide 
excisions with repeated skin grafting. The patients who 
had previous chemotherapy were almost exclusively from the 
first ten patients we treated. Only one patient had been 
treated by radiotherapy, reflecting the widely held belief 
that malignant melanoma is a radio-resistant tumour
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(1.4.4).
11.5.6. Pre-operative investigation/assessment
We included thoraco-abdominal CT-scans as part of the pre­
operative assessment of candidates for therapeutic 
isolated limb perfusion because we would not usually 
perfuse patients with established systemic metastases. No 
patient with unexpected systemic metastases was identified 
in this way however, and CT-scans failed to demonstrate 
the extent of lymphadenopathy which precluded safe 
isolated limb perfusion on two occasions. On the basis of 
this evidence, the practical benefits of CT-scans in this 
setting are unproven. Again the patients with probable 
systemic metastases may not have been referred for 
perfusion, because of selection by the referring doctors, 
and it may be reasonable for us to obtain fewer CT-scans 
in future.
11.5.7. Anaesthesia and per-operative monitoring
We have only used general anaesthesia for isolated limb 
perfusion, and regional anaesthesia could only be 
considered where systemic heparinisation is not proposed. 
Although we do not routinely aim to achieve full "cardiac" 
heparinisation, we believe that systemic heparinisation 
helps to reduce the risks of thrombotic and embolic 
complications of the vascular manipulations involved in 
isolated limb perfusion. Furthermore the degree of 
sympathetic block associated with spinal and epidural 
anaesthesia may produce systemic hypotension during 
perfusion, risking leak from the limb to the rest of the
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body394 and compromise the haemodynamic response to
i
relative hypovolaemia at the end of perfusion.
For the hour of perfusion the limb is maintained by a 
perfusate, which consists of a mixture of the priming 
fluid and the blood trapped in the leg vasculature at the 
time of cannulation. The perfusate has a low haematocrit. 
At the end of perfusion the perfusate is drained from the 
limb and is largely replaced by Ringer's lactate. 
Therefore the circulating volume within the limb is 
effectively lost, and only partially replaced with 
crystalloid solution, at the end of perfusion. The average 
blood loss was estimated at approximately 1.4 litres in 
the series of 15 patients reported by Goldberg and
T O  A , ,
colleagues’^ ^ . Furthermore there is evidence that systemic 
vascular resistance may be reduced by a vasodilatation 
response to exposure of the skin to sustained high
O  Q  C  ,
temperatures^ . If there is no attempt to pre-load the 
systemic circulation, or to replace immediately the 
circulating volume which is lost at the end of isolated 
limb perfusion then there is a serious risk of circulatory 
collapse, particularly in an older patient who may have a 
limited cardiac reserve. This is why central venous 
manometry has been described as routine and why it has 
been suggested that pulmonary artery wedge pressure 
monitoring should be considered in patients with poor 
cardiac reserve396. Central venous pressures were 
routinely monitored in our early experience but 
anticipation and correction of volume depletion, has 
resulted in a diminished need for invasive monitoring.
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II.5.8. Technique of isolated limb perfusion
For lower limb perfusion we favour vascular access by the 
iliac vessels because they are usually of adequate calibre 
for cannulation, and because direct perfusion of both the 
deep and superficial femoral systems is achieved.
The retro-peritoneal dissection results in less gastro­
intestinal upset than a laparotomy, and is usually 
straightforward unless there is extensive peri-vascular 
tumour or if there has been a previous ilio-inguinal 
dissection, perfusion, or appendicectomy.
Particular care is taken during dissection to identify and 
divide all (named and un-named) branches of the external 
iliac vessels, which might allow "leakage" during 
perfusion. This also results in a length of free artery 
and vein, for ease and safety of manipulation during 
cannulation.
In perfusion of the upper limb the anomalous and 
frequently multiple venous drainage can cause problems. 
Satisfactory isolation of the arm combined with perfusion 
of the regional nodes is less likely to be feasible than 
in the leg, because of the extensive periscapular 
anastomoses and the geometry of the shoulder. Using our 
standard technique of iliac perfusion, fluorescein 
staining of the skin of the inguinal region, right up to 
the tourniquet is usually seen. It is likely that this 
implies adequate perfusion of the inguinal lymph nodes but 
similar perfusion of the axilla is not possible, without a 
greater risk of systemic leak.
Schraffordt Koops and colleagues348 describe the routine 
use of a second perfusion at six weeks in patients with
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tumour in a sampled superficial inguinal node (femoral 
perfusion), and in patients with melanoma affecting the 
foot (popliteal perfusion). A significant incidence of 
foot drop in his early experience has led him to advocate 
the routine use of "prophylactic11 fasciotomy, to 
decompress the anterior compartment of the leg397. It 
would appear that compartment syndromes were more commonly 
seen in the early days of perfusion (when low flow rates 
were used) and especially with the introduction of 
hyperthermic perfusion (producing increased oxygen 
demand). Wieberdink has suggested that the problem is due 
to tissue hypoxia and that it is circumvented by "high" 
flow rates398. In common with most centres211'357'390 we 
do not consider that "prophylactic" fasciotomy is 
indicated after routine isolated limb perfusion.
There are numerous other subtle technical differences 
between the perfusion regimes described in various 
centres. The physio-pharmacological consequences of such 
differences may prove to be of critical importance (see 
Chapters III and IV).
It is clear, mostly from conversation with many clinicians 
who were practising in the early days of isolated limb 
perfusion, that major morbidity and occasional mortality 
due to complications of isolated limb perfusion were the 
simple reasons why the popularity of the treatment waned 
in the U.K. after a vogue in the early 1960s. There are 
relatively few unfavourable reports on isolated limb 
perfusion in the literature356'399, but clinicians are 
perhaps reluctant to publish poor results. The resurgence 
of perfusion began with the failure of new cytotoxic drugs
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to make a convincing impact on melanoma, combined with the 
publication of major series by careful 
investigators211'329'330'333'357 which showed that the 
treatment could be performed safely and effectively. It 
should come as no surprise that (as with any surgical 
technique) the best results are obtained by those who have 
not merely flirted with the technique, but who have taken 
it, adapted it and developed their own routine over the 
years. Technical factors which may critically determine 
the quality of clinical results may not have been 
highlighted in the literature concerning isolated limb 
perfusion, but in this complex mode of treatment it is 
clear that there is ample scope for disaster as a 
consequence of sloppy technique.
II.5.9. Therapeutic isolated limb perfusion
In our series of patients with evaluable tumour the 
overall response rate was close to 100% (Table 18). The 
incidence of complete response was particularly 
encouraging when compared with the results for systemic 
chemotherapy (see 1.4.2.). It should however be borne in 
mind that cutaneous and nodal metastases may be more 
likely to respond to systemic chemotherapy than visceral 
(e.g. lung, liver) metastases248'251'252'253, and this 
might tend to bias results in favour of isolated limb 
perfusion.
Examples of the response to isolated limb perfusion are 
illustrated in the series of clinical photographs (see 
Figs. 9A, B and 10A-D).
"Disease-free" survival is not an appropriate parameter
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for our series of therapeutic perfusions because a 
significant proportion of the patients do not have the 
tumour excised. Table 19 shows where and when recurrences 
developed in our patients after therapeutic isolated limb 
perfusion. In this context "recurrence" refers to those 
patients whose residual disease progresses, perhaps after 
initial response, as well as those who develop new 
lesions. Therefore the term "recurrence-free survival" may 
be applied to describe the time interval between 
therapeutic perfusion and subsequent progression of 
existing melanoma or de novo recurrence. Combined with the 
response data (Table 18) , the figures indicate that 
temporary regional control of melanoma is achievable with 
isolated limb perfusion.
Some of our patients treated by therapeutic isolated limb 
perfusion have since died due to metastatic disease. An 
unknown number of the patients who developed systemic 
metastases would have occult systemic metastases at the 
time of isolated limb perfusion, and it is unlikely that 
the regional treatment would prevent these occult lesions 
from becoming manifest systemic metastases. It is 
interesting that the lymph nodes seem to be a relatively 
uncommon site of subsequent recurrence in this series. 
This could be due to patient selection, it may be an 
effect of treatment, or perhaps it is due to under­
diagnosis of nodal disease in the face of more obvious 
regional or systemic tumour.
For completeness the survival data is illustrated in Fig. 
8. The life-table estimate for probability of survival to 
three years after therapeutic isolated limb perfusion in
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our series (M.D. Anderson Stages II-IIIAB) is about 35% 
(cf. Table 14).
Overall our results for therapeutic isolated limb 
perfusion, in terms of response rates, disease control and 
survival are certainly encouraging and in keeping with 
results from other centres (1.5.4., Tables 13 and 14).
In none of our patients has amputation been necessary, 
either for progression of disease or because of 
complications of isolated limb perfusion.
II.5.10. Repeat isolated limb perfusion
Our early experience led us to believe that repeat 
isolated perfusion of the leg was most satisfactory if the 
iliac vessels could be re-cannulated at the second 
operation. On three of seven occasions this was not 
technically possible, and the femoral vessels were 
cannulated instead. In two of these cases perfusion was 
terminated prematurely because of poor flow and suspected 
"leak" from the leg to systemic circulation, but both had 
been perfused for at least thirty minutes. As a result of 
experience gained with these cases and because of further 
responses at the second perfusion, we consider that repeat 
perfusion is a worthwhile procedure, but we have recently 
modified our technique.
In the more recent cases coming to repeat isolated limb 
perfusion we have tended to place the tourniquet around 
the root of the limb but cannulate distally at the femoral 
or popliteal vessels. Good perfusion of the whole limb can 
thus be achieved, circumventing the need for a potentially 
hazardous retroperitoneal dissection.
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It has not been proven that there is any advantage to be 
gained from the use drugs other than melphalan, alone or 
in combinations, during initial or repeat therapeutic 
isolated limb perfusion368.
II.5.11. Adjuvant isolated limb perfusion
Three of the patients treated by adjuvant perfusion later 
in our series were managed according to the M.R.C. Trial 
protocol. 5 others were randomised to surgery alone, and 
clearly no meaningful comparison can be made between such 
small groups. I have described how accrual to this trial 
was slow in Scotland (see II.5.2.), and in November 1987 
the M.R.C. withdrew its support because the accrual rate 
was similarly poor across the U.K. Existing data has been 
transferred to the British Association of Surgical 
Oncology (B.A.S.0.), who plan to continue the trial in the 
U.K.
Although we only perfused three patients in the context of 
the M.R.C. protocol we were concerned that two of these 
patients developed severe regional toxicity after 
perfusion. A 48 year old lady developed marked swelling of 
the limb associated with cellulitis and interdigital 
sepsis 19 days after adjuvant isolated limb perfusion and 
she had to be re-admitted to our ward for treatment 
including antibiotics. In the second case a 49 year old 
man (C.M.) with a 2.3mm thick primary melanoma was 
referred from Inverness after randomisation, and he 
developed swelling of the limb (Fig. 11), associated with 
severe pain in the muscles of the calf. At seven days 
after perfusion there was a rise in serum transaminase
136
enzymes (AST and ALT), and the serum creatine kinase level 
was grossly elevated at >3 000units, indicating significant 
muscle damage. Both of these patients made a full and 
satisfactory recovery, but the man developed obvious 
wasting of all muscle groups in the limb with a 
symptomatic foot-drop and he had to walk with a stick for 
two months after perfusion.
We were keen to determine why these problems arose. The 
major differences between the M.R.C. protocol and our 
standard method were that the protocol required that 
melphalan should be given in a total dose of 2mg/kg body 
weight, and administered as three aliquots during the hour 
of perfusion. Hence the total doses given to these 
patients were somewhat higher than our standard regime 
would have involved, and we would have given the smaller 
doses as single boluses. Subsequent pharmacokinetic 
studies were designed to determine whether the mode of 
administration influenced the exposure of tissues to 
cytotoxic drug, and hence whether the observed toxicity 
was likely to be due to total dose or mode of 
administration (see Chapter III).
Considering all the adjuvant perfusions, it is important 
to note that although most of these patients have lesions 
greater than 3.5mm thick, 11 of 15 have had no problem 
with melanoma at a median follow-up of 29 months (Table
20). Furthermore, only one patient has suffered local 
recurrence or in transit disease after adjuvant perfusion 
and she was the patient discovered to have involved iliac 
glands at the time of perfusion.
Although the W.H.O./E.O.R.T.C. trial (1.5.5.) should
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answer whether adjuvant perfusion is effective, there are 
potential objections to such a large scale multi-centre 
study, particularly with a complex treatment like isolated 
limb perfusion, in that it will be difficult to ensure 
that uniform perfusion techniques are used in all 
participating centres. The treatment will be applied to 
many small, perhaps unrepresentative samples from many 
quite different populations. Such criticisms have already 
been made of previous W.H.O./E.O.R.TC. studies by those 
who contend that significant benefits to sub-groups may be 
hidden217.
We believe that the significant toxicity we have observed 
using the M.R.C. protocol is not acceptable in the context 
of an adi uvant trial. There are certain advantages in 
studying a group of patients treated by a single team of 
investigators. Therefore it is proposed that in Scotland 
we should prospectively study adjuvant perfusion by 
comparing the clinical results of those referred for 
perfusion with those not referred for perfusion, using the 
established framework of the Scottish Melanoma Group. In 
such a study we would consider adjuvant isolated limb 
perfusion for any patient with a primary malignant 
melanoma thicker than 1.5mm.
II.5.12. Physiology of isolated limb perfusion
In the series of 57 patients for whom we have data on 
arterial flow rates during iliac perfusion it can be seen 
that there is considerable variability in the flow rates 
used (Table 21) . This is because no specific attempt has 
been made to achieve a pre-set value for any case, apart
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from the series in which we studied melphalan 
pharmacokinetics. In general the tendency has been to 
commence with a low flow rate of about 50-100ml/min and 
increase the rate to a maximum stable level, without 
inducing excessive pressures in the lines or rapid changes 
in the reservoir volumes. We have not measured arterial or 
venous pressures in the limb directly during perfusion. So 
far as possible we have tried to maintain constant 
conditions in the isolated circuit but occasionally some 
additional fluid (in divided amounts, up to 3 00ml) has to 
be added to the reservoir because of vasodilatation, with 
a fall in reservoir volume which is not associated with 
any leak of cytotoxic drug into the systemic circulation. 
Our mean flow rate is similar to those used in other 
centres211'318'350'381'400, higher than those in some 
early series322, but lower than the flow rates (up to 
1.21/min) achieved by the advocates of "pressure regulated 
perfusion"354'401. It is not clear that there is any 
definite benefit from very high flow rates, though it is 
obvious that ischaemia of normal tissue should be avoided 
by achieving at least a physiological flow rate during 
isolated limb perfusions400.
In the1 11 patients in whom we recorded the temperature in 
muscle and skin, we demonstrated that the use of deeply 
placed needle thermistors was unnecessary because there 
was no significant difference between the skin surface and 
intramuscular temperatures throughout the treatment (Table
21) . We measured the temperature at two sites on the limb 
because of the patient who suffered a superficial burn due 
to mal-function of the single thermistor probe, leading to
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under-estimate of tissue temperature (see II.5.13).
Our main reason for monitoring temperature continuously 
was to avoid damage to normal tissues.
The larger series (n=60) of cutaneous temperatures shows 
that our method of warming the limb achieves satisfactory 
moderate hyperthermia by the end of perfusion in most 
cases (the series includes a few instances where the 
heated water blanket was unavailable or punctured per- 
operatively!). The maximum cutaneous temperature achieved 
in this series was 41.2°C. It is perhaps surprising that 
there was no significant temperature difference between 
the thigh and calf, since one might have expected the 
vessels supplying the warm, insulated limb to act as a 
counter-current multiplier system and generate higher 
temperatures distally.
At the temperature levels achieved in this series one 
would not expect any cytotoxic effect due to heat alone, 
because the specific cytotoxic effect of hyperthermia is 
usually described at temperatures over 41.5°c326'402. It 
is often stated that hyperthermia is "synergistic" with 
certain cytotoxic drugs352 but the use of hyperthermia 
with melphalan is paradoxical because the drug has a short 
half-life and because it is even more rapidly hydrolysed 
to inactive metabolites in warmer conditions (see also
III.3.4., Figs. 19,21,25).
It is likely that the generation of at least physiological 
temperatures (normothermia, 37°C) will be required to 
prevent vasoconstriction and shunting, to allow adequate 
tissue perfusion. A recent clinical study indicated that 
isolated limb perfusion with "controlled normothermia"
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(tissue temperatures 37-38°C) seemed to produce similar 
results to perfusion with "mild hyperthermia"344.
No attempt was made to measure tumour temperature in our 
study. The accurate measurement of intra-tumoral 
temperature is difficult, as there is often uneven 
distribution of heat within larger tumour masses. Some 
have indicated that sluggish blood flow within the 
abnormal vessels of tumour masses causes poor heat 
dissipation, resulting in selective heating of tumour 
tissue403'404. The interaction of hyperthermia and 
melphalan cytotoxicity is examined in greater detail in 
Chapter IV.
When the vessels are clamped for cannulation prior to 
perfusion the limb is temporarily ischaemic and it becomes 
somewhat acidotic as anaerobic metabolism proceeds. 
Originally the oxygenator was used simply to maintain 
viability of the limb during treatment, though it was 
postulated even in the earliest report317, that high 
arterial oxygen tensions might increase the efficacy of 
"radiomimetic" drugs like melphalan. Indeed it was later 
shown in a murine model that hyperbaric oxygen enhanced 
the anti-tumour activity of nitrogen mustard405'406, and 
that an elevated tissue P02 may be cytotoxic to hamster 
melanoma407.
The measured gas tensions in our patients (Table 22) show 
that the initial ischaemic acidosis is soon corrected and 
reversed, and that a high P02 is maintained on the 
arterial side of the circuit throughout the time of 
perfusion. We have made little attempt to control Pc02 ln 
the circuit, and the carbon dioxide is rapidly extracted
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from the circuit by diffusion across the oxygenator, with
the result that the arterial ?C02 ^as fallen as l°w as
6mmHg in our patients. There is a resultant tendency
towards respiratory alkalosis within the perfused limb,
which progresses during the hour of perfusion (with pH
rising as high as 7.8). In none of our patients has there
been any problem with tetanic muscle spasms, described by
Krementz and colleagues408, and which led them to
recommend the use of a 95%/5% mixture of oxygen and carbon 
• •Tiftdioxide x to supply the oxygenator.
It can be seen that although the conditions in the leg are 
controlled, they are not "physiological". Isolated limb 
perfusion affords a unique opportunity to manipulate the 
tumour micro-environment to influence the cytotoxic effect 
of anti-cancer agents. Since we have seen no significant 
morbidity on account of the alkalosis within the limb we 
have not made any attempt to correct it.
It is interesting to consider the possible effects of such
a profound alkalosis in the tumour-bearing limb. A degree
of vasoconstriction might be expected due to the
relatively low PCq2 (a potent vasodilator) and the high
Pq2t kut it is postulated that tumour vessels, which are
abnormal structurally and functionally409, might not
respond as do normal vessels. In this way there may be
preferential shunting of perfusate into the tumour
vascular bed, with an enhancement of the anti-tumour
effect. Conversely melphalan is more stable at lower pH
values410, and it has been suggested that tumour uptake
of the related drug nitrogen mustard may be greater when
318the perfusate is acidified . These mechanisms might act
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to reduce the cytotoxic effect of melphalan in alkalotic 
conditions. Melphalan has been shown to have no
significant effect on pH, peripheral resistance or oxygen 
consumption in vivo411. The interaction of melphalan 
cytotoxicity and pH is considered later in this thesis 
(Chapter IV).
The advocates of "pressure regulated perfusion" (i.e. the 
use of continuous monitoring of venous and arterial 
pressures to maintain the limb arterial pressure 15mmHg 
less than systemic arterial pressure), who achieve 
remarkably high flow rates354'401 may do so because they 
maintain normal blood gas tensions in the limb during 
perfusion, and in their system the vasoconstrictor effects 
of low Pqq2 and high P02 will be absent.
II.5.13. Complications and toxicity
Although we describe our early experience with a complex 
form of treatment, we are pleased to report no life or 
limb threatening complication of isolated limb perfusion 
in this series.
One of the patients (Table 23) suffering a deep venous 
thrombosis also developed pulmonary thrombo-embolism, and 
this was the most serious general complication, but does 
not seem to be a particular risk of isolated perfusion in 
this series. The patient who bled post-operatively quickly 
developed a haematoma in the wound, which was explored 
before the patient returned to the ward. A small vessel in 
the wound edge was the cause.
The regional toxicity due to melphalan in isolated limb 
perfusion can be described according to the index
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described by Wieberdink and colleagues400 (see Table 25). 
We would agree with their view that grade I reactions 
indicate undertreatment and that responses graded as II 
and III are probable indicators of optimal dosage.
I believe that the nerve problems in our three patients 
were due to local pressure from the tourniquet rather than 
due to the cytotoxic drug, because the doses given to 
these patients were not high. The patient who suffered a 
thermal burn was only our second patient, and the problem 
arose due to a mal-functioning thermocouple and the lack 
of a protective layer between the patient's skin and the 
heated water blanket. Fortunately the burn was superficial 
and did not necessitate skin grafting. In the remaining 
three patients the regional toxicity was directly due to 
melphalan. I have already indicated (II.5.11.) how two of 
the three patients we treated by adjuvant isolated limb 
perfusion as part of the Medical Research Council trial 
are in the group who suffered grade IV reactions. The 
other patient (Fig.22) was given a high total dose because 
of his body weight, and the dose was given in divided 
aliquots as in the M.R.C. protocol.
There was remarkably little in the way of systemic upset 
associated with isolated limb perfusion with melphalan, 
though our recovery room staff have indicated that they 
believe the perfusion patients are more nauseated and 
vomit more than routine surgical cases. This does not 
appear to be a problem after the first post-operative 
night, and may be due to the cytotoxic, anaesthetics or 
analgesics.
None of the haematological problems listed in Table 23
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required any specific treatment, and all recovered 
spontaneously. The leucopenia usually began about seven to 
ten days post-operatively, and hence we ask the patient's 
general practitioner to check the full blood count for a 
few weeks after the patient is discharged home.
II.5.14. Hospital stay
The longest hospital stay (43 days) was in a patient who 
had wide excision, skin grafting, and adjuvant isolated 
limb perfusion under the one general anaesthetic. 
Unfortunately the graft failed to take because of sepsis, 
resulting in the protracted stay in hospital. 
Interestingly the same procedure has been performed on two 
other occasions without complication.
Most patients can be mobilised within 24-48 hours after 
isolated limb perfusion, and they are allowed home once we 
are happy for them to travel the (often considerable) 
distance home. The resulting medians of hospital stay and 
post-operative stay (11 & lOdays) are appropriate for
elective major surgery in the age group treated.
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II.6. CONCLUSIONS
The major conclusion to be drawn from this report of our 
experience with isolated limb perfusion is that we can 
safely perform the technique in Glasgow.
Our clinical results show very encouraging response rates 
after therapeutic perfusion, at least as good as those 
reported by other perfusion groups (Tables 13 and 14).
The value of adjuvant isolated limb perfusion is as yet 
unproven, and we will be treating patients in this way 
only in the context of a clinical trial.
The pilot studies describing the physiology of isolated 
limb perfusion have indicated avenues for possible 
investigation, which we have pursued, and which I will 
describe in the following chapters.
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CHAPTER III
PHARMACOKINETICS OF MELPHALAN IN ISOLATED LIMB PERFUSION
.111.1. MELPHALAN
III.1.1. Drug development
Melphalan (L-phenylalanine mustard; L-PAM; L-sarcolysine; 
NSC-8806; CB3025) is currently the drug of first choice in 
isolated limb perfusion for melanoma (see 1.6.2.). Its 
full chemical name is p-{di(2-chloroethyl)) amino-L- 
phenylalanine and the chemical structure is illustrated in 
Fig. 12.
The anti-tumour activity of mustard gas was recognised in 
A 1 0 •the 193 0s^x , and nitrogen mustards were developed for use
in haematological malignancies in the 1940s313'413.
Melphalan was one of many substances which were derived
from the nitrogen mustards in the early 1950s. The
synthesis and biological activity of the phenylalanine
derivative were reported by Bergel and Stock414'415 and by
4 1 ftLarionov and co-workers .
It was originally hoped that the combination of the amino 
acid phenylalanine (which is involved in melanin 
synthesis) with the nitrogen mustard moiety might result 
in selective activity against malignant melanoma299. The 
L-isomer, melphalan, is more active than the D-isomer, 
medphalan415. Melphalan is the active component of the 
racemic (DL) form, merphalan or sarcolysine, and melphalan 
is therefore the isomer of choice.
Early in vivo work showed that the Harding-Passey murine 
melanoma could be controlled by melphalan to an extent not 
matched by other treatments315, in subsequent clinical
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trials299'417'418'243 however, the response rate of 
advanced melanoma to conventional systemic administration 
of melphalan has been no better than that obtained by most 
other single agents (1.4.2.). Using high dose systemic 
melphalan with or without autologous bone marrow rescue, 
patients require intensive support but response rates of 
up to 70% have been reported by some workers260'261'310. 
Similarly the use of high dose melphalan in isolated limb 
perfusion aims to exploit the apparent dose-response 
relationship, while avoiding the risks of major toxicity 
to bone marrow and gut.
Although melphalan has been used for thirty years in the 
treatment of a variety of malignancies419, relatively 
little work has been done to determine the fate of 
administered drug420. This is due to the lability of the 
compound and the lack of appropriate assays419 until 
recent years.
III.1.2. Mechanism of action of melphalan
In common with the other nitrogen mustards, melphalan is a 
bifunctional alkylating agent which can react and bind 
with cellular macromolecules such as DNA (deoxyribonucleic 
acid), RNA (ribonucleic acid) and proteins. It is 
currently thought that DNA is the major cytotoxic target 
for melphalan and cross-links between adjacent strands of 
DNA have been particularly implicated in the mechanism of 
action421'422'423. However, other effects on DNA e.g. base 
mis-coding424 and DNA-protein cross-linking425 may also 
have a role in the cytotoxic effect of melphalan. In a 
human melanoma cell line in vitro it has been shown that
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maximum levels of DNA inter-strand cross-links are reached 
6-12 hours after melphalan exposure (cf. nitrogen mustard, 
peak levels immediately after exposure) in spite of the 
labile nature of the molecule423. The hypothesis proposed
AOfZ ,
by Kohn is that rapid binding of the drug to a single 
strand of DNA as a mono-adduct is followed by a delayed 
interstrand cross-link when the second chloroethyl group 
binds to the complementary strand of DNA.
For the drug to be effective in the treatment of cancer it 
is therefore essential that enough active drug should 
penetrate to the nuclei of malignant cells. In vitro 
experiments have shown that the transport of melphalan 
into lymphoblasts427 and leukaemic cells428'429 occurs by 
active carrier mechanisms. In L1210 (murine leukaemia) 
cells in vitro the uptake of melphalan is a temperature- 
sensitive, partly sodium-dependent, active process with 
cell:medium accumulation of approximately 5:1 at 37°C429. 
This process is competitively inhibited by physiological 
concentrations of the L-isomers of the amino acids leucine 
and glutamine, with a corresponding reduction in melphalan
. . A O Q , ,
cytotoxicity . Interestingly, m  vitro, the amino acid 
phenylalanine does not interfere with melphalan uptake427. 
Phenylalanine has little effect on the cytotoxicity of 
melphalan to leukaemic cells430 and it does not inhibit 
melphalan cytotoxicity to cultured melanoma cells431. 
Melphalan rapidly effluxes from cultured cells into 
melphalan-free medium432, by a separate mechanism, and at 
least 75% of radio-labelled intracellular melphalan is 
free to leave the cell429.
The clinical implications of these experimental results
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are not yet clear, but now that there is a satisfactory 
assay for melphalan the basic clinical pharmacokinetics 
can be described. The cytotoxic effect of melphalan is 
likely to be influenced by special features of the
isolated limb perfusion circuit, and some of these 
influences may act by altering pharmacokinetics.
III.1.3. Measuring melphalan
The first reported attempts to describe the 
pharmacokinetics of sarcolysine were made in 1957 by 
Cohn433 who used 14C-labelled drug in a rat model. The 
distribution of radio-activity could be described but the 
proportions due to parent drug, hydrolysis products or 
metabolites were unknown. In the original report of 
clinical isolated limb perfusion Creech and colleagues317 
described the use of a qualitative in vivo bio-assay to 
determine the duration of anti-tumour activity in the
perfusate. Klatt and colleagues434 described a
colorimetric method for the analysis of alkylating agents 
in blood and tissues. This required the use of
nitrobenzylpyridine and was specific for alkylating 
activity, but could not distinguish between melphalan and 
its monohydroxy- hydrolysis product. The technique 
involved significant heating of samples (which we now know 
would increase hydrolysis of the parent compound) and 
lacked sensitivity, only being able to detect alkylating 
activity in excess of 5/ig/ml of plasma419. To improve the 
sensitivity for clinical assay of melphalan, Chirigos and 
Mead reported a spectrofluorometric method, but they found 
that the specificity of this assay was poor435.
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Sensitive and specific gas-liquid chromatography was used 
by Goras and colleagues to measure melphalan for drug 
formulation436, but the method is not applicable to 
biological systems. With the advent of high performance 
liquid chromatography (HPLC), sensitive and specific 
methods which were easy to apply to biological systems 
became practical. HPLC methods for melphalan assay were 
thus developed436'437'438.
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III.2. HPLC
Chromatographic systems permit the separation and analysis 
of the components in a mixture because of the 
differential association of constituents between a mobile 
and a stationary phase. Many chromatographic techniques 
have been developed, and each is suited to particular 
tasks. For example, gas-liquid chromatography (GLC) is 
suitable for analysing volatile substances, or volatile 
derivatives of non-volatile compounds but the technique 
often requires heat. High performance liquid 
chromatography (also known as high pressure liquid 
chromatography) allows the detection and measurement of 
heat-labile biological substances at ambient temperatures 
and without the need for expensive derivatisation. HPLC is 
now widely used for the detection and measurement of 
biological compounds.
In the 1960s, Giddings439N) demonstrated how GLC theory 
could be applied to liquid chromatography. Later that 
decade the first high performance liquid chromatographs 
were reported440'441'442. The use of high pressures 
overcame the effect of the higher viscosity of liquid 
compared with gas. In the early days the use of single or 
dual wave-length ultraviolet (UV) detectors meant that 
very small amounts (nanogram quantities) could only be 
measured for suitable UV-absorbing compounds. Variable 
wave-length UV detectors have enabled the detection of 
such small amounts of a wider range of compounds.
The efficiency and speed of HPLC were improved by the 
introduction of new support materials which allow the 
separation of compounds over a relatively short distance
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of solute travel e.g. Horvath^® described the use of 
glass beads coated with an ion-exchange resin.
In classical chromatography the column is gravity fed and 
separation takes hours or even days. HPLC makes accurate 
analysis possible in minutes (which is comparable with 
GLC). The use of HPLC has greatly facilitated the study of 
substances like melphalan.
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III.3. PHARMACOKINETICS
111.3.1. Introduction
The study of pharmacokinetics is concerned with the 
absorption, distribution, biotransformation and excretion 
of drugs443. For a given dose these factors govern the 
concentration of drug at the site of action and they 
determine how the concentration varies with time.
In the special circumstances of isolated limb perfusion, 
absorption and excretion of melphalan are relatively 
unimportant. The dose administered, its distribution, bio­
transformation and the time of exposure are likely to be 
important because these factors may be varied and 
controlled in the isolated limb perfusion system.
111.3.2. Dose
No previous formal phase I (dose escalating) study of 
melphalan in isolated limb perfusion has been reported.
The dose of melphalan used in isolated limb varies from 
centre to centre. In most series the dose is calculated on 
the basis of body weight, and the most commonly 
recommended dose for an iliac perfusion is 1-1.5mg per 
kilogram of body weight318'334'338'340'350'362. In a few 
studies it has been suggested that doses as high as 2mg/kg 
can be given211'215.
It is increasingly common for the dose of melphalan to be 
calculated on the basis of measured limb volume354 as 
advocated by Wieberdink400. The rationale for this method 
of dosimetry is that limb volume varies considerably, and 
does not correlate closely with body weight400. 
Wieberdink's study400 was a retrospective study in which
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toxic reactions were graded and related to melphalan dose. 
Although Wieberdink is convinced that limb volumetry is 
superior to body weight as a basis for melphalan 
dosimetry, his was not a formal phase I study, 87% of the 
patients were treated in a harrow dose range (9-llmg/l 
limb volume) and all three patients treated with higher 
doses received more than 13mg melphalan per litre limb 
volume400.
Apart from the total dose administered, it is clear that 
the volume of perfusate in which this dose is dispersed 
will determine the effective concentration of drug. In 
reports of isolated limb perfusion it is remarkable that 
this critical factor has rarely been considered. 
Formerly it was believed that the perfusate volume was 
mainly determined by the prime400, but the total volume of 
perfusate also includes blood trapped in the limb vessels 
at the start of perfusion. The volume trapped in the limb 
vessels will vary depending on whether the artery or vein 
is clamped and cannulated first, and on how long 
cannulation takes. The volume trapped in limb vessels may 
be a litre or more444'445. Furthermore the volume of prime 
varies between 600ml213'349 and two litres211. In fact, 
the volume of prime is often omitted in 
reports340'354'357'359'364, even in studies of melphalan 
pharmacokinetics446'447.
It is not known whether the dose of melphalan is better 
given as a single bolus, or in divided aliquots during 
isolated limb perfusion448. We were concerned by the 
toxicity observed in patients treated according to the 
M.R.C. protocol for adjuvant isolated limb perfusion,
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which required that melphalan should be given in divided 
aliquots during perfusion (II.5.11.). The original 
rationale for dividing the dose was to minimise the 
consequences of "leakage" and it is not clear whether 
there is any pharmacokinetic advantage in bolus or divided 
dose administration.
III.3.3. Distribution
Clearly it is one of the major objectives of isolated limb 
perfusion to confine the distribution of administered 
cytotoxic drug to the tumour-bearing region. Ideally 
higher levels of cytotoxic would be generated in malignant 
tissue than in normal tissues.
There have been several studies of drug levels achieved in 
perfusate during isolated limb perfusion with
melphalan444'446'449'450'451. In whole blood a constant 
fraction of about 37% of total melphalan is present within 
erythrocytes, and this fraction is independent of 
melphalan concentration452. The fraction binding to plasma 
proteins (mainly albumin) is constant at low 
concentrations of melphalan, but at high concentrations 
(>10/xg/ml) small increases in total melphalan result in 
larger increases in pharmacologically active free 
melphalan452.
Attempts have been made to estimate the proportion of 
administered melphalan which distributes to the tissues of 
the leg semi-quantitatively450 and quantitatively453. One 
previous publication describes the measurement of tissue 
concentrations of melphalan achieved by isolated limb 
perfusion448 in three patients.
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Some data on systemic levels of melphalan during perfusion 
has been obtained446'451. However it would be expected 
that even if isolation of the limb were perfect during 
perfusion then some re-distribution of melphalan might 
occur after re-connection of the normal circulation. A 
proportion of the administered dose, not washed out by 
flushing at the end of isolated limb perfusion, may be 
free to distribute in the systemic circulation. There have 
been no previous reports on the relationship between 
melphalan levels in the limb during perfusion related to 
systemic levels during and after perfusion.
111.3.4. Biotransformation
In aqueous solution it has been shown that melphalan 
decomposes to give monohydroxy-melphalan and dihydroxy- 
melphalan454. Monohydroxy-melphalan is much less cytotoxic 
than the parent compound and dihydroxy-melphalan has no 
anti-tumour activity455'456. Using HPLC to measure 
melphalan incubated in various fluids of different 
compositions it has been established that melphalan is 
more stable at low temperatures410'435'438,in acidic 
fluids410, and in the presence of protein452'457 and 
chloride ion410. Thus melphalan may be relatively 
protected from hydrolysis in protein-rich environments 
like the extracellular space or within the cell.
111.3.5. Duration of perfusion
The duration of isolated limb perfusion with melphalan is 
usually one hour213'331'444 but it may be as short as 45 
minutes359 or as long as two and a half hours327'446.
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There is no clinical trial based evidence to suggest that 
the optimal duration for isolated limb perfusion has been 
found. In spite of the short half-life of melphalan in 
aqueous solution, and the relatively short time of 
exposure involved in isolated limb perfusion, it may be 
that the drug is somewhat protected from hydrolysis once 
it leaves the vascular compartment. Furthermore, as 
discussed in III. 1.2., the drug in the tissues may
• • A 0 ^continue to form cross-links for hours after exposure . 
Hence there may be relatively little therapeutic gain 
achievable by prolonged clinical isolated limb perfusion, 
if maximal safe doses are already being given.
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III.4. AIMS
The aims of my studies were:
1) to measure and compare melphalan concentrations in 
perfusate during isolated limb perfusion, with the levels 
in the systemic circulation during and after perfusion,
2) to study the pharmacokinetics of melphalan in 
isolated limb perfusion, as the dose was increased in a 
phase I study,
3) to compare the pharmacokinetics of bolus dose with 
divided dose administration, and
4) to measure the tissue levels of melphalan achieved by 
isolated limb perfusion.
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III.5. PATIENTS, MATERIALS AND METHODS
III.5.1. Clinical perfusions
Local Ethical Committee approval was granted for all 
studies described here.
After a simple review of our experience with the first 2 6 
patients treated by isolated limb perfusion, it was 
confirmed that, because of the absence of melphalan- 
induced toxicity, there was scope for a phase I clinical 
study. In the context of this study it was decided to 
study melphalan pharmacokinetics.
Candidates for inclusion in the study were all those 
patients coming to external iliac perfusion for melanoma. 
The starting dose of melphalan was 1.5mg/kg body weight, 
which is the maximum dose recommended in the protocols on 
which our technique is based213'362. In the absence of 
significant toxicity we planned that the dose would be 
escalated by increments of 0.25mg/kg body weight.
The perfusion technique has been described (II.3.3.). 
Pharmacokinetic data was acquired on a total of 28
consecutive patients. The three main groups were:
\
A. 11 patients who had isolated limb perfusion by our 
standard method and melphalan dose of 1 .5mg/kg body 
weight, given by a single bolus injected into the venous 
line at the start of perfusion,
B. 9 patients who had a standard isolated limb perfusion 
with a melphalan dose of 1.75ma/ka body weight, given by a 
single bolus (as Group A), and
C. 6 patients who had standard isolated limb perfusion 
except for the melphalan dose of 1.75mg/kg body weight,
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which was injected into the venous line in three aliquots. 
at 0, 15 and 30 minutes during perfusion (as in the M.R.C. 
protocol).
Group B comprises patients in the second stage of our 
phase I study.
Group C patients were treated with the same dose as Group 
B, but it was given in divided amounts for comparison of 
the pharmacokinetic profile with that of group B. This was 
done because of our concern about the toxicity we observed 
with the M.R.C. protocol (II.5.11) for adjuvant perfusion. 
Pharmacokinetic data was also recorded for two of the 
three patients whom we treated according to the M.R.C. 
protocol.
III. 5.2. "Mock11 Perfusions
"Mock" perfusions were performed on 2 occasions to study 
how the levels of melphalan changed with time in a closed 
circuit consisting of identical perfusion apparatus (i.e. 
excluding the patient from the circuit) . In the "mock" 
perfusions, melphalan (lOOmg) was added to the standard 
prime (one unit of packed red blood cells + 750ml
Hartmann's solution). The perfusate was allowed to 
recirculate at 37°C and 39°C and samples were drawn, as in 
the clinical perfusions, at 5 minute intervals for 
melphalan assay. Melphalan was also incubated at 37°C and 
42°C in human plasma and in Eagle's Minimum Essential 
Medium (MEM) , at an initial concentration of 2 0/zg/ml for 
4 hours. Serial samples were taken for melphalan assay by 
HPLC.
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111.5.3. perfusate sampling protocols
In all cases a 5ml sample of perfusate was obtained from 
the arterial and venous ports of the oxygenator at 
2,5,10,15,20,25,30,35,40,45,50 and 60 minutes. In clinical 
perfusions 5ml samples were also drawn from the patient's 
radial arterial line before perfusion, at 15,30 and 60 
minutes (during perfusion), and at 75,90,120,150,180,240 
and 300 minutes (after perfusion).
All perfusate and blood samples were collected in lithium 
heparin tubes, mixed, and immediately placed on ice. 
Samples were centrifuged (2,500r.p.m. for 10 minutes) 
within one hour, then the plasma was separated and stored 
at -20°C for the minimum possible time before melphalan 
analysis by HPLC.
111.5.4. Tissue samples
Samples of malignant melanoma tissue, as well as normal 
fat and skin, were excised from accessible sites during 
and after perfusion from 15 patients (i.e. all patients 
coming to perfusion with visible nodules during the course 
of the pharmacokinetic studies).
When tissue was obtained it was immediately placed in a 
universal container and immersed in liquid nitrogen. 
Thereafter the tissue was stored at -20°C for the minimum 
possible time until melphalan assay. At the time of assay, 
tissue samples were thawed, weighed, minced with scissors 
and scalpel, then homogenised using an Ultra Turrax 
homogeniser in a volume of ice cold 0.01M NaH2P04/lmM EDTA 
at pH3.1. Care was taken to minimise heating of specimens 
during preparation. Samples were further homogenised using
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a Potter 'S’ homogeniser. The final volume is measured and 
duplicate 1ml samples of homogenate from each specimen 
were used for assay and subsequent analysis was as for 
plasma specimens, including the use of internal standard.
III.5.5. Melphalan assay by HPLC
The sensitive and specific HPLC assay which we used is 
based on the method described by Chang and colleagues438. 
10/xg of dansyl proline (Sigma) is added to a one 
millilitre or less portion of the thawed plasma sample. In 
the analysis dansyl proline acts as an internal standard, 
a substance which is chemically similar to melphalan (the 
losses of which parallel the losses of melphalan) but 
which generates a distinct peak on the chromatogram.
Four volumes of acetonitrile (BDH, HPLC Grade) with 1% 
hydrochloric acid (BDH, Analar Grade) are then added to 
the plasma in 15ml conical centrifuge tubes. The sample is 
vortex-mixed immediately for 15 seconds and then 
centrifuged at 2,000 r.p.m. for 10 minutes to precipitate 
protein. The clear supernatant is then transferred to 
30ml vials, and the volume is reduced to 300jul or less 
under vacuum using a Buchler vortex evaporator 
(approximately 25minutes at 30°C). The volume of the 
sample is then made up to 500/il with 20% methanol (BDH, 
HPLC Grade). The samples are transferred to autosampler 
vials, sealed and loaded in the autosampler.
The samples are injected by an Altex autosampler (Model 
500, Beckman RIIC) which has a 100/xl loop (50p. s. i.) . An 
Altex solvent programmer (Model 420, Beckman RIIC) and an 
Altex solvent pump (Model 100A, Beckman RIIC) deliver the
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mobile phase at 1.5ml/minute to a 250x4mm stainless steel 
column (Waters) , packed with jLtBondapak C18 (Waters) . The 
elution buffer consists of 50ml 0.01M NaH2P04 and 50ml 
methanol titrated to pH 3.0 with phosphoric acid (BDH, 
Analar Grade).
Eluted melphalan and dansyl proline were detected by a UV 
detector (Model LC-UV, Pye Unicam) set at 261nm 
wavelength. The UV spectrophotometer range was 0.01 or
0.02 A.U. The recorder was set at lmv and the chart run at 
lOcm/hr.
The data was processed by a recorder-integrator (Model 
DP88, Pye Unicam) which measures the areas under peaks on 
the elution chromatogram. The tR (retention time) value 
for melphalan was 6.68 minutes, and for dansyl proline 
9.57 minutes.
Standard curves were generated which confirmed the 
accuracy of the method over the range of melphalan 
concentrations 0.2-200/zg/ml (correlation coefficient, r =
0.9894). The coefficient of variation (standard 
deviation/mean x 100) for 20 identical samples at 2/xg/ml 
was 4.2%.
Ill.5.6. Pharmacokinetic analysis
The concentration time curves for bolus administration 
(groups A & B) were described by bi-exponential curves 
(Fig.13), fitted by the method of non-linear least squares 
(fitting by an "in-house" programme based on the 
Marquhardt458 algorithm - see Fig.14 and III.6.2.).
To estimate the tissue exposure to (or bio-availability 
of) melphalan during isolated limb perfusion, the area
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under each concentration time curve was calculated for 
clinical and mock perfusions. The area under the curve 
(AUC) was calculated by the trapezoidal rule, from time 
zero to sixty minutes (AUCq _60) for the arterial and 
venous concentrations in perfusate (AUCa and AUCV ). The 
same method was used to calculate the total AUC (AUCq^ )  
for systemic exposure to melphalan during and after 
perfusion (AUCg).
Incomplete mixing in the immediate phase after injecting 
the bolus of melphalan resulted in relatively wide 
variation in the levels measured in perfusate at two 
minutes. These values (included in Tables 26, 27 & 28)
were therefore omitted from graphical illustration and 
calculations.
Estimates of the tissue uptake of melphalan were 
calculated using two methods:
a) From the Fick principle459, the amount of a substance 
taken up by an organ per unit of time is equal to the 
arterial level minus the venous level (A-V difference), 
multiplied by blood flow,
i.e. (1) E = (A-V) x Q
when E = extraction rate, A = arterial level, V = venous 
level & Q = flow rate; assuming that arterial blood is 
the sole source of the substance.
Considering a controlled system like the isolated limb 
perfusion circuit, the amount of substance extracted by 
the limb can be estimated as being equal to the 
extraction rate multiplied by duration of perfusion. When 
a series of paired arterial and venous measurements are 
available, the AUCa and AUCV can be introduced into the
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equation.
i.e. for melphalan in isolated limb perfusion,
(2) MELex = E x time = <AUCa “ AUCv> x Q
when MELex = amount of melphalan extracted,
E = extraction rate, t = duration of perfusion,
AUCa = arterial AUC, AUCV = venous AUC, 
and Q = flow rate.
Assuming that Q is constant, and that MELex is 
accounted for by tissue uptake alone.
b) Briele described a semi-quantitative method for
estimating the proportion of drug extracted by the 
perfused limb using the percentage change in AUC with 
time459. It is assumed that the entire AUCq_60 is an 
overestimate of melphalan exposure, because a proportion 
of administered drug is discarded when the perfusate is 
washed out at the end of perfusion. To account for this, 
the area bounded by lines having their origin at the 60 
minute point concentration and projected back to the x and 
y axes is subtracted from the total A U C q _ 6 q  (cf. Fig. 13). 
The change in percentage of derived A U C q _ 3 0  and AUC30_60 
is used to calculate the percentage of melphalan
remaining in the perfusate which is then plotted against 
time, for comparison with the values obtained in a "mock" 
perfusion (Figs. 15,16,17).
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III.6. RESULTS
111.6.1. Perfusate versus systemic melphalan levels
Tables 26, 27 and 28 show the concentrations of melphalan 
measured in perfusate and systemic circulation for 
patients in Groups A, B and C expressed as means with 
standard deviations and standard errors. Illustrating the 
data for Group A, Fig. 18 shows that the perfusate levels 
of melphalan are much higher than systemic levels during 
and after isolated limb perfusion. Error bars are omitted 
for clarity of presentation. Table 29 shows the arterial 
and venous AUC q _60, and the systemic AUCq ^oq for each 
patient in Groups A, B and C. It is clear that within all 
three groups the median AUCS is much lower than the AUCa 
or AUCV . No statistically significant difference was 
detected between the AUCS values of Group A versus Group 
B, or of Group B versus group C (Mann-Whitney). The higher 
dose regimes are not associated with any increase in 
systemic exposure (AUCS).
111.6.2. Pharmacokinetics and Phase I study
Fig. 13 shows the curves describing arterial and venous 
melphalan levels during isolated limb perfusion in Groups 
A and B. Again the small error bars are omitted for 
clarity. The mean arterial and venous melphalan 
concentration time curves for Group A and Group B can be 
fitted to lines described by bi-exponential equations of 
the form:
ct = A.e~a,t +
where C^ . is concentration at time "t" mins,
A and B are intercepts on the log concentration
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axis at t=Omins, of the two linear components of
the curve describing logC against time,
and a and (3 are the rate constants of these two
components460.
The fitted lines are illustrated in Fig. 14. The values 
for the parameters A, B, a and /?, are given in Table 30, 
along with the half-life (t^) values derived from the 
fitted lines.
Figs. 15 and 16 show the curves describing melphalan 
concentrations in perfusate during "mock" perfusion at 
37°C and 39°C. Lines were fitted (Fig. 19) to describe 
these curves according to the mono-exponential equations: 
C^ . = 98.4 x e-0,013**' for the 37°C experiment, 
where t ^ 2 = 51 •6 minutes; 
and Cj. = 104 x e“0,02 for the 39 °C experiment,
where ti = 3 6.6 minutes.'I
It can be seen that the half-life of melphalan in the (3 
phase t^ /3 of clinical perfusions is longer than the t^a 
and it approximates to the values for the half-life times 
in the "mock" perfusions.
Tables 26, 27, 29 and Fig 13. show that increasing the
dose of melphalan from 1.5 to 1.75 mg/kg body weight 
resulted in higher levels of melphalan in perfusate. 
Comparing drug exposure in perfusate (Table 29) the values 
for AUCa and AUCV are both significantly greater in Group 
B than in Group A (p values <0.01, Mann-Whitney).
The regional toxicity for patients in the phase I study is 
described in Table 31. In group B we saw Wieberdink grade 
III reactions on two occasions. Since we had not seen such 
toxicity in either group A or in the pilot group of 26
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patients, and because of the toxicity encountered with the 
2mg/kg dose in the M.R.C. protocol (II.5.11) it was 
decided that 1.75mg/mg body weight was close to the 
maximal dose for our system.
111.6.3. Bolus or divided dose?
Fig. 2 0 shows the curves describing melphalan 
concentration after bolus (Group B) or divided dose (Group 
C) administration of melphalan 1.75mg/kg body weight. From 
data in Table 29, there is no significant difference 
between Group B and Group C (Mann-Whitney) in either the 
AUCa , AUCV or AUCS . Table 31 shows that the incidence of 
regional toxicity is also similar in Groups B and C.
111.6.4. Calculations of tissue uptake of melphalan
The results for the calculation of MELex, according to the 
Fick principle, in the three groups of patients are given 
in Table 32, along with the same calculation for a "mock" 
perfusion at 39°C.
The t^ of melphalan in human plasma in vitro was 114 
minutes at 37°C and 60 minutes at 42°C (see Fig. 21). In 
the "mock" perfusions the t^ values (III.6.1.) were less 
than in vitro incubations (Figs. 21 & 25), suggesting that 
hydrolysis proceeds more rapidly or that a significant 
amount of melphalan may be "lost" to the constituents of 
the circuit and to the cellular components of the 
perfusate. Assuming that hydrolysis is similar in the 
three groups, the combined results of the calculations in 
table 32 suggest that approximately 25-40% of administered 
melphalan distributes to the tissues of the leg (after
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correction for the proportion "lost" to the circuit) 
during isolated limb perfusion.
The slopes of the concentration time curves after bolus 
dose administration (Fig. 14, Table 30) indicate that 
melphalan disappears from perfusate more rapidly in the 
first half-hour of perfusion. Equation (2) can be applied 
separately to the AUCq_30 and the AUC30_60 for Groups A, B 
and C. Table 33 shows that after bolus administration 
(Groups A & B) more melphalan is apparently taken up 
during the first thirty minutes of perfusion than during 
the second thirty minute period. Melphalan extraction 
seems to continue during the second thirty minute period, 
especially after divided dose administration.
The results for calculations based on Group A and B data 
according to the method of Briele and colleagues456 are 
illustrated in Fig. 17. Using this method, the results for 
Groups A and B were remarkably similar.
III.6.5. Tissue concentrations of melphalan
41 tissue^ specimens for melphalan assay were taken from 15 
patients with recurrent melanoma at 55 minutes during 
isolated limb perfusion.
The measured tissue levels of melphalan are shown in Table 
34. The levels in tumour were significantly higher than 
levels in surrounding fat (p<0.01, Wilcoxon signed rank 
test), but not significantly different from levels in 
adjacent normal skin.
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III.7. DISCUSSION
III.7.1. Systemic exposure to melphalan
Although there has been increasing interest in the 
pharmacokinetics of isolated limb perfusion, there has 
been no previous work which quantifies the total systemic 
exposure to melphalan resulting from this treatment.
It is important to realise that good surgical technique, 
including awareness of anatomical variations and thorough 
dissection of the vessels, help to prevent sudden major 
"leaks" to the systemic circulation during perfusion. Even 
with perfect operative technique, however, there is a 
variable but inevitable escape from the "isolated" limb 
and this may be due to "leakage" through intra-osseous 
femoral vessels, vessels passing through the obturator 
foramen or calcified branches of the cruciate anastomosis 
which may not be occluded by the tourniquet. After 
isolated limb perfusion a proportion of the melphalan 
taken up by the tissues of the limb may diffuse back into 
bloodstream and be "washed out" into the systemic 
circulation.
Studies have shown, using radio-labelled albumin, that the 
measured "leak" from perfusate to the systemic circulation 
during isolated limb perfusion may be as much as 
4 0%445'446/450, deSpite very low systemic melphalan levels 
during perfusion446'445. On such evidence it is claimed 
that the radio-labelled albumin method simply over­
estimates the "leak" of melphalan445 but this line of 
argument neglects several important factors. Albumin is a 
relatively stable large molecule which will tend to remain 
within the vascular compartment. In contrast melphalan is
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continually degraded by hydrolysis in aqueous 
environments, and the fraction of melphalan which "leaks" 
from the isolated limb to the systemic circulation will 
partition within a much larger volume of distribution 
(intravascular and interstitial fluid). Furthermore some 
of the melphalan taken up by the tissues (of the perfused 
leg and the rest of the body) may be protected from 
hydrolysis by associating with tissue proteins457'461 and 
released later, when the melphalan concentration gradients 
are reversed after perfusion. Thus a significant fraction 
of the administered melphalan dose could "leak" and be 
"washed out" from the perfusate to systemic circulation, 
yet produce only low systemic plasma concentrations.
It is clearly important to establish whether the complex 
and expensive technique of isolated limb perfusion 
genuinely achieves its major aim i.e. maximum levels of 
melphalan in the tumour-bearing limb and minimum systemic 
exposure. For these reasons we measured systemic melphalan 
levels during and for several hours after perfusion to 
' determine the total systemic exposure (Tables 26,27,28 & 
Fig. 18) , described by the systemic AUCq^  (AUCs) .
The peak concentrations of melphalan were much higher in 
perfusate than in the systemic circulation in all three 
groups (ratios of peak perfusate:systemic levels in /xg/ml 
- A 45:0.76, B 75.3:0.53, C 44:0.4).
Recent studies describing the pharmacokinetics of high- 
dose systemic intravenous melphalan (assay by HPLC) have 
shown mean AUC values of approximately 400/xg.min/ml in 
adults448'462'463. From Table 29 it can be seen that in 
all our patients the AUCa and AUCV are both much higher
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than this. In the great majority the AUCS is much lower, 
being over 3OOjLig.min/ml in only two patients. The mean 
ratio of AUCa/AUCs in our patients was 16.1/1.
I have therefore shown in this consecutive series, that 
isolated limb perfusion successfully achieves very high 
levels of melphalan in the limb perfusate, with little 
systemic exposure to melphalan during or after perfusion.
111.7.2. Pharmacokinetics of bolus administration
The concentration time curves describing melphalan in 
perfusate after bolus administration (Fig. 13) are 
biphasic, conforming to a two compartment model. In groups 
A and B the t^ (half-life) for the first, or a phase, was 
shorter than in the (3 phase. The concentration time curves 
for "mock" perfusions were monophasic, conforming to a one 
compartment model. The t^ in the (3 phase of clinical 
perfusion is similar to the half-life observed throughout 
"mock" perfusions, when the rate of decay depends on 
hydrolysis plus losses in the perfusion circuit.
It is inferred that association of melphalan with the 
perfusion apparatus and cellular components of perfusate 
account for the difference between the concentration time 
curves for in vitro incubations in plasma (Fig. 21) and 
"mock" perfusions (Figs. 15, 16 & 19). Similarly the rapid 
loss of melphalan from perfusate in the a-phase of 
clinical isolated limb perfusion is ascribed mainly to 
uptake by the tissues of the limb.
111.7.3. Phase I study and dosimetry
To take full advantage of the potential benefit of
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isolated limb perfusion it is important that the tumour- 
bearing limb is subjected to the maximal safe melphalan 
exposure, which is a function of time and concentration 
and which can be quantified by the perfusate AUC.
There is a trend towards melphalan dosimetry for isolated 
limb perfusion according to limb volume318. The 
measurement of limb volume by water displacement400 can be 
a cumbersome procedure, particularly in older patients, 
unless there is a suitable safe hoist. There have been no 
reports describing the accuracy and reproducibility of 
limb volumetry by water displacement. In a small
prospective study, Van Os and colleagues (using lOmg/litre 
of limb volume) found that the equivalent of 1.77mg/kg 
body weight could be given safely in their patients (their 
previous mean dose 1.44mg/kg)464. Similar results would 
have been obtained in their study if the higher doses had 
simply been administered on the basis of body weight. For 
patients of "average build" body weight is an acceptable 
basis on which to calculate dose in isolated limb
perfusion, but the use of limb volume dosimetry may be of 
specific value in the management of patients who have an 
abnormal habitus, or amputees.
It is generally accepted that a lower total dose of
melphalan should be used when perfusing smaller regions of
the body e.g. axillary perfusion. In this setting the
limb volume method for dosimetry results in doses which
are probably inadequate464 since they are even lower than
*
those calculated on the basis of body weight390. Although 
the rationale is plausible the practical benefits of 
routine dosimetry by limb volume are unclear.
174
It has been recommended that other factors to be 
considered when calculating the dose of melphalan to be 
administered include complexion and hair colour465'333 - 
fair-skinned red-heads being supposedly more susceptible 
to toxicity than those of a dark complexion but these 
recommendations have not been validated.
Body weight is obtained easily and reproducibly on the 
ward, without special equipment. We believed that since no 
formal phase I study had been carried out using body 
weight for dosimetry such a study should be completed 
before adopting routine limb volume dosimetry.
In the phase I study it was found that the dose of 
melphalan could be increased from 1.5mg/kg body weight 
(Group A) to 1.75mg/kg (Group B) with an acceptable 
slight increase in regional toxicity (Table 31). The peak 
levels of melphalan were higher after 1.75mg/kg than after 
1.5mg/kg, and the higher levels were maintained during 
perfusion. Comparison of the perfusate AUC data for Groups 
A and B (Table 29) confirms that the higher dose resulted 
in significantly greater bio-availability of melphalan 
within the limb, without any increased systemic exposure. 
It is interesting to note that of the five cases which had 
an AUCS value greater than 2 OO/zg. min/ml none suffered 
significant systemic toxicity and, in particular, there 
was no detected bone marrow toxicity.
In reports of isolated limb perfusion it is remarkable 
that the volume of perfusate, which critically determines 
the effective concentration of melphalan, has been so 
neglected. The volume of prime is easily measured directly 
but the volume of blood trapped in the limb vasculature
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is probably more variable. We have discussed how the 
volume of priming fluid varies in descriptions of isolated 
limb perfusion according to different authors (III.3.2). 
We used a fixed volume of prime and a standard cannulation 
sequence, but some of the variability in our 
pharmacokinetic results is likely to be due to the 
variable volume of trapped limb blood which contributes to 
the total perfusate volume.
Benckhuijsen and colleagues444 and Lejeune445 have 
recently described elegant methods for estimating 
perfusate volume (which equals the volume of prime plus 
the volume of blood trapped in the limb at cannulation). 
The validity of these methods has not been confirmed, but 
the attraction is that, based on pharmacokinetic 
parameters, accurate knowledge of the perfusate volume 
would allow the administration of a dose calculated to 
produce a predictable concentration (and AUC) in 
perfusate. Assuming that cytotoxic effect and toxicity are 
mainly dependent on melphalan concentration and AUC, this 
would represent an advance on dosimetry by body weight or 
limb volume. In an ideal hypothetical situation, this new 
approach would be combined with knowledge of the relative 
sensitivities of an individual patient's tumour (and 
normal tissue) to cytotoxic drugs, allowing "tailored" 
therapy.
Ill,7.4. Bolus or divided dose?
Our experience with the M.R.C. protocol for adjuvant 
isolated limb perfusion led us to question whether the 
mode of administration (bolus or divided dose) was as
176
important as total dose in determining regional toxicity, 
perhaps because of different pharmacokinetics.
While conducting our phase I study we treated two patients 
according to the M.R.C. protocol for adjuvant isolated 
limb perfusion. The significant regional toxicity suffered 
by one patient (Wieberdink grade IV, see II.5.11 and Fig. 
11) was associated with high values for AUCa 
(3117min. jLtg/ml) and AUCV (2797min./xg/ml) , after 
administration of melphalan (2mg/kg) in three divided 
doses to a total of 180mg (cf. Groups A & B in Table 29) . 
The other patient was given lOOmg according to the 
protocol, producing AUCa of 1765min. /zg/ml and AUCV of 
2359min.^g/ml without any toxicity.
Once we determined that melphalan could be safely given as 
a bolus dose of 1.75mg/kg body weight (Group B, Table 31), 
we set out to discover whether divided dose administration 
at this dose' level (Group C) resulted in greater AUCa and 
AUCV values. There was no significant difference in these 
values between the two groups. However one patient in 
Group C (total dose 175mg ; AUCa 2116 min.jug/ml) suffered 
a severe reaction (Wieberdink Grade IV, see Fig 22).
A possible explanation for these observations is that we 
routinely use a rather lower priming volume than some of 
those involved in preparing the M.R.C. protocol332. Our 
method may result in relatively high perfusate 
concentrations. Were this the case then a relationship 
between regional toxicity and AUCa and/or AUCV would be 
expected. From Table 29 it can be seen that serious 
regional toxicity bore no clear relationship to these 
values. The incidence of regional toxicity, however, is
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low in our small series.
I have shown shown that up to 165mg of melphalan can be 
given safely as a bolus (calculated as 1.75mg/kg body 
weight) during isolated limb perfusion, and that there is 
no apparent pharmacokinetic advantage in divided dose 
administration.
III.7.5. Calculations of tissue uptake of melphalan
It would clearly be desirable to know what proportion of 
administered melphalan is taken up by the tissues of the 
leg, and also to discover how that proportion is 
distributed among the different tissues (especially any 
differences between benign and malignant). With this 
knowledge the effects of various manipulations (e.g. 
changing dose of drug, duration of perfusion or 
temperature) could be assessed.
It has been suggested that cellular uptake mechanisms for 
melphalan may be saturable in the perfused limb444'450. 
This is the first study where paired arterial and venous 
samples of perfusate were obtained for melphalan analysis 
throughout the hour of isolated limb perfusion. Hence we 
could use the perfusate AUC data in Formula (2) which is 
derived as described (III.5.6) from the Fick principle. 
Uncorrected, the results tend to overestimate the amount 
of melphalan taken up by the leg (MELex) at 45-60% of 
administered dose. It is important to realise that the 
melphalan concentration measured is the plasma 
concentration, and that although hydrolysis is corrected 
for, melphalan is known to rapidly associate with the 
cellular components of blood4^0 '4^2 in a ratio of
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cells:plasma equal to approximately 1:1444. During the 
hour of perfusion a fraction of the administered dose 
(approximating to the haematocrit as %) partitions to the 
red blood cells, and this contributes to the 22% 
correction factor as calculated by applying Formula (2) to 
the "mock" perfusion (see Table 32).
The uncorrected results for a similar calculation using 
the AUC q _3q and AUC30_6q values (Table 33) seem to 
support the suggestion that melphalan uptake mechanisms in 
the tissues of the leg are less effective in the second 
half-hour after bolus administration (Groups A & B), but 
dividing the dose (Group C) allows continued drug uptake 
during this period. It is not clear whether this is 
advantageous, or whether it is preferable to generate very 
high peaks by bolus administration. Yet another strategy 
would be to administer the cytotoxic by infusion into the 
arterial line of the circuit, while slowing the flow rate 
to maximise the effect of first-pass extraction. 
Homogeneous mixing of melphalan within the perfusate might 
be achieved by injecting the drug via the arterial line 
during the course of one circulation time400.
Briele and colleagues450 described a method for 
calculating the uptake of melphalan semi-quantitatively. 
Our results (Fig. 17) are similar to those obtained in 
the original paper450 although it appears that in our 
patients (Group A & B) there is continuing uptake of 
melphalan by the leg in the second half-hour of perfusion. 
Briele has suggested that the duration of perfusion can be 
reduced, because no uptake of melphalan by the leg was 
calculated in the second half-hour, and this was
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attributed to a saturable cellular uptake mechanism450. 
There are flaws in this argument, however. Firstly, an 
initial step in the method of calculating the percentage 
change in AUC is the subtraction of a portion of the total 
AUC (III.5.6.), which involves an assumption that the 
actual concentration of melphalan is unimportant in 
determining tissue uptake. In fact, in a tumour-bearing 
limb the effective plasma concentration will govern 
concentration gradients, which are particularly important 
determinants of drug diffusion in poorly vascularised 
tissues e.g. ischaemic tumour nodules. Secondly, it is 
probably important to maintain effective concentration 
gradients for at least a minimum time (which will vary 
depending on the cytotoxic drug used) because of the 
existence of barriers to penetration of cytotoxics309, 
especially when it is known that even intracellular 
melphalan can egress rapidly down concentration 
gradients432.
Estimates of tissue uptake based on changes in perfusate 
concentration of melphalan (e.g. our Fick based 
calculations, the work of Briele450 and Benckhuijsen453) 
are merely indicators of the dynamic situation in the 
limb as a whole, but the critical question relates to the 
concentration of melphalan which is achieved at the site 
of action i.e. tumour cell DNA. The changes in perfusate 
concentration of melphalan will be, at best, crude 
indicators of critical events which govern the passage of 
melphalan from the capillary lumen to the melanoma cell 
nucleus.
Hence, and because we obtained different results using an
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identical method to Briele and colleagues450, I believe 
that it is premature to advocate shorter periods of 
perfusion.
Ill•7•6• Tissue levels of melphalan
In one previous report melphalan concentrations have been 
measured in the limb perfusate and tissues of three 
patients having isolated limb perfusion448. The main 
findings were that more melphalan was detectable in tumour 
than in subcutaneous fat, and that clinical response may 
be correlated with tumour concentration of melphalan448. 
Initially, in our studies, it was hoped to obtain 
sufficient tissue samples for analysis of the time course 
of tissue levels of melphalan. It has already been 
explained that many of our patients were referred after 
excision of recurrent melanoma and very few patients had 
multiple tumour nodules large enough for assay for 
melphalan. It was therefore decided to take as many 
samples as possible at the one time point, towards the end 
of perfusion. The tissue concentrations of melphalan which 
we measured seem to be lower than those recently 
calculated by Benckhuijsen and colleagues453 but their 
estimates are derived from a selected sub-group of 
perfusate time-concentration curves and are expressed in 
terms of /ig/ml of tissue water (approximately equivalent 
to 60% of tissue mass). Furthermore, as they admit, tumour 
uptake cannot be calculated from their estimates of total 
tissue uptake and, as others have shown, distribution 
within tumour masses may be uneven309.
We were encouraged that the concentrations of melphalan in
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large necrotic tumour nodules were similar to those in 
well perfused normal tissue like skin, and greater than 
the concentrations in fat. Furthermore, most of our tissue 
specimens were obtained during perfusion from the upper 
part of the thigh or inguinal region which may not be as 
well perfused as the lower leg and foot. The tissue levels 
in the distal part may well be higher than those we 
measured in the proximal part.
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III.8. CONCLUSIONS
Isolated limb perfusion successfully and consistently 
achieves the aim of exposing the tumour-bearing limb to 
high concentrations of melphalan, while minimising 
systemic exposure.
Following bolus administration of melphalan the 
concentration time curve is biphasic, with a t^a of 4- 
8 minutes and t^ /3 of 33-180 minutes. Melphalan seems to be 
taken up by the tissues of the leg mainly during the first 
30 minutes of isolated limb perfusion. However perfusion 
should last longer than 30 minutes to maintain the 
concentration gradients which drive the drug through 
diffusion barriers to the target cells.
In a phase I study we have shown that, using our standard 
technique of isolated limb perfusion, melphalan can be 
given safely in a bolus dose of 1.75mg/kg body weight (up 
to 165mg total dose).
There was no pharmacokinetic advantage in divided dose 
administration, and no increased regional toxicity as a 
consequence of bolus dose administration.
It is encouraging that isolated limb perfusion achieved 
levels of melphalan in large necrotic tumours which were 
higher than the levels in fat, and similar to the levels 
in well-vascularised healthy skin.
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CHAPTER IV
IN VITRO STUDIES
IV.1. BACKGROUND
IV.1.1. Introduction
Clinical isolated limb perfusion presents a unique 
opportunity to alter the physio-pharmacological 
environment of a tumour in order to maximise the 
therapeutic effects of the cytotoxic drug used, while 
minimising systemic toxicity and maintaining the viability 
of the normal tissues of the limb. Differences in 
perfusion techniques have evolved around the world 
empirically (see 1.5.2., II.5.8. & 12.) and the importance 
of resulting variables in the system (e.g. duration of 
perfusion, concentrations of drug, temperature, pH and P02 
in perfusate and tissues) is largely unknown. There have 
been no adequate clinical studies addressing such 
questions although isolated limb perfusion has been
. . 1 1 7  “l i o  ,
practised for thirty years Until such trials are
reported, we must be guided by the results derived from 
appropriate experimental models.
It should be possible to exploit the special physio- 
pharmacological conditions within the limb which may allow 
us to enhance the anti-tumour effect of melphalan on 
malignant melanoma cells. In preceding chapters I have 
described our clinical method of isolated limb perfusion 
and the associated physio-pharmacology. Simple systemic 
administration of cytotoxic agents is clearly an 
inappropriate model for the special conditions associated 
with isolated limb perfusion.
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In this chapter variables which may be of importance in 
determining the efficacy of isolated limb perfusion are 
examined in vitro.
IV.1.2. The multicellular tumour spheroid model
In recent years there has been pressure to reduce animal 
experimentation for ethical as well as financial reasons. 
Simultaneously there has been a dramatic increase in the 
application of in vitro tissue culture techniques, and 
recently there has been more success in the culture of 
human tumour cells.
For a combination of these reasons, in my efforts to 
optimise the clinical results of isolated limb perfusion, 
I have used in vitro models, particularly multicellular 
tumour spheroids.
Most routine cell cultures are maintained as a monolayer, 
a two-dimensional sheet of flattened cells, anchored to 
the base of a plastic or glass vessel and immersed in 
liquid culture medium. However, three-dimensional 
aggregates of animal cells have been used in embryology 
since the original work on morphogenesis by Holtfreter in 
1944466. Using cellular aggregates formed from single cell 
suspensions, in 1957, Moscona467 demonstrated the invasive 
potential of malignant melanoma cells in vitro. It was 
subsequently shown that tumour cells had a greater 
tendency than normal cells to form aggregates468. 
Multicellular tumour spheroids (Fig. 23) are three- 
dimensional aggregates of tumour cells which take more or 
less spherical forms. In suspension culture spheroids grow 
by division of cells in the outer viable rim which is the
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part most accessible to nutrients in the liquid culture 
medium.
In this three-dimensional tumour model, even with small 
spheroids, there are metabolic
gradients469'470/471,472,473,474, resulting proliferation 
gradients475'476'477'478'479'480, and drug penetration 
barriers481'482'483. These features are important 
characteristics of tumours in vivo which are not apparent 
in monolayers or single cell suspensions. The growth of 
multicellular tumour spheroids follows Gompertzian
kinetics, like the growth of tumours in vivo484. The 
three-dimensional spheroid system is particularly 
attractive as a model for the solid tumours, which have 
generally proved more difficult to treat than other 
malignancies, and where "resistance" to therapy seems to 
be partly related to the three-dimensional nature of the 
primary tumour and its metastases.
Multicellular tumour spheroids can be regarded as a system 
of intermediate complexity between tumour cells in 
monolayer tissue culture and similar cells growing as 
xenografts in vivo. The size, morphology and growth 
pattern of the multicellular tumour spheroid makes it a 
particularly attractive model for the avascular micro­
metastasis.
Sutherland and associates were first to report the use of 
"multicellular spheroid" aggregates in experimental 
radiation therapy475'485'486'487. They observed that the 
spheroids had a similar structure to murine475'485 and
4 88human tumour nodules . The cell survival curves after
experimental radiation therapy in this in vitro model
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resembled those of solid tumours475'485. In recent years 
the potential of this model for the experimental 
chemotherapy of human tumour cell lines has begun to be 
exploited (Table 35).
We have developed the use of the multicellular tumour 
spheroid model in our studies because this system allows 
us to simulate the uniquely controlled but abnormal 
physio-pharmacology which prevails in the limb during 
isolated perfusion.
IV.1.3. Drug levels and duration of perfusion
Studies of melphalan pharmacokinetics in isolated limb 
perfusion indicate that the plasma levels of the drug are 
much higher and more sustained than can be achieved even 
by high systemic doses with autologous bone marrow rescue 
(III. 6.1.). It is important that the levels of drug used 
in an in vitro model should be similar to those achieved 
clinically. The relevant measurement is the level of 
melphalan in and near tumour nodules which will be related 
to, but not equivalent to, plasma levels of the drug. In 
accordance with the results of my own work on plasma and 
tissue pharmacokinetics of melphalan in isolated limb 
perfusion (Chapter III), the concentration range of 1- 
16jLtg/ml is used in most in vitro experiments described in 
this chapter.
Our routine for clinical isolated limb perfusion involves 
a one hour exposure to melphalan but the optimum 
time/concentration relationship has not been established. 
Tissue pharmacokinetics are dependent on plasma 
pharmacokinetics but distribution within the different
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tissues is variable (III.6.4.). The efficacy of melphalan 
depends upon the formation of chemical cross-links, a 
process which reaches a maximum several hours after 
exposure to the drug423. Hence the relationship between 
duration of exposure to melphalan in isolated limb 
perfusion and the resulting cytotoxic effect is complex. 
There have been no previous studies describing the 
relationship between duration of exposure to melphalan and 
cytotoxic effect. As a base-line it is therefore 
appropriate to consider the effect of varying the duration 
of exposure in an in vitro model which is based on, but 
simpler than, clinical isolated limb perfusion.
IV.1.4. Melphalan and temperature
As demonstrated for our patients (II.4.4., Table 21), the 
temperature of the limb is usually less than 37°C before 
isolated limb perfusion. In 1960 Rochlin325 showed that 
without active heating the limb temperature drops further 
during isolated limb perfusion. From elementary physiology 
it can be anticipated that low perfusate temperatures
would be associated with vasoconstriction, increased 
perfusate viscosity, and poor perfusion of the tumour- 
bearing limb. The cellular uptake of melphalan by active
497 498 49Qcarrier ' ' 5 would also be reduced in hypothermic
conditions. To minimise these effects it seems appropriate
to perfuse the limb at a temperature close to the
physiological normal of 37°C.
As discussed in 1.5.2. , the value of heating the limb
above the "normal" physiological temperature of 37°C, i.e. 
hyperthermia, in isolated limb perfusion with melphalan is
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controversial and there is no definitive clinical study to 
indicate the optimal temperature conditions. Although 
widely quoted213'350'364 as demonstrating the advantage of 
hyperthermic isolated limb perfusion, Stehlin's 
work327'329 has already been criticised in this thesis 
(1.5.2.). Furthermore, normothermic perfusion has been 
reported to achieve response rates as high as hyperthermic 
isolated limb perfusion344.
The rationale for hyperthermic isolated limb perfusion 
with melphalan is founded on the selective sensitivity of 
malignant cells to heat, and on the enhancement of 
melphalan cytotoxicity by heat. Heat has a long history in 
the treatment of cancer. Direct applications of red hot 
irons were used in the treatment of cutaneous cancers in 
the times of Ramajama (2000BC), Hippocrates (400BC) and 
Galen (200AD)489. The evolution of modern methods of 
hyperthermia for cancer treatment has been 
documented326'489'490'. Giovanella491 has summarised the 
experimental evidence that malignant cells are more 
sensitive than normal cells to hyperthermia.
The combination of hyperthermia plus regional chemotherapy
was first used to enhance the cytotoxic effect on tumours
• 4 Q 9 4 Q 8 .m  1960 . Shmgleton and colleagues^*3 used regional
hyperthermia to enhance the local action of cytotoxic
drugs (including melphalan) along with systemic
hypothermia to reduce marrow toxicity. Suzuki494 indicated
that regional perfusion systems were particularly suitable
for administering hyperthermia. He observed that tolerance
to heat was likely to be variable depending on the
relative sensitivity of tumour and normal tissues, and
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that certain labile drugs may be inactivated by heat.
When used clinically in the treatment of cancer, regional 
perfusion with hyperthermia alone (up to 45.8°C, for up to 
6 hours 50 minutes) produced some encouraging responses 
but was associated with unacceptable morbidity and 
mortality326. Damage to normal tissues was due to a 
combination of poor perfusion (low flow rates), direct 
hyperthermic damage and haemolysis. Some reports have 
shown no systematic difference in heat sensitivity 
comparing normal and malignant cells495'496. In other 
studies where malignant cells have been shown to be more 
sensitive than normal cells to heat329, or heat plus
4Q7 4Q8 4QQmelphalan*^ ' the normal cells were not those of 
the tissues which prove dose-limiting in isolated limb 
perfusion. In an elegant biochemical study of isolated 
perfusion Ghussen and Isselhard500 have shown that damage 
to the muscle of the canine limb is dose-limiting at 
temperatures greater than 43°C for one hour.
It is paradoxical that melphalan should be used so widely 
in hyperthermic isolated limb perfusion because melphalan 
is a labile substance which is hydrolysed to inactive 
metabolites more rapidly at higher temperatures419'438. 
Indeed, Cavaliere501 has stated that melphalan becomes 
ineffective at temperatures greater than 41.8°C. In spite 
of this, some studies using in vitro assays have indicated 
that hyperthermia may enhance melphalan cytotoxicity, 
especially at temperatures over 42°C497. Furthermore, in 
an in vivo study of thermochemotherapy (41°C) with various
cytotoxic drugs, an absolute therapeutic gain was found
498 . .only for melphalan^0 and this gain could not be explained
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fully by changes in melphalan pharmacokinetics499.
Since the relationship between temperature and melphalan 
cytotoxicity is controversial, I set out to explore the 
interaction using a controlled in vitro system (to 
circumvent any vascular effects of temperature or 
melphalan) and conditions which were closely modelled on 
those which occur in isolated limb perfusion for melanoma.
IV.1.5. Melphalan and verapamil
Verapamil is a phenylalkylamine which blocks the 
transmembrane flux of calcium ions (calcium channel 
blocker) and it is best known clinically as a vasodilator 
and anti-arrhythmic502. Verapamil is a potent vasodilator 
which increases tumour blood flow in tumour-bearing
C  A O
rats u . It is interesting that in mice bearing 
experimental fibrosarcomas504'505 and in human melanoma 
xenografts505 verapamil appeared to enhance melphalan 
cytotoxicity without influencing the fractional 
distribution of cardiac output. It was shown that 
verapamil altered the pharmacokinetics and increased 
tumour uptake of melphalan505. The vaso-active drug 
hydralazine has also been shown to selectively enhance the 
cytotoxic effect of melphalan in vivo, perhaps by reducing 
tumour blood flow and decreasing the rate at which 
melphalan is cleared from the tumour tissue506.
Cancer cells may be inherently resistant to a cytotoxic 
drug or they may acquire resistance by exposure to the 
drug. Verapamil has been shown to partly overcome acquired 
resistance to chemotherapeutic agents, and to a lesser 
degree, to potentiate the efficacy of these drugs against
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sensitive cells . Verapamil reduces acquired adriamycin- 
resistance in human lung cancer cell lines508 and in human 
glioma cell lines509, probably by blocking the active 
efflux mechanisms which drive cytotoxic drug from the 
cell. Verapamil may also enhance the chemotherapeutic 
efficacy of adriamycin and thiotepa against human bladder 
cancer cell lines510, and it may increase the efficacy of 
vincristine against primary human colorectal cancer 
tissue511.
Unfortunately, for systemic chemotherapy, the 
concentration of verapamil required for the anti­
resistance effect may be higher than the maximum prolonged 
plasma concentration which can be safely maintained 
clinically (0.45/zM)512. In isolated limb perfusion it 
should be possible to use much higher levels of verapamil 
in the perfusate, albeit for shorter time periods.
I chose to study the possible interaction between 
verapamil and melphalan in vitro, and hence in a system 
where vascular effects are absent.
IV.1.6. Melphalan and pH
Melphalan is more stable in acidic conditions410 and we 
found that the perfusate tends to alkalosis during our 
standard isolated limb perfusion (II.4.4.). pH has been 
shown to influence both the cellular uptake of cytotoxic 
drug483 and the sensitivity of tumour cells to 
hyperthermia513. pH may also affect the affinity of 
melphalan for cellular and plasma proteins. Since pH can 
be adjusted easily during isolated limb perfusion, I 
studied the effect of pH on melphaian cytotoxicity in
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vitro.
IV.1.7. Solvents and amphotericin-B
Solvents used to prepare anticancer drugs may have a 
cytotoxic effect on cells in culture e.g. ethanol, 
dimethyl sulphoxide514. Amphotericin-B (Fungizone, Gibco) 
which is routinely used in culture media has been reported 
to have a cytotoxic effect on mammalian cells at 43 °C 
and may enhance the cytotoxic effect of anti-cancer 
drugs516. Therefore specific in vitro experiments were 
designed to take account of these variables.
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IV.2. AIMS
The aims of my in vitro studies were:
1) to grow multicellular tumour spheroids from 
established human malignant melanoma cell lines.
2) to minimise experimental artefact and compare the 
results of experimental chemotherapy with melphalan in 
conditions analogous to those in clinical isolated limb 
perfusion.
3) to study the influence of a) temperature, b) time of 
exposure, c) verapamil, and d) pH on melphalan 
cytotoxicity in the human melanoma spheroid model.
4) to compare the results of the spheroid assay, with 
the results of standard colony forming assays using 
disaggregated spheroids and monolayers of the same cell 
line.
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IV.3. MATERIALS AND METHODS
IV.3.1. Cell lines
The cell lines used in these studies were B0008, B0010 and 
MEL57. All three are established human malignant melanoma 
cell lines. The characteristics of B0008 and B0010 
(originally denoted Hs294T and Hs852T, respectively) were 
first described by Creasey and colleagues517 of the 
University of California, Berkeley, U.S.A., from whom the 
cell lines were obtained. MEL57 was originally provided by 
Dr. C. Sorg of the Universitats Hautklinik, Munster, West 
Germany. All three cell lines are commonly used in our own 
and other laboratories, and the cells have been karyotyped 
(to confirm human origin), confirmed DOPA-positive 
(melanocytic) and regularly checked to be mycoplasma-free.
IV.3.2. Routine cell culture conditions
In these experiments all cell lines were maintained in 
Eagle1s Minimum Essential Medium (MEM) supplemented with 
foetal calf serum (10%), L-glutamine, penicillin, 
streptomycin and amphotericin-B (Table 3 6) . The 
antibiotics and anti-fungal are added routinely because 
sepsis can be a major problem in experiments involving 
multiple manipulations and prolonged culture.
Strict aseptic technique was rigorously observed in 
preparing and performing each stage of all tissue culture 
experiments. Any infected or possibly infected experiments 
were abandoned, and the results are not reported.
IV.3.3. Formation of spheroids
An outline of the spheroid experiment protocol is
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illustrated in Fig. 24. Cells were harvested from near 
confluent monolayers after initial washing in Earle's 
salts (Gibco) . The cells were lifted off with 0.25% 
trypsin (Gibco) in Earle's salts, the trypsin was 
neutralised with supplemented MEM, and the cells were 
dispersed by repeated pipetting.
The resultant cell suspensions were used to initiate 
spheroids, by the "agar underlay" (also known as "liquid 
overlay") static method525'526. Cells are seeded at high 
density (5xl05 cells per flask) in 5ml of supplemented MEM 
into 25cm2 flasks (Nunclon), which were previously base- 
coated with 5ml 1.25% Noble agar (Difco) in supplemented 
MEM. The mixed agar/MEM coating does not allow cells to 
adhere to the surface of the tissue culture vessels and 
should prevent leaching of nutrients from the liquid MEM. 
Flasks were thereafter incubated in an atmosphere of 7% 
C02 at 100% humidity. In cell lines which form spheroids, 
small spheroids (approximately 200-250/zm) usually form 
within a few days, ready for experimental treatment.
IV.3.4. Experimental chemotherapy: drugs, pH
Melphalan (Alkeran Injection, Wellcome) was obtained from 
the manufacturer (in gram quantities from a single 
manufacturing run) as the sterile anhydrous base ( >98%
pure drug), as supplied for intravenous administration, 
and 50mg aliquots were prepared and stored. For each 
experiment the drug was prepared freshly as for clinical 
administration. The powdered melphalan base was rapidly 
dissolved in the manufacturer's solvent (hydrochloric 
acid and ethanol) to produce the hydrochloride salt
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immediately prior to use. This solution was then diluted 
in the supplied diluent (propylene glycol-K2HP04 buffer) 
to give lOmg/ml. Thereafter the solution was passed 
through a non-absorbent 0.2/xm filter (Flowpore D, Flow) 
and serially diluted in MEM to appropriate final 
concentrations. Melphalan was always made up freshly 
before use, put on ice and added to cultures within ten 
minutes.
In separate control incubations at 37 °C and 42 °C the 
concentration of melphalan in supplemented MEM was 
measured by HPLC (Figs. 25 & 26) . Thus the effects of
temperature and pH on melphalan decompostition were 
studied in vitro, in conditions similar to those of 
spheroid treatment.
Verapamil was obtained as the pure anhydrous drug 
(Cordilox Injection, Abbott). The drug was freshly 
dissolved for each experiment in phosphate buffered saline 
(Dulbecco's, Gibco), passed through a 0.2/zm filter, and 
then diluted serially to appropriate concentrations in 
MEM.
For studies of melphalan cytotoxicity in acidic and 
alkaline conditions, supplemented MEM was titrated to pH7 
with IN HCl, and to pH8 with molar NaOH. In experiments 
controlled for the presence of spheroids and melphalan a 
pH meter (Pye Unicam) was used to confirm that the desired 
pH was maintained throughout the period of drug exposure.
IV.3.5. Experimental chemotherapy: spheroids
Three or four days after initiation, the spheroids from 
several flasks were pooled, allowed to sediment in
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Universal containers (Sterilin) and single cells were 
removed with the supernatant. The spheroids were 
resuspended in fresh MEM, sorted into equal amounts and 
transferred into thin-walled glass scintillation vials. 
The volume in each vial was made up to 5ml with fresh MEM. 
Freshly prepared solutions of melphalan (prepared as 
above) in MEM were added to each vial in a 5ml volume to 
give an appropriate range of final concentrations (based 
on levels achieved clinically in isolated limb perfusion). 
The vials were sealed with "Parafilm" (American Can Co.) 
and immersed in a water bath (Grant) at a pre-set 
temperature between 31-44.5°C (±0.1°C). The vials were
then maintained in controlled temperature conditions in 
the insulated water-bath for varying time periods. During 
the period of treatment the vials were shaken at ten 
minute intervals by hand.
At the end of the period of treatment the spheroids were 
transferred to Universal containers, and allowed to 
sediment. The medium with drug was immediately removed and 
the spheroids were then washed, three times, in ice cold 
MEM. The spheroids were then resuspended in MEM at 
approximately 37°C and decanted into 5cm tissue culture 
Petri dishes (Flow).
Under laminar flow conditions, individual spheroids of 
approximately 250/m diameter were selected under low power 
microscopy (x40, Olympus inverted microscope, Model CK) . 
Using a Pasteur pipette and Pi-pump (Shuco International), 
one spheroid was transferred from the Petri dish to each 
well of a 24-well plate (Corning 25820). The wells had 
been previously base-coated with 1% agar in MEM, and
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each contained 0.5ml liquid MEM. The multi-well plates
were incubated thereafter at 37 °C in an atmosphere of 7%
C02 at 100% humidity. Once a week 0.5ml of fresh
supplemented MEM was added to each well.
IV.3.6. Measurement of spheroid growth
In spheroid experiments there were usually six treatment 
groups, with 24 spheroids in each group. Each individual 
spheroid in every well of the multi-well plates was 
measured two or three times weekly. The cross-sectional 
area of each spheroid was measured using a 
"Micromeasurements11 image analysis system coupled via a 
television camera to an inverted optical microscope527. 
Area measurements were subsequently converted to volumes, 
assuming spherical geometry, using an "in-house" computer 
program.
IV.3.6. Spheroid disaggregation
After the transfer of selected spheroids to multi-well 
plates approximately two hundred spheroids remained in the 
Petri dishes. The remaining spheroids were transferred in 
MEM to fresh agar base-coated flasks and incubated for a 
24-hour recovery period before disaggregation for 
colony forming assay. The spheroids were allowed to 
sediment in Universal containers and the supernatant MEM 
was removed. The spheroids were washed with Earle's salts, 
then after 5-10 minutes incubation with 0.125% trypsin in 
Earle's salts at 37°C, the trypsin was removed and 
replaced with fresh MEM. The spheroids were mechanically 
disaggregated to a single cell suspension by repeated
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pipetting and colony forming assays were then performed as 
for the cells from monolayers (IV.3.8.).
IV.3.7. Treating monolayers
Cells were seeded at 5xl04/ml in 5ml supplemented MEM and 
placed in replicate 25cm2 flasks (same concentration of 
cells in 15ml MEM in 80cm2 flasks for higher drug doses 
and temperatures). The flasks were incubated at 37°C for 
three days. At this stage, with the cells in the 
exponential growth phase, the MEM was decanted and 
replaced with MEM containing freshly prepared melphalan at 
concentrations similar to those used in the spheroid 
experiments. The flasks were sealed with "Parafilm" and 
immersed in the same water bath as spheroids at controlled 
temperatures, usually for one hour. The flasks were shaken 
by hand at ten minute intervals during drug exposure. 
Following exposure to melphalan the monolayers were washed 
three times with ice cold medium, then replenished with 
MEM at 37°C and returned to the incubator for a 24-hour 
recovery period. The MEM was then decanted, the monolayers 
rinsed with Earle's salts and, after 5 minutes exposure to
0.125% trypsin in Earle's salts at 37°C, the cells were 
harvested and the trypsin was neutralised with fresh MEM. 
From each treated monolayer a single cell suspension was 
obtained for colony forming assay by repeated pipetting.
IV.3.8. Colony forming assays
The single cell suspensions (from disaggregated spheroids 
or monolayers) were diluted and seeded at 1000 cells per 
5ml MEM in 60x15 tissue culture Petri dishes (Nunclon
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Delta) for controls and most treatment groups. For some of 
the higher drug concentrations and higher temperatures, 
more cells were seeded (at approximately the same cell 
density) in larger dishes. Four replicate plates were set 
up for each treatment group. Each plate was scrutinised at 
day 0 to ensure that single cell suspensions were plated. 
After incubation at 37 °C for 10-14 days in an atmosphere 
of 7% C02 and 100% humidity, the MEM was decanted and
colonies fixed and stained with a 1:10 solution of carbol 
fuchsin ('Ziehl Neelson1, RA Lamb) in distilled water. 
Colonies of at least 40 cells were counted and the 
average plating efficiency for the untreated cells of the 
B0008 cell line was 12%. Following convention, the plating 
efficiency of the untreated cells was normalised to 100% 
and the results for treated cells were expressed as a 
percentage of control clonogenic survival.
IV.3.9. End-points and analysis
An advantage of the spheroid model is the fact that 
several end-points can be derived from the experimental 
data528'529.
Serial measurement of spheroid volume allowed the 
construction of growth curves for the various experimental 
groups, taking median spheroid volume as the dependent 
variable for each group. From the spheroid growth curves 
the time for the median spheroid volume to reach lOx the 
original volume can be obtained and this is termed the 
growth delay (for control groups) or the regrowth delay 
(of treated groups).
The growth curve of each Individual spheroid in a plate
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was used to calculate the median regrowth delay data. The 
computer program calculated 95% confidence limits about 
the median volumes and regrowth delay data, with allowance 
for small sample size (n<30).
At higher doses of effective treatments an increasing 
proportion of spheroids fail to regrow during the period 
of observation. The proportion of spheroids which fail to 
regrow can be expressed as the percentage "cured" . This 
proportion tends to increase with the more effective 
treatments, and "cured" spheroids cannot simply be 
excluded from an analysis of results. In our studies 
"cured" spheroids were assigned an arbitrary regrowth 
delay of 1000 days (to prevent inappropriate exclusion 
from calculations of regrowth delay).
Clonogenic cell survival was estimated directly by 
disaggregating spheroids and using conventional colony 
forming assays. An estimate of clonogenic cell survival 
in intact spheroids can also be derived from the regrowth 
curves of treated spheroids by the process of back- 
extrapolation530'531. This method requires that regrowth 
curves of treated spheroids should eventually return to 
the same growth pattern as control spheroids (Fig. 27) . 
The surviving fraction (S) of clonogenic cells is taken 
to be the ratio of the volume obtained by back- 
extrapolation of the regrowth curve (VE : the volume from 
which the spheroid "apparently " regrew) to the volume 
actually measured on day 0 (VQ).
i.e. S = VE — V q
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and log S = log VE - log VQ
This method does not entail disruption or explantation of 
the spheroid and should be free from artefacts due to such 
manipulations.
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IV.4. RESULTS
IV.4.1. General
The results for each experiment are given as tables 
showing values for the growth curves (median log volumes 
with 95% confidence intervals) , regrowth delay, and 11 % 
cured" (Tables 37A-62C); together with graphs of spheroid 
growth curves and regrowth delay (Figs. 28A-52B) For 
clarity of presentation the confidence intervals are 
omitted from figures showing growth curves.
IV.4.2. Control Experiments
Experiment 1 (See Tables 37A.B.C; Ficrs. 28A &. B}_
Pilot studies were conducted with B0008 melanoma spheroids 
and the results confirmed that, in keeping with measured 
tissue levels (see Chapter III), an appropriate melphalan 
concentration range for one hour exposure at 37°C would be 
0-16/ig/ml. Experiment 1 was also designed to show any 
cytotoxic effect of the Alkeran solvent (acid/alcohol) or 
the solvent/diluent mixture at concentrations equivalent 
to those in melphalan 32/zg/ml.
Experiments 2 & 3 (See Tables 38A.B.C. 3 9A .B .C ; Figs.
29A.B. 30A & B)
Experiment 2 was conducted to determine whether 
amphotericin-B (a routine additive in supplemented MEM) 
was cytotoxic to B0008 melanoma spheroids at 37°C or if 
there was any significant interaction between 
amphotericin-B and melphalan at 37°C.
Experiment 3 was designed to show whether amphotericin-B 
or the Alkeran solvent was cytotoxic at 4 3 °C, either 
independently or in combination.
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IV.4.3. B0010 cell line
Experiment 4. (see Tables 40A & Cj_ Fig. 31)
B0010 cells formed typical "tight" multicellular tumour 
spheroids but all groups grew very slowly during the 
period of observation.
IV.4.4. MEL57 cell line
Experiment 5 & 6 (see Tables 41A.B ,C , 42A.B,C; Figs. 32A,B 
33A.B)
The MEL57 cell-line seemed to form less tightly packed 
spheroids than either B0008 or B0010. These spheroids grew 
more rapidly than the B0008 spheroids, and the regrowth 
delay of control MEL57 spheroids was significantly less. 
Experiment 6 was a study of thermo-chemotherapy with 
melphalan in the MEL57 spheroid model, using 41 °C 
incubations.
IV.4.5. Melphalan and temperature
Experiments 7j_ 8 & 9 (see Tables 43A.B,C, 44A,B, C 45A,B,C 
& Figs. 34A.B, 35A.B, 36A.B)
In these experiments B0008 spheroids were treated with 
melphalan, for one hour in hypothermic conditions at 
temperatures relevant to clinical isolated limb perfusion 
(31°C and 35°C).
Experiments 10. 11 & 12 (see Tables 46A.B.C, 47A.B,C.
48A.B.C: Figs. 37A.B, 38A,B, 39A.B)
B0008 spheroids were treated with melphalan for one hour 
in normothermic conditions (37°C).
Experiments 13-19 (see Tables 49A.B.C. 50A .B .C , 51A.B.C.
52A.B.C. 53A.B.C, 54A,B,C, 55; Figs. 40A.B. 41A.B . 42A.B.
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43A,B . 44A.B. 45A.B)
B0008 spheroids were treated with melphalan for one hour 
over a range of clinically achievable hyperthermic 
temperatures from 39°C to 44.5°C.
IV.4.6. Melphalan and incubation time
Experiments 20 & 21 (see Tables 56A.B.C 57A,B,C; Figs.
46A.B. 47A.B)
B0008 spheroids were exposed to melphalan at 37°C for time 
intervals from 15 minutes to 2 hours.
Experiment 22 (see Tables 58A.B,C; Figs. 48A,B)
This experiment was performed as Experiments 7 and 8 
except that controls and drug exposures were incubated for 
3 0 minutes rather than one hour.
IV.4.7. Melphalan and verapamil
Experiments 23. & 24 (See Tables 59A.B.C. 60A,B.C; Figs.
49A.B. 50A.B
The influence of verapamil on melphalan cytotoxicity in 
the B0008 spheroid model was assessed in these duplicate 
experiments.
IV.4.8. Melphalan and pH
Experiments 25 & 26 (See Tables 61A.B.C. 62A.B.C? Figs.
51A.B. 52A.B
Melphalan cytotoxicity and the effect of pH during drug 
incubation was studied using large spheroids (Experiment 
25) and small spheroids (Experiment 26).
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IV.4.9. Comparison of assays
The "percentage cured" data from Experiments 7-19 are 
summarised in Fig. 53. In this graph each point represents 
the percentage of spheroids "cured" in a single plate. 
The lines join the values from separate plates in the same 
experiment.
The dose/survival curves for thermochemotherapy with 
melphalan in the B0008 cell line are illustrated, as 
derived:
a) by colony forming assay of disaggregated spheroids 
(Fig. 54),
b) by back-extrapolation from the spheroid growth curves 
(Fig. 55) and
c) by colony forming assay of cells treated as exponential 
phase monolayers (Fig. 56).
In Figs. 54 and 56 each point represents the mean of four 
replicate plates for each experiment. The lines link 
points derived from the same experiments.
In Fig. 55 each point is the result of a single estimate 
of surviving fraction, according to the method of back- 
extrapolation (IV.3.9. & Fig.27).
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IV.5. DISCUSSION
IV.5.1. Model systems for isolated limb perfusion
In any model system the aim is to reproduce clinical 
conditions as closely as possible. In vivo, the ideal 
representation of clinical isolated limb perfusion would 
entail the use of isolated limb perfusion in an 
appropriate animal model because systemic administration 
of a drug is associated with quite different physio- 
pharmacological conditions. During isolated perfusion high 
doses of cytotoxic drug are given in order to achieve and 
maintain high concentrations within the perfused region, 
and the major organs of excretion play little role in 
handling melphalan.
In vivo studies of the physiology of isolated limb 
perfusion have been performed in the dog411'532'533, and 
rat534'535. A rabbit model, originally described by Mori 
in 1962^36, has been used recently to study the 
pharmacokinetics of 5-fluorouracil in various forms of 
regional chemotherapy (including isolated limb perfusion) 
for intramuscular VX-2 carcinoma in the hind limb377.
The larger mammal models are closer analogies to clinical 
perfusion than rat and murine systems, but there is a lack 
of a representative melanoma tumour and the financial 
costs of large animals are high. There are several murine 
melanoma cell lines but the technical demands of 
cannulating, perfusing and repairing small mammal vessels 
are obvious. In theory it should be possible to grow human 
melanoma xenografts on nude rats which might be treated by 
isolated perfusion. Survival experiments, with serial 
measurement of treatment efficacy are feasible but they
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would require great technical expertise and would 
inevitably be time consuming and costly.
In fact, there have been no definitive studies of the 
therapeutic results of different methods of isolated limb 
perfusion for malignant melanoma in an animal model. 
Implanted animal tumours (in syngeneic hosts) and human 
tumour xenografts (in immuno-deficient animal hosts) may 
be used to represent spontaneous tumours and metastases 
but they have their limitations537. There is increasing 
recognition of inter-species differences in metabolism and 
immunology, and the results of experiments in in-bred 
laboratory animals cannot be directly extrapolated to the 
clinical situation.
The particular advantages of using in vitro models include 
the fact that a greater number of standard experimental 
"tumours" can be studied than would be practical 
clinically or in animal experiments. The physio- 
pharmacological conditions of clinical isolated limb 
perfusion can be better reproduced and are easier to 
maintain in vitro than after systemic administration in 
vivo. Many variables, including those associated with 
host metabolism, immunology and physiology; the "tumour 
bed effect", host cell infiltration and oedema may be 
circumvented by using in vitro models530.
The effects of therapeutic manipulations can be studied at 
the cellular level using various types of cell culture.
The primary culture from a human tumour biopsy is 
initially composed of a heterogeneous tumour cell 
population, of low growth fraction. Previously it was 
hoped that testing of primary cell cultures using the
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Human Tumour Stem Cell Assay538'539 would provide chemo- 
sensitivity information about an individual patient's 
tumour analogous to the information obtained about 
bacteria by antibiotic sensitivity testing. This system 
has not yet fulfilled its promise and there are important 
criticisms of the use of stem cell assays for predicting 
tumour sensitivities540'541'542'543'544.
After passage or sub-culture the cell line expands and 
the growth fraction tends to increase, with the provision 
of large amounts of consistent tumour-derived material. An 
established or continuous cell line can be maintained in 
culture indefinitely but not all tumour cell lines become 
continuous, and some die out after a few subcultures 
(finite cell lines). Continuous cell lines are attractive 
sources of experimental material because they are easily 
maintained, but they are necessarily derived from a 
selected subpopulation and may not be entirely 
representative of the original parent tumour.
In common with most other workers in the field we grew 
spheroids from continuous cell-lines for use in this 
series of experiments. Cells from early passages of human 
tumours, including malignant melanoma545, have been used 
to form and study spheroids. These early passage cells may 
prove to be better than continuous cell lines as 
indicators of how an individual patient's tumour will 
behave, but the prediction of chemosensitivity was not an 
aim of my work.
IV.5.2. Limitations of in vitro systems
When considering the results obtained from any in vitro
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model there are important limitations of such systems, 
which should caution against direct extrapolation to the 
clinical situation. The major limitation, -common to most 
vitro methods, is the lack of an assessment of normal 
tissue response to treatments. Furthermore certain physio- 
pharmacological conditions may tend to promote tumour 
sensitivity to a drug at the cellular level in vitro, but 
in the more complex clinical setting such effects may be 
enhanced or negated by the simultaneous effects of the 
same conditions on other systems e.g. tumour (or normal 
tissue) vasculature. With these provisos, the results of 
in vitro experiments are indicative, but not predictive of 
what may happen in vivo and clinically.
IV.5.3. Control experiments
The alcohol in the proprietary acid/alcohol melphalan 
solvent is diluted more than 3000-fold (when equivalent to 
melphalan 32/zg/ml) , and the acid is buffered when the 
diluent is added. Thus neither acid nor alcohol would be 
expected to have a significant cytotoxic effect on cells 
in these experiments or clinically.
In Experiment 1 the control growth curves were very 
similar suggesting that the solvent and solvent/diluent 
had little cytotoxic effect. Regrowth delay of spheroids 
treated with the solvent with or without diluent was 
similar to that of control spheroids. There were no 
differences in the "percentages cured" comparing these 
groups.
In the spheroids treated with 6/xg/ml melphalan there is a 
period of little or no growth followed by regrowth of the
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spheroids i.e. regrowth is delayed. At higher 
concentrations of melphalan there is little or no increase 
in the median spheroid volume during the- month of the 
experiment. This is reflected in the long regrowth delay 
values and can be quantified by the proportions of 
spheroids "cured".
In Experiment 2 amphotericin-B (Fungizone, FZ) did not 
affect spheroid growth and had no significant effect on 
melphalan cytotoxicity.
The results of Experiment 3 showed no significant 
difference between the subsequent growth of spheroids 
incubated for one hour at 37 or 43°C in MEM with (+FZ) and 
without amphotericin-B (FZ-free). In this experiment 
exposure to 43°C and a high concentration of acid/alcohol 
solvent, with and without amphotericin-B, had no 
significant effect on subsequent spheroid growth.
The lack of a measurable effect due to amphotericin-B is 
probably because of the low concentration (2.5/xg/ml) used 
in these spheroid experiments.
IV.5.4. B0010 spheroids
In Experiment 4 the B0010 cell line formed typical 
spheroids but they grew poorly as compared with the B0008 
and MEL57 cell lines. A high percentage of the B0010 
spheroids failed to increase volume significantly during 
the course of the experiment and this is illustrated by 
the flat profile of the growth curve (note the different 
y-axis on Fig. 31) and the high "percentage cured". 
Regrowth delays could not be calculated because most of 
these spheroids failed to increase their volume ten-fold.
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\Interestingly the B0010 cell line also gives rise to a 
much less aggressive tumour in vivo compared with the 
B0008 cell line517.
IV.5.5. MEL57 spheroids
In Experiments 5 & 6 the regrowth curves of treated MEL57 
spheroids seem to follow a different pattern as compared 
with the regrowth curves of treated B0008 spheroids. With 
increasing doses of melphalan or hyperthermia the 
spheroids grow at progressively slower rates. Hence the 
regrowth curves do not run parallel with the control 
curves and the method of back-extrapolation (IV.3.9. &
Fig.27) cannot be applied to derive dose-survival curves 
from the spheroid growth data.
Large multinucleated "giant" cells were noted on 
microscopy of treated MEL57 spheroids, but they were seen 
only rarely in MEL57 controls and never in B0008 or B0010 
spheroids. In the more heavily treated spheroids the giant 
cells comprised a greater fraction of the total cell 
population. Similar appearances have been described after 
experimental radiotherapy of lung cancer spheroids, and it 
has been postulated that such giant cells may be lethally
'V
damaged but metabolically active cells546. Such cells may 
distort regrowth curves in vitro but they might not be 
expected to survive in vivo.
In my experiments with MEL57 spheroids the cytotoxic 
effect of melphalan seemed to be enhanced by incubation at 
41 °C, but this was not statistically significant at all 
doses of melphalan.
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IV.5.6. B0008 spheroids, hypothermia and melphalan
In Experiments 7-18 the B0008 human melanoma multicellular 
tumour spheroid model has been used to examine the 
influence of temperature on melphalan cytotoxicity at the 
cellular level, in a system which is independent of 
vascular effects. The growth curves and regrowth delay 
data are discussed first. In a separate section the 
"percentages cured", and dose/survival curves are 
considered (see IV.5.13.).
Experiments 7 and 8 were conducted in identical conditions 
(31 °C incubations) and though the pattern of results is 
similar, the spheroids in Experiment 8 seemed less 
responsive to melphalan. In general the spheroids in 
Experiment 8 were significantly smaller than in those in 
Experiment 7. The smaller spheroids might be expected to 
be more sensitive to treatment (cf. experiments 25 & 26) 
but the regrowth delay of control spheroids was longer in 
Experiment 7 than in Experiment 8. Indeed the regrowth 
delay of control spheroids in Experiment 7 was longer than 
that of control spheroids in most of the other experiments 
involving B0008 spheroids.
The growth curves and regrowth delay data of Experiments 
7-9 suggest, but fail to show statistically, that 
hypothermia significantly reduces melphalan cytotoxicity 
in vitro. There was certainly no evidence that hypothermia 
enhanced melphalan cytotoxicity by reducing the rate of 
its hydrolysis.
IV.5.7. B0008 spheroids, normothermia and melphalan
Most tissue culture and in vivo experiments are conducted
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at 37 °C, yet this is not the "normal" temperature of the 
skin of the extremities either before or during isolated 
limb perfusion (cf. Table 21, II. 5.12 .)
Experiment 10 was performed early in the series, several 
months before Experiments 11 and 12 which are duplicates. 
The median spheroid volume was less in Experiment 12, yet 
the smaller spheroids seemed to be more resistant to 
melphalan.
There was a linear relationship between regrowth delay and 
melphalan concentration at 37°C in the concentration range 
studied.
IV.5.8. B0008 spheroids, hyperthermia and melphalan
Experiments 13 and 14 (39°C) were duplicate experiments,
although the spheroids in Experiment 13 were larger on Day 
0. Again the smaller spheroids appeared less sensitive 
than the larger spheroids.
In the three experiments conducted at 42.5°C, (Experiments 
16,17 & 18) the regrowth delays were significantly longer 
per unit dose of melphalan than those following 
incubations at 41°C (Experiment 15) or lower.
There was no evidence that the cytotoxic effect of 
melphalan was diminished at the higher temperatures.
In Experiment 18, two control plates were included, in one 
the spheroids were selected and "picked off" immediately 
after experimental treatment and in the other the process 
of "picking-off" was delayed for two hours. This was done 
to confirm that there was no bias due to the differing 
time interval between treatment and selection. In any 
experiment this delay was never more than two hours. This
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delay had no significant effect on the growth curve or 
regrowth delay of spheroids in the relevant plates in 
Experiment 18.
Hyperthermia alone showed no significant cytotoxic effect 
in the spheroid system until 44.5°C was reached 
(Experiment 19) , when growth curves could not be plotted 
because greater than 50% of control spheroids incubated at 
44.5°C failed to regrow. In this particular experiment the 
results could only be described in terms of "percentage 
cured" (Table 55, Fig. 53).
In vivo hyperthermia is associated with vasodilatation and 
increased flow in the vessels of normal tissues. Tumour 
blood vessels are less responsive, may dissipate heat less 
well, and this may result in more damage to tumour 
tissue547. Furthermore, vascular damage and thrombosis may 
be caused by hyperthermia, and this may explain the 
greater cytotoxicity of heat in vivo compared with in 
vitro548'549. Murray and colleagues have recently 
emphasised the importance of the vascular response to 
chemotherapy by showing that a significant proportion of 
tumour shrinkage may be due to loss of vascular volume550. 
My spheroid experiments have shown that the cytotoxic 
effect of melphalan is significantly enhanced by 
hyperthermia, in a system which is not dependent on 
vascular effects.
IV.5.9. Melphalan and duration of exposure
The results of Experiments 2 0 & 21 show the near-linear 
relationship between duration of exposure to melphalan at 
37°C and the regrowth delay of treated B0008 spheroids
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(Figs. 46B & 47B).
The median initial spheroid volume was similar in 
Experiments 7 and 22. All half-hour exposures were 
associated with a significantly reduced cytotoxic effect, 
comparing the growth curves and regrowth delay with those 
of Experiments 7 and 8. These experimental data support my 
contention (III.7.5.) that it is premature to advocate 
such short periods of isolated limb perfusion (as 
suggested by Briele450).
IV.5.10. Melphalan and verapamil
There was no evidence from Experiments 23 and 24 that 
verapamil was itself cytotoxic in the B0008 melanoma 
spheroid model. Nor was there any evidence that verapamil 
5 or 10/ig/ml enhanced melphalan cytotoxicity. In fact, 
verapamil tended to decrease melphalan cytotoxicity 
(Experiment 23, plate 3 vs. plate 6 - Fig. 49B) , and
increasing the verapamil concentration seemed to reduce 
melphalan cytotoxicity further (plate 4 vs. plate 5 - Fig. 
49B) .
IV.5.11. Melphalan and pH
In Experiments 25 & 26 there was no significant difference 
between the regrowth of controls incubated at pH 7, 7.4 or 
8 for one hour. There was a trend towards reduced regrowth 
delay i.e. reduced cytotoxic effect, at higher pH values 
in Experiment 25 (large spheroids - Fig. 5IB) and this 
trend was confirmed,.by the results of Experiment 26 (small 
spheroids - Fig. 52B).
Although the drug is known to be stabilised in acidic
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conditions, melphalan was incubated in supplemented MEM - 
titrated to pH values 7, 7.4 and 8 - and no difference in 
the rate of hydrolysis was detected (Fig. 26).
The increased cytotoxicity of melphalan in acidic 
conditions has not been described before. It may be due to 
an effect on the known active carrier mechanisms, to an 
effect on protein binding or a combination of these 
factors.
IV.5.12. Variability of spheroid results
Within each experiment the results are consistent, but 
there is some variability between experiments. Throughout 
care was taken to standardise technique from experiment to 
experiment. The observed variability between separate 
experiments (done on separate days) may reflect 
differences which are difficult or impossible to control. 
From inspection of control spheroid growth curves the 
initial size of a spheroid would be expected to affect its 
growth pattern, smaller untreated spheroids tending to 
grow more rapidly. Smaller spheroids have a larger growth 
fraction than large spheroids513 and may be more 
susceptible to therapy if the growth fraction is 
accessible by treatment. Spheroids of similar sizes were 
selected as far as possible.
An alternative hypothesis is that in any one experiment 
the predominant clone, sub-clone or blend of cells within 
the cell line may differ causing different growth 
patterns. Spheroids initiated in several different flasks 
were always pooled for experiments to minimise the 
potential for bias.
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Experiments were conducted over a period of eighteen 
months, during which time the ambient temperatures in the 
laboratory varied. This may have influenced spheroid 
growth, although the spheroids were only removed from the 
incubator for measuring or replenishing culture medium. It 
was not possible to use a single batch of foetal calf 
serum, and the quality of supplemented MEM was therefore 
another potential source of variability. There was no 
particular pattern to support a seasonal or a MEM effect 
on spheroid growth. Genetic "drift" was minimised by 
using spheroids of established cell lines at similar 
passage numbers.
IV.5.13. Comparison of assays
In the studies of experimental chemotherapy, melphalan 
showed a clear dose-response relationship with all three 
cell lines. The melphalan dose-response relationship for 
the B0008 and Mel57 cell-lines can be quantified by the 
regrowth delay or "percentage cured".
In general there is a trend for increasing cytotoxicity of 
melphalan at higher temperatures. This is illustrated by 
the increasing regrowth delays obtained by Experiments 7-
18 (Figs. 34B, 35B, 36B,   45B) . Similarly Fig. 53
summarises the "percentage cured" data, and shows a 
gradation from very low values for incubations at 31°C, to 
high values for incubations at 44.5°C. Neither regrowth 
delay nor "percentage cured" data can be related directly 
to a conventional dpse-survival curve.
To enable comparison of assays, and validate a method for 
deriving dose-survival curves from spheroid data, Figs.
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54, 55 & 56 show the curves based on:
a) colony forming assay of disaggregated spheroids,
b) back-extrapolation from spheroid growth curves
and c) colony forming assay of exponential monolayers.
As illustrated in Fig. 27, derivation of surviving
fraction by back-extrapolation from multicellular tumour 
spheroid growth curves depends on the treated spheroids 
regrowing parallel to the control spheroids. B0008 
spheroids tend to regrow at the same rate, independent of 
melphalan dose (e.g. Fig 38A, 39A) . Clonogenic cell
survival cannot be derived from the spheroid growth curves 
of all cell lines546. For example, Fig. 32 shows how MEL57 
spheroids regrow more slowly after higher doses of 
melphalan. The back-extrapolation method is therefore 
appropriate for B0008 spheroids but not for MEL57 
spheroids. The particular advantage when this method can 
be applied is that direct comparison can be made with the 
dose-survival curve obtained after conventional colony 
forming assay of disaggregated B0008 spheroids and 
monolayers.
In these studies, using thermochemotherapy with melphalan 
and the B0008 cell line, we have found close concordance 
between the dose-survival curves derived from intact 
spheroid growth curves, from disaggregated spheroids and 
monolayers.
These dose-survival curves all tend to support the 
hypothesis that melphalan cytotoxicity is enhanced by 
hyperthermia.
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IV.6. CONCLUSIONS
Initial studies have shown that we can grow multicellular 
tumour spheroids from established human melanoma cell 
lines. This three-dimensional system appears to be an 
appropriate model for avascular micro-metastasis, and we 
have used spheroids in studies of experimental 
chemotherapy. The multicellular tumour spheroid model has 
proved particularly valuable in the study of contributory 
factors which would be difficult to study in other 
systems. Three dimensional models are especially 
attractive to those of us researching treatments for the 
solid tumours, which have generally proved more difficult 
to treat than other malignancies.
The important conclusions of these studies are that:
1) Hyperthermia (>37°C) enhances the cytotoxic effect of
melphalan, though heat alone is not cytotoxic to spheroids 
at temperatures less than 43°C for one hour.
2) Hypothermia (<37°C) tends to reduce the cytotoxic
effect of melphalan.
3) There is a simple relationship between duration of
exposure and cytotoxic effect.
4) Verapamil does not enhance melphalan cytotoxicity.
5) The B0010 cell line forms spheroids which grow poorly
in conditions which allow B0008 and Mel57 spheroids to
grow well.
6) Melphalan cytotoxicity is enhanced at lower pH
values, and this effect is not simply due to decreased 
hydrolysis of melphalan.
7) Similar dose-survival curves are derived from
spheroid experiments by back-extrapolation from growth
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curves, from colony forming assay of disaggregated 
spheroids and from colony forming assay of exponential 
monolayers.
The implications for clinical isolated limb perfusion are 
that:
a) the limb should be warmed to greater than 37 °C during 
isolated limb perfusion because melphalan cytotoxicity is 
enhanced by hyperthermia and reduced by hypothermia.
b) the results of one hour exposure to the achieved 
tissue concentrations may be improved by longer exposures, 
and shorter periods of clinical isolated limb perfusion 
are probably inappropriate.
c) the addition of verapamil during isolated limb 
perfusion with melphalan would not be expected to improve 
results, unless the vaso-active effect governs melphalan 
enhancement.
d) the cytotoxic effect of melphalan may be enhanced by 
correcting the alkalosis which develops if the perfusate 
is oxygenated with 100% 02.
